A publication of the
American Pharmaceutical Association—
the National Professional Society
of Pharmacists

JOURNAL OF PHARMACEUTICAL SCIENCES

INDEX TO AUTHORS
INDEX TO SUBJECTS

VOLUME 67
JANUARY TO DECEMBER, 1978

Published monthly under the supervision of the Board of Trustees

MARY H. FERGUSON
Editor

SHELLY ELLIOTT
Production Editor

JANIS KELLY
Copy Editor

EDWARD G. FELDMANN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

BELLE R. BECK
Editorial Secretary

DAVID BOHARDT
Director of Publications

L. LUAN CORRIGAN
Assistant Director of Publications

EDITORIAL ADVISORY BOARD

John Autian
Norman R. Farnsworth
William O. Foye
William J. Jusko
Herbert A. Lieberman
David E. Mann, Jr.
Gerald J. Papariello
Edward G. Rippie

© Copyright 1978 by the American Pharmaceutical Association; all rights reserved.

AUTHOR INDEX

A

Abdel-Monem, M. M., and Mikhail, E. A., inhibitors of *polyamine biosynthesis VI: 2,5-diamino-2-(cyanomethyl)pentanoic acid, a potential irreversible inhibitor of ornithine decarboxylase,* 1174
——and Ohno, K., polyamine metabolism III: urinary acetyl polyamines in human cancer, 1671
Abdine, H., *see* Munson, J. W., 1775
——*see* Wahbi, A. M., 140
Abdou, H. M., Ast, T. M., and Cioffi, F. J., semiautomated system for high-pressure liquid chromatographic determination of dissolution rate of fludrocortisone acetate tablets, 1397
Ableidinger, W., *see* Hartmann, V., *98*
Abou-Gharbia, M. A., Su, T. T., and Joullié, M. M., synthesis of spirofluorenes of biological interest, *953*
Abrams, L. S., Weintraub, H. S., Patrick, J. E., and McGuire, J. L., comparative bioavailability of a *lipophilic steroid, 1287*
——*see* Weintraub, H. S., 1406
Abu-Shady, H., and Girgis, E. H., *spectrophotometric* determinations of 3-dimethylaminomethylkhellin hydrochloride and khellin, 618
Adams, W. P., *see Johnson, R. N., 1218*
Adir, J., *see* Miller, A. K., 1192
Aggarwal, N. D., *see* Lazer, E. S., 1656
Ahuja, S., *see* Mollica, J. A., 443
Aisaka, A., *see* Hara, Y., 1334
Alaimo, R. J., and Goldenberg, M. M., *synthesis and* antiulcerogenic evaluation of 2-(substituted phenylimino)-2*H*-quinolizines, 1183
——*Pelosi, S. S., and Freedman, R., synthesis and* antibacterial evaluation of 2-(substituted phenylureido)-4-thiocyanatobenzothiazoles, 281
Al-Ani, N. I., and Borazan, H. N., interactions of caffeine and theophylline with *p*-cresol: UV studies, *1381*
Albert, K. S., Ayres, J. W., DiSanto, A. R., Weidler, D. J., Sakmar, E., Hallmark, M. R., Stoll, R. G., DeSante, K. A., and Wagner, J. G., influence of kaolin–pectin suspension on digoxin bioavailability, 1582
——DeSante, K. A., Welch, R. D., and DiSanto, A. R., pharmacokinetic evaluation of a drug interaction *between kaolin–pectin and clindamycin, 1579*
Alberts, D. S., *see* Chang, S. Y., 679, 682
Alexander, K. S., Laprade, B., Mauger, J. W., and Paruta, A. N., thermodynamics of aqueous solutions of parabens, 624
Ali, A. A., *see Geneidi, A. Sh., 114*
Allen, L. M., see Pelsor, F. R., 1106
Allen, L. V., Jr., Levinson, R. S., and Martono, D. D., *dissolution rates of hydrocortisone and prednisone* utilizing sugar solid dispersion systems in tablet form, 979
Allen, P. V., *Rahn, P. D., Sarapu, A. C., and Vanderwielen, A. J.,* physical characterization of erythromycin: anhydrate, *monohydrate, and dihydrate* crystalline solids, 1087
Alteras, M., see Weinstein, S. H., 547
Alton, K. B., *and Patrick, J. E., high-performance liquid* chromatographic assay for suprofen, a potent new analgesic, in plasma, 985
Amick, E. N., *see* Weddle, O. H., 1033
Amiya, T., *see* Nakano, N. I., 1005
Amos, B., *see* Matin, S. B., 923
Andersen, K.-J., and Schjønsby, H., intrinsic factor-mediated binding of cyanocobalamin to cholestyramine, 1626
Anderson, C. C., see Thompson, E. B., 1476
Ando, H. Y., Ho, N. F. H., Higuchi, W. I., and Shipman, C., Jr., kinetics of drug transport and concurrent metabolism in human cell cultures I: theory, 606
Andrade, J. D., *see* Chen, C. N., 38
Arancibia, A., *see* Barnett, G., 224
Arceneaux, J. H., Kohn, H., Steenberg, M. L., and Buckley, J. P., syntheses and pharmacological activity of *N*-acyl-substituted imidazolidinethiones and thioimidazolines, 600
Armstrong, W., *see* Schultz, J. S., 696
Asher, I., *see* Schwartzman, G., 398
Ashley, J. J., see Ryan, A. J., 306
——*see* Upton, R. A., 310
Ashmore, J. W., *see* Kupchan, S. M., 865
Ast, T. M., *see* Abdou, H. M., 1397
Atkinson, A. J., Jr., *see* Gibson, T. P., 1178
Atkinson, J., *see* Balazs, T., 1355
Attia, I. A., *see* Youssef, M. K., 556
Austin, K. L., and Mather, L. E., simultaneous quantitation of morphine and paraben preservatives in morphine injectables, 1510
Axelson, J. E., *see* Jamali, F., 466
——*see* Tam, Y. K., 1073
——*see Venkataramanan, R., 201*
Ayim, J. S. K., *see* Dwuma-Badu, D., 433
Ayres, J. W., *see* Albert, K. S., 1582
——*see Walker, R. B., 558*
Ayyub, G. E., *see* Bikhazi, A. B., 939
Azarnoff, D. L., *see* Shen, D. D., 916
Azaz, E., *see* Donbrow, M., 1676

B

Baba, S., *see Morishita, S.-I., 757*
Bachman, G. L., Baker, J. W., and Roman, D. P., synthesis and antimicrobial properties of 3-substituted 1,2-benzisothiazole 1,1-dioxides, 1323
Bailey, K., identification of a street drug as *N*-ethyl-*1-phenylcyclohexylamine, a phencyclidine analog,* 885
Bakar, S., and Niazi, S., simplified method to study *stability of pharmaceutical systems,* 141
Baker, J. F., see Peterson, J. E., 1425
Baker, J. W., *see Bachman, G. L., 1323*
Balazs, T., Herman, E., and Atkinson, J., comparison of effects of quinidine and dihydroquinidine on ca*nine heart, 1355*
Balint, L., see Bonevski, R., 1474
Banerjee, S., Basu, P. S., and Mitra, C., inhibition of rat liver mitochondrial monoamine oxidase by chloramphenicol and 2-amino-1-p-nitrophenyl-*propane-1,3-diol, 480*
Banks, W. F., see Peterson, J. E., 1425
Bapatla, K. R., see Ramachander, G., 1326
Bare, J. J., *see Muni, I. A., 289*
Barletta, M. A., Lehr, D., and Guideri, G., hemodynamic alterations in *isoproterenol-induced cardiac ar*rhythmias in corticoid-treated rats, 1390
——Staab, R., Lau Cam, C., and Lynch, V. D., effects *of pharmacological intervention on infarct size* following induced myocardial infarction in rats, 1643
——*see Clair, A. G., 1002*
Barnes, G. T., *see* McGregor, M. A., 364, 1054
Barnett, G., Lockwood, T., Arancibia, A., and Benet, L. Z., ascorbate stimulation of salicylate absorption in isolated rat intestine, 224
Barr, A., *see Van Lear, G. E., 1662*
Barr, M. L., and Kustin, K., interactions between polymyxin B and divalent nickel in near-neutral aqueous media, 1313
Barrett, M. J., DeFries, R., and Henderson, W. M., rapid determination of gold in whole blood of arthritis *patients using flameless* atomic absorption spectrophotometry, 1332
Barth, H., *see* Lakings, D. B., *831*
Bartilucci, A. J., see Madan, P. L., 409
Bartošek, I., Daniel, S., and Sýkora, S., differential *pulse polarographic determination of submicrogram* quantities of carmustine and related compounds in biological samples, 1160
Bass, R. G., *see* Glennon, R. A., 1762
Bassendowski, D. L., *see* Hamon, N. W., 1539
Basu, P. S., *see* Banerjee, S., 480
Basu Chaudhary, K. C., *see* Ghosal, S., 1768
Bates, D. K., *see* Repke, D. B., 1167
Bates, R. T., *see* Owerbach, J., 1250
Baum, R. G., and Cantwell, F. F., determination of salicylic acid and aspirin in multicomponent tablets *by liquid chromatography on a nonionic resin,* 1066
Bayne, W., see Chandrasekaran, S. K., 1370
Belmonte, A. A., and Tsai, W., benzocaine diffusion from polyethylene glycol through human stratum corneum, 517
Bending, M. R., *see* Finch, R. E., 1489
Benet, L. Z., see Barnett, G., 224
——*see* Lee, C. S., 470
——*see* Peck, C. C., 12
Benson, G. A., see Spillane, W. J., 226
Benson, W. R., *see Doherty, R., 1698*
Berman, J. A., *see* Shani, J., 344
Bethke, H., *see* Hartmann, V., 98
Bhalara, D. D., *see Devani, M. B., 661*
Bhargava, H. N., new *in vivo* evidence for narcotic agonistic property of leucine-enkephalin, 136
Bhattacharyya, J., Stagg, D., Mody, N. V., and Miles, D. H., constituents of *Spartina cynosuroides:* isolation and ^{13}C-NMR *analysis of tricin, 1325*
Biehl, E. R., Wooten, R., Kenner, C. T., and Graham, R. E., kinetic and mechanistic studies of blue tet*razolium reaction with phenylhydrazines, 927*
——*see* Graham, R. E., 360, 792
Biener, R., see Gottschalk, L. A., 155
Biggs, J. T., *see Ziegler, V. E., 554*
Bikhazi, A. B., and Ayyub, G. E., kinetics of aggregation of human platelets, 939
Billets, S., *see* Craig, J. C., 483
Biswas, K., see Ghosal, S., 721, 1768
Bivins, B. A., *see Schroeder, H. G., 508*
Blanchard, J., Schwartz, J. A., Byrne, D. M., and Marx, D. B., comparison of two methods for obtaining size distribution characteristics of particulate matter in large-volume parenterals, 340
Blanton, C. D., Jr., *see Briggs, F. H., 735*
Blessel, K. W., *see* Carstensen, J. T., 48, 982
Blickenstaff, R. T., *see* Steinrauf, L. K., 1739
——*see Tao, I. Y. C., 283*
Block, J. H., see Walker, R. B., 558
Blodinger, J., *see Fink, D. W., 837, 1415*
Blomster, R. N., *see* Perdue, G. P., 1322
Blum, M. R., see Chapron, D. J., 1018
Bodor, N., *Roller, R. G., and Selk, S. J., elimination of* a quaternary pyridinium salt delivered as its dihydropyridine derivative from brain of mice, 685
——Sloan, K. B., Kuo, Y.-N., and Higuchi, T., controlled delivery of theophylline: chemistry of 7-acyl- *and 7,7′-acylditheophylline derivatives, 1045*
Boehlert, J. P., *see* Burce, G. L., 424
Bogaert, M. G., see Rosseel, M. T., 802
Bohannon, T. E., *and Wen, L.-F. L., methods for stor*age of antimicrobial effectiveness test inoculum suspensions below freezing, 815
Bonenfant, P. A., *see* Van Lear, G. E., 1662
Bonevski, R., Momirović-Čuljat, J., and Balint, L., inhibition of *epinephrine oxidation in weak alkaline* solutions, 1474
Bonfilio, A. C., see Walkling, W. D., 945
Boone, L., *see Capomacchia, A. C., 1042*
Bopp, B. A., Dren, A. T., Ebert, D. M., and Geiszler, A. O., local anesthetic activity and acute toxicity of *N-heptyl-1, 2, 3, 4-tetrahydro-6-methoxy-1-naphthylamine methanesulfonate, 882*
——*see* Dren, A. T., 880
Borazan, H. N., *see* Al-Ani, N. I., 1381
Born, G. S., see Hinkle, G. H., 795
Bouche, R., Draguet-Brughmans, M., Flandre, J. P., Moreaux, C., and Van Meerssche, M., ketonic oxidation products of cyclobarbital, 1019
Bourne, D. W. A., *see Chungi, V. S., 560*
Boutis, L., *see* Catsoulacos, P., 1342
Bouwsma, O. J., Stewart, J. T., and Capomacchia, A. C., characterization of pharmacologically important prototropic species derived from a pyridinemethanol antimalarial by electronic absorption and fluorescence spectroscopy, 1224
Bowmer, C. J., and Lindup, W. E., Scatchard plots with a positive slope and role of albumin concentration, 1193

Boykin, D. W., Jr., *see* Davidson, M. W., 737
Bracci, A., *see* Finkelstein, E., 1447
Bracke, M., *see* Demeester, J., 729
Brannon, J. L., *see* Hirsch, C. A., 231
Brannon, W., *see* Schwartzman, G., 398
Braun, J., *see* Vinh, C. T., 731
Breon, T. L., Petersen, H., Jr., and Paruta, A. N., three-dimensional molecular illustrations I: isoelectron density contours and isoelectrostatic energy contours, 67
——Petersen, H., Jr., and Paruta, A. N., three-dimensional molecular illustrations II: isoelectrostatic energy contour spheres of influence applied to narcotic molecules, 73
Breuer, A., *see* Segal, R., 1169
Briggs, F. H., Pelletier, W. T., and Blanton, C. D., Jr., pyrrole, furan, and thiophene oxamates as potential antiallergy agents, 735
Briley, M. R., *see* Otani, T. T., 520
Brochmann-Hanssen, E., and Wunderly, S. W., biosynthesis of morphine alkaloids in *Papaver bracteatum* Lindl., 103
Brooks, D. T., *see* Ludden, T. M., 371
Brooks, M. A., *see* Hackman, M. R., 842
Browder, H. P., *see* Weaver, F. A., 1009
Brown, L. W., high-pressure liquid chromatographic assays for clindamycin, clindamycin phosphate, and clindamycin palmitate, 1254
——high-pressure liquid chromatographic determination of cycloheximide in ointment and suspension formulations, 669
Brown, R. D., and Manno, J. E., ESTRIP, a basic computer program for obtaining initial polyexponential parameter estimates, 1687
Bruce, R. B., *see* Maynard, W. R., 1753
Brynes, S., Fiorina, V. J., Cooney, D. A., and Milman, H. A., potential antitumor agents *via* inhibitors of L-asparagine synthetase: substituted sulfonamides and sulfonyl hydrazides related to glutamine, 1550
Buckley, J. P., *see* Arceneaux, J. H., 600
Buice, R. G., *see* Calvert, R. T., 205
Bult, A., and Klasen, H. B., structures of silver sulfonamides, 284
Buogo, A., and Cattaneo, P., inhibition by paromomycin of R-factor transfer of tetracycline resistance between *Escherichia coli* and *Salmonella pullorum*, 35
Burce, G. L., and Boehlert, J. P., separation and quantitation of possible degradation products of procarbazine hydrochloride in its dosage form, 424
Burke, D. H., cobaltous chloride-induced hypothermia in mice I: effect of pretreatment with anticholinergic drugs, 799
Burns, H. D., Sowa, D. T., and Marzilli, L. G., improved synthesis of *N*-(2,6-dimethylphenylcarbamoylmethyl)iminodiacetic acid and analogs, 1434
Burns, L. B., Stedman, R. J., and Tuckerman, M. M., polynitro aromatic compounds in analytical chemistry II: reaction of menadione with 2,4-dinitrophenylhydrazine, 258
Burrous, S. E., *see* Snyder, H. R., Jr., 413
Bush, J. H., *see* Fujii, A., 713
Butler, L. D., *see* Dakkuri, A., 357
Butterfield, A. G., Cooper, J. K., and Midha, K. K., simultaneous determination of procainamide and *N*-acetylprocainamide in plasma by high-performance liquid chromatography, 839
——Lovering, E. G., and Sears, R. W., simultaneous determination of reserpine and hydrochlorothiazide in two-component tablet formulations by high-performance liquid chromatography, 650
Byrn, S. R., and Dolch, G. D., analysis of binding of daunorubicin and doxorubicin to DNA using computerized curve-fitting procedures, 688
Byrne, D. M., *see* Blanchard, J., 340

C

Cadwallader, D. E., *see* Underwood, F. L., 1163
Caldwell, J. H., Thomford, N. R., and Kakumoto, Y., assessment of enterohepatic circulation of ^{3}H-digoxin with a minimal interruption technique, 415
Calvert, R. T., Hulshoff, A., Buice, R. G., and Kostenbauder, H. B., bilirubin dynamics in the the Gunn rat during phototherapy, 205
Cannon, J. G., *see* Sharabi, F. M., 1639
Cantwell, F. F., *see* Baum, R. G., 1066
Capomacchia, A. C., and Schulman, S. G., binding of 3-aminoacridinium and 7-aminoquinolinium monocations to double-stranded DNA: evidence for nonlinear binding isotherm in intercalative region, 89
——Vallner, J. J., and Boone, L., aggregation of dantrolene to human serum albumin, 1042
——*see* Bouwsma, O. J., 1224
Cardinal, J. R., Chang, Y., and Ivanson, D. D., solubilization of naphthalene by sodium cholate and pattern of self-association of sodium cholate in 0.15 *M* sodium chloride, 854
——*see* Chang, Y., 174, 994
——*see* Zentner, G. M., 1347, 1352
Carlotti, M. E., *see* Gasco, M. R., 168
Carney, C. F., *see* Hurwitz, A. R., 138
Carstensen, J. T., Lai, T. Y.-F., and Prasad, V. K., USP dissolution IV: comparison of methods, 1303
——Wright, J. L., Blessel, K. W., and Sheridan, J., USP dissolution test II: sigmoid dissolution profiles from directly compressed tablets, 48
——Wright, J. L., Blessel, K., and Sheridan, J., USP dissolution III: semilogarithmic dissolution patterns of tablets in rotating-basket assemblies, 982
——*see* Mehta, A., 905
——*see* Streng, W. H., 384
Catsoulacos, P., Politis, D., Boutis, L., and Papageorgiou, A., new compounds: antitumor activity of 3β-hydroxy -13α- amino-13,17 -seco-5α- androstan-17-oic-13,17-lactam 4-[*p*-[bis(2-chloroethyl)amino]phenyl]butyrate, 1342
Cattaneo, P., *see* Buogo, A., 35
Caudal, F., *see* Sioufi, A., 243
Cavagnol, J. C., *see* Meyer, M. C., 1659
Cavanaugh, M. H., *see* Wolshin, E. M., 1692
Chabot, M., *see* Huynh-Ngoc, T., 1456
Chainey, M. G., *see* Munro, A. C., 1197
Chakrabarti, D. K., *see* Ghosal, S., 1768
Chan, K. K., and Watson, E., GLC–mass spectrometry of several important anticancer drugs II: doxorubicin and daunorubicin aglycone analogs, 1748
——*see* Watson, E., 1243
Chan, P. S., *see* Warren, J. D., 1479
Chan, Y.-L., *see* Cohen, J. L., 1093
Chan, U.-M., *see* El-Feraly, F. S., 347
Chandler, R. F., *see* Hooper, S. N., 1157
Chandrasekaran, S. K., Bayne, W., and Shaw, J. E., pharmacokinetics of drug permeation through human skin, 1370
Chang, S. Y., Alberts, D. S., Farquhar, D., Melnick, L. R., Walson, P. D., and Salmon, S. E., hydrolysis and protein binding of melphalan, 682
——Alberts, D. S., Melnick, L. R., Walson, P. D., and Salmon, S. E., high-pressure liquid chromatographic analysis of melphalan in plasma, 679
Chang, Y., and Cardinal, J. R., light-scattering studies on bile acid salts I: pattern of self-association of sodium cholate, sodium glycocholate, and sodium taurocholate in aqueous electrolyte solutions, 174
——and Cardinal, J. R., light-scattering studies on bile acid salts II: pattern of self-association of sodium deoxycholate, sodium taurodeoxycholate, and sodium glycodeoxycholate in aqueous electrolyte solutions, 994
——*see* Cardinal, J. R., 854
Chao, G. C., *see* Stoll, R. G., 1328
Chapron, D. J., Blum, M. R., and Kramer, P. A., evidence for a trimodal pattern of acetylation of isoniazid in uremic subjects, 1018
Charette, C., *see* Hubbard, J. W., 1571
——*see* Midha, K. K., 975
Chatterji, D. C., and Gallelli, J. F., thermal and photolytic decomposition of methotrexate in aqueous solutions, 526
——Frazier, A. G., and Gallelli, J. F., identification and quantitation of impurities in methotrexate, 622
——Greene, R. F., and Gallelli, J. F., mechanism of hydrolysis of halogenated nitrosoureas, 1527
Chaturvedi, A. K., Rowell, P. P., and Sastry, B. V. R., relationships between chemical structure and inhibition of human placental choline acetyltransferase by keto analogs of acetylcholine, 657
Chaudhari, A., *see* Chaudhary, S. K., 1507
Chaudhary, M., *see* Chaudhary, S. K., 987, 1507
Chaudhary, S. K., Chaudhary, M., Chaudhari, A., and Parmar, S. S., anticonvulsant and antiproteolytic properties of 3,5-disubstituted oxadiazole-2-thiones and their inhibition of respiration in rat brain homogenates, 1507
——Kumar, S., Parmar, S. S., and Chaudhary, M., anticonvulsant and antiproteolytic properties of 2,5-disubstituted oxadiazoles and their inhibition of respiration in rat brain homogenates, 987
Chaudhuri, R. K., Zymalkowski, F., and Ghosal, S., selective demethylation of polymethoxyxanthones with aqueous piperidine, 1321
——*see* Ghosal, S., 721
Chen, C. N., Coleman, D. L., Andrade, J. D., and Temple, A. R., pharmacokinetic model for salicylate in cerebrospinal fluid, blood, organs, or tissues, 38
Chen, C. P., *see* Darling, C. M., 860
Cheng, C., *see* Cohen, J. L., 1093
Cheung, A., *see* Culcasi, M., 1190
——*see* Jee, J., 438
Chheda, G. B., *see* Hong, C. I., 569
Chiang, C.-W., Fuller, G. C., Frankenfeld, J. W., and Rhodes, C. T., potential of liquid membranes for drug overdose treatment: *in vitro* studies, 63
Chib, J. S., Stempien, M. F., Jr., Mierzwa, R. A., Ruggieri, G. D., and Nigrelli, R. F., physiologically active substances from marine sponges V: isolation of physiologically active compounds from the sponge *Verongia archeri*, 264
Chiccarelli, F. S., *see* Van Lear, G. E., 1662
Chien, Y. W., Rozek, L. F., and Lambert, H. J., microsealed drug delivery systems I: *in vitro–in vivo* correlation on subcutaneous release of desoxycorticosterone acetate and prolonged hypertensive animal model for cardiovascular studies, 214
——*see* Lee, H. K., 847
Chimirri, A., *see* Fenech, G., 1432
Chiou, C. Y., treatment of neuroblastoma in mice with bromoacetylcholine and bromoacetate, 331
——*see* Trzeciakowski, J., 531
Chiou, W. L., simplified derivation of Chiou-Hsu equation for rapid estimation of total body drug clearance during constant-rate intravenous infusion, 1776
——Gadalla, M. A. F., and Peng, G. W., simple, rapid, and micro high-pressure liquid chromatographic determination of endogenous "true" creatinine in plasma, serum, and urine, 182
——Peng, G. W., Gadalla, M. A. F., and Nerenberg, S. T., comparison of plasma creatinine levels in patients determined by high-pressure liquid chromatography, automated analysis, and boiling alkaline picrate method, 292
——*see* Gadalla, M. A. F., 869
——*see* Nation, R. L., 805
——*see* Peng, G. W., 710, 1036
——*see* Slonek, J. E., 1462
Cho, M. J., *see* Frank, S. G., 1665
——*see* Fung, H.-L., 971
Choudhari, S. R., *see* Thakar, K. A., 587
Chowhan, Z. T., pH–solubility profiles of organic carboxylic acids and their salts, 1257
——and Palagyi, L., hardness increase induced by partial moisture loss in compressed tablets and its effect on *in vitro* dissolution, 1385
——and Pritchard, R., effect of surfactants on percutaneous absorption of naproxen I: comparisons of rabbit, rat, and human excised skin, 1272
——Pritchard, R., Rooks, W. H., II, and Tomolonis, A., effect of surfactants on percutaneous absorption of naproxen II: *in vivo* and *in vitro* correlations in rats, 1645
Chu, S.-Y., high-pressure liquid chromatographic determination of 8-hydroxycarteolol in plasma and urine using electrochemical detection, 1623
Chun, A. H. C., *see* Doluisio, J. T., 1586
Chungi, V. S., Bourne, D. W. A., and Dittert, L. W., drug absorption VIII: kinetics of GI absorption of methotrexate, 560
Cioffi, F. J., *see* Abdou, H. M., 1397
Claeys, M., *see* Rosseel, M. T., 802

Clair, A. G., and Barletta, M. A., modified technique using perfused isolated guinea pig lung to determine effect of an aerosol constituent on pulmonary dynamics, 1002
Clark, M. L., *see* Kaul, P. N., 60
Clarke, D. D., *see* Gershon, H., 715
Clemans, S., *see* Peterson, J. E., 1425
Cocuzza, E., *see* De Simone, R., 1695
Cohen, A. I., *see* Funke, P. T., 653
——*see* Puar, M. S., 850
Cohen, J., *see* Mollica, J. A., 443
Cohen, J. L., Cheng, C., Henry, J. P., and Chan, Y.-L., GLC determination of caffeine in plasma using alkali flame detection, 1093
Cohn, L. B., *see* Meyer, R. C., 1636
Colaizzi, J. L., *see* Goehl, T. J., 404
——*see* Strum, J. D., 568, 1399
Colburn, W. A., absorption of saccharin from rat urinary bladder, 1493
——and Gibaldi, M., plasma protein binding of diazepam after a single dose of sodium oleate, 891
——and Gibaldi, M., use of MULTDOS for pharmacokinetic analysis of ethosuximide data during repetitive administration of single or divided daily doses, 574
Cole, J. R., *see* Hoffmann, J. J., 1633
Coleman, D. L., *see* Chen, C. N., 38
Commarato, M. A., *see* Kaplan, H. R., 132
Comstock, T. J., *see* Kates, R. E., 269
Conti, F., *see* De Simone, R., 1695
Cook, E. S., *see* Fujii, A., 713
Cook, J. R., *see* Unger, S. H., 1364
Cooke, G. C., *see* Kossoy, A. D., 722
Cooney, D. A., *see* Brynes, S., 1550
Cooney, D. O., *in vitro* evidence for ipecac inactivation by activated charcoal, 426
——*see* Daly, J. S., 1181
Cooper, J. K., *see* Butterfield, A. G., 839
——*see* Hubbard, J. W., 1563, 1571
——*see* Midha, K. K., 279
Cotellessa, L., *see* Marcucci, F., 1470
Cox, B., *see* Steinrauf, L. K., 1739
Cox, J. S. G., *see* Woodard, G. D., 1403
Cradock, J. C., *see* Rahman, A., 611
Craig, J. C., Waller, C. W., Billets, S., and Elsohly, M. A., new GLC analysis of urushiol congeners in different plant parts of poison ivy, *Toxicodendron radicans*, 483
Craig, W. A., *see* Welling, P. G., 1057
Cramer, M. B., *see* Lemke, T. L., 1377
Creaven, P. J., *see* Pelsor, F. R., 1106
Cressman, W. A., *see* Walkling, W. D., 948
Crouthamel, W. G., *see* Day, S. T., 1518
Culcasi, M., Cheung, A., Shingai, E., Jee, J., and Lim, P., determinations of amygdalinamide, amygdalin acid, and 2-propanol in amygdalin dosage forms from Mexico, 1190
Cunningham, R. F., Israili, Z. H., and Dayton, P. G., new spectrophotofluorometric assay for probenecid, 434
Cutie, A., *see* Sciarra, J. J., 1428

D

Daabis, N. A., *see* El-Banna, H. M., 1631
Dakkuri, A., Butler, L. D., and DeLuca, P. P., sustained release from inert wax matrixes III: effect of povidone on tripelennamine hydrochloride release, 357
——Schroeder, H. G., and DeLuca, P. P., sustained release from inert wax matrixes II: effect of surfactants on tripelennamine hydrochloride release, 354
——*see* Schroeder, H. G., 350
Daly, J. S., and Cooney, D. O., omission of pepsin from simulated gastric fluid in evaluating activated charcoals as antidotes, 1181
Daniel, S., *see* Bartošek, I., 1160
D'Arconte, L., *see* de Silva, J. A. F., 752
Darling, C. M., and Chen, C. P., rearrangement of *N*-benzyl-2-cyano-2-(hydroxyimino)acetamide, 860
Daver, J., *see* Garrett, E. R., 145
Davidson, M. W., and Boykin, D. W., Jr., synthesis of *as*-triazines as potential antiviral agents, 737
Davignon, J. P., *see* Rahman, A., 611
Davila, I., *see* Ludden, T. M., 371
Davis, C. S., *see* Schwan, T. J., 1022
Davis, I., *see* Garceau, Y., 826, 1360
Day, J. L., Tterlikkis, L., Niemann, R., Mobley, A., and Spikes, C., assay of mercaptopurine in plasma using paired-ion high-performance liquid chromatography, 1027
Day, S. T., Crouthamel, W. G., Martinelli, L. C., and Ma, J. K. H., mechanism of fluorometric analysis of tetracycline involving metal complexation, 1518
Dayton, P. G., *see* Cunningham, R. F., 434
De, K. K., *see* Shiau, G. T., 394
De Fabrizio, F., separation and spectrophotometric determination of theophylline and hydroxyethyltheophylline in a pharmaceutical syrup, 572
DeFries, R., *see* Barrett, M. J., 1332
De Groote, A. M. C., *see* Neumann, M. G., 1283
De Leenheer, A. P., and Gelijkens, C. F., GLC determination of floxuridine in plasma using a thermionic nitrogen detector, 417
DeLong, A. F., Polk, A., Martin, G., Smyth, R. D., and Reavey-Cantwell, N. H., GLC assay of fenclorac in human plasma, 1171
DeLuca, P. P., *see* Dakkuri, A., 354, 357
——*see* Schroeder, H. G., 350, 504, 508
Demeester, J., Bracke, M., Vochten, R., and Lauwers, A., differential spectrophotometric determination of tyrosine and tryptophan in pharmaceutical amino acid solutions, 729
Dennis, M., *see* Vaughan, D. P., 663
de Oliveira, M. M., Linardi, M. C. F., and Sampaio, M. R. P., effects of quinone derivatives on an experimental tumor, 562
Der Marderosian, A., *see* Liberti, L. E., 1487
DeSante, K. A., *see* Albert, K. S., 1579, 1582
DeSantis, L. M., and Schoenwald, R. D., lack of influence of rabbit nictitating membrane on miosis effect of pilocarpine, 1189
——*see* Schoenwald, R. D., 1280
de Silva, J. A. F., Munno, N., D'Arconte, L., and Strojny, N., spectrofluorometric determination of alkoxy-substituted benzylimidazolidinones in biological fluids, 752
De Simone, R., Conti, F., Lovati, M. R., Sirtori, M., Cocuzza, E., and Sirtori, C. R., new microporous cholestyramine analog for treatment of hypercholesterolemia, 1695
Deslauriers, R., Hasan, F., Lodge, B. A., and Smith, I. C. P., assignment by ^{13}C-NMR spectroscopy of configuration at C-5 in 17α-ethylestran-17β-ol, an impurity in the anabolic steroid ethylestrenol, 1187
Desnoyers, P., *see* Garrett, E. R., 145
Devani, M. B., Shishoo, C. J., Patel, M. A., and Bhalara, D. D., spectrophotometric determination of isoniazid in presence of its hydrazones, 661
de Vos, D., *see* Driessen, O., 1494
Dewey, R., *see* Hwang, B., 1095
DeYoung, J. L., Tan, H. G. H., Huber, H. E., and Zoglio, M. A., effect of ionization on absorption of cephalosporins, 320
Diana, F., *see* Hanna, S., 1723
Di Carlo, F. J., *see* Leinweber, F.-J., 129
——*see* Zuleski, F. R., 1138
Digenis, G. A., *see* Martin, G. E., 110
Dimmock, J. R., Kowal, D. K., Turner, W. A., Smith, P. J., Noble, L. M., and Pannekoek, W. J., synthesis of diastereoisomeric 4-dimethylamino-3-phenyl-2-butanols and related esters for antimicrobial evaluation, 401
——Nyathi, C. B., and Smith, P. J., synthesis and evaluation of 1-(hydroxyphenyl)-1-nonen-3-ones and related compounds for antineoplastic and antimicrobial activities, 1543
——Smith, P. J., Noble, L. M., and Pannekoek, W. J., synthesis of oximes, aziridines, and allyl alcohols derived from substituted 1-phenyl-1-nonen-3-ones as potential cytotoxic and antitumor agents, 1536
——*see* Hamon, N. W., 1539
Dinovo, E., *see* Gottschalk, L. A., 155
Di Paolo, T., molecular connectivity in quantitative structure–activity relationship study of anesthetic and toxic activity of aliphatic hydrocarbons, ethers, and ketones, 566
——structure–activity relationships of anesthetic ethers using molecular connectivity, 564
DiSanto, A. R., *see* Albert, K. S., 1579, 1582
Dittert, L. W., *see* Chungi, V. S., 560
——*see* Doluisio, J. T., 1586
Dix, R. K., *see* Walkling, W. D., 948
Djokić, S., *see* Lazarevski, T., 1031
Doherty, R., Benson, W. R., Maienthal, M., and Stewart, J. McD., crystal and molecular structure of equinidine, 1698
Dolch, G. D., *see* Byrn, S. R., 688
Doluisio, J. T., Smith, R. B., Chun, A. H. C., and Dittert, L. W., pentobarbital absorption from capsules and suppositories in humans, 1586
——*see* Yakatan, G. J., 252
Donahue, J., *see* Rucki, R., 1297
Donbrow, M., and Touitou, E., estimation of dissolution rate of salicylamide in complexing media using a theoretical diffusion model, 95
——Azaz, E., and Pillersdorf, A., autoxidation of polysorbates, 1676
Draguet-Brughmans, M., *see* Bouche, R., 1019
Dren, A. T., Bopp, B. A., Ebert, D. M., Geiszler, A. O., Holland, J. B., Horrom, B. W., and Dunnigan, D. A., local anesthetic activity and acute toxicity of *N*-substituted 1,2,3,4-tetrahydro-1- and 2-naphthylamines, 880
——*see* Bopp, B. A., 882
Driessen, O., de Vos, D., and Timmermans, P. J. A., adsorption of fluorouracil on glass surfaces, 1494
Driscoll, J. S., *see* Hirata, T., 157
Dunnigan, D. A., *see* Dren, A. T., 880
du Soulch, P., *see* Laika, D., 591
Dwuma-Badu, D., Ayim, J. S. K., Fiagbe, N. I. Y., Knapp, J. E., Schiff, P. L., Jr., and Slatkin, D. J., constituents of West African medicinal plants XX: quindoline from *Cryptolepis sanguinolenta*, 433

E

Ebersole, J. W., *see* Strum, J. D., 568
Ebert, D. M., *see* Bopp, B. A., 882
——*see* Dren, A. T., 880
Edelson, J., *see* Lee, F. H., 1038
——*see* Peterson, J. E., 1425
Eisenberger, P., *see* Hanna, S., 84
Ekman, B., and Sjöholm, I., improved stability of proteins immobilized in microparticles prepared by a modified emulsion polymerization technique, 693
Ekman, B., *see* Kober, A., 107
Eksborg, S., extraction of daunorubicin and doxorubicin and their hydroxyl metabolites: self-association in aqueous solution, 782
El-Banna, H. M., solid dispersion of pharmaceutical ternary systems I: phase diagram of aspirin–acetaminophen–urea system, 1109
——Daabis, N. A., and El-Fattah, S. A., aspirin stability in solid dispersion binary systems, 1631
——Khalil, S. A., and Gouda, M. W., solid dispersion of pharmaceutical ternary systems II: dissolution studies on aspirin–acetaminophen–urea system, 1112
El Falaha, B., *see* Toama, M. A., 23
El Fatatry, H. M., *see* Toama, M. A., 23
El-Fattah, S. A., *see* El-Banna, H. M., 1631
El-Feraly, F. S., and Chan, Y.-M., isolation and characterization of the sesquiterpene lactones costunolide, parthenolide, costunolide diepoxide, santamarine, and reynosin from *Magnolia grandiflora* L., 347
Elgebaly, S. A., *see* Hall, I. H., 552, 1232, 1235
El-Masry, S., *see* Khalil, S. A. H., 1358
Elnenaey, E. A., *see* Soliman, F. S. G., 411
El-Rabbat, N. A., and Omar, N. M., colorimetric determination of catecholamines by 2,3,5-triphenyltetrazolium chloride, 779
El-Rashidy, R., and Niazi, S., binding of butylated hydroxyanisole to human albumin using a novel dynamic method, 967
Elsohly, M. A., Turner, C. E., Phoebe, C. H., Jr., Knapp, J. E., Schiff, P. L., Jr., and Slatkin, D. J., anhydrocannabisativine, a new alkaloid from *Cannabis sativa* L., 124
——*see* Craig, J. C., 483
El-Yazbi, F. A., *see* Wahbi, A. M., 140

Emele, J. F., *see* Ramachander, G., 761, 1326
Evans, B. K., James, K. C., and Luscombe, D. K., quantitative structure–activity relationships and carminative activity, 277

F

Farquhar, D., *see* Chang, S. Y., 682
Farrokhsiar, M., *see* Shafiee, A., 125
Fawzi, A. B., *see* Maghssoudi, R. H., 32
Feldman, S., *see* Ravis, W. R., 245
Fell, J. T., *see* Lerk, C. F., 935
Fenech, G., Chimirri, A., and Ficarra, R., thiazole derivatives as potential chemotherapeutic agents: homolytic arylation of thiazole with phenylazotriphenylmethane, 1432
Ferguson, W. J., *see* Repke, D. B., 1167
Fernández, J., *see* Monge, A., 1025
Fiagbe, N. I. Y., *see* Dwuma-Badu, D., 433
Ficarra R., *see* Fenech, G., 1432
Finch, R. E., Bending, M. R., and Lant, A. F., use of a nitrogen detector for GLC determination of fluorouracil in plasma during single- and combined-agent chemotherapy, 1489
Fink, D. W., Fink, H. C., Tolan, J. W., and Blodinger, J., difference spectrophotometric determination of *p*-hydroxybenzoic acid in presence of its esters, 837
——Martin, R. P., and Blodinger, J., facile separation of sulfonamides from their degradates by liquid–liquid extraction, 1415
Fink, H. C., *see* Fink, D. W., 837
Finkel, J. M., and Hill, D. L., fluorometric assay for measuring biological half-life of coralyne sulfoacetate in dogs and monkeys, 1331
Finkelstein, E., Quintiliani, R., Lee, R., Bracci, A., and Nightingale, C. H., pharmacokinetics of oral cephalosporins: cephradine and cephalexin, 1447
Fiorina, V. J., *see* Brynes, S., 1550
Fixley, M., *see* Shen, D. D., 916
Flanagan, D. R., *see* Schneider, H., 1620
Flandre, J. P., *see* Bouche, R., 1019
Flaum, I., contamination of pharmaceutical products, 1
Folen, V., *see* Schwartzman, G., 398
Fong, B. C., *see* Gangarosa, L. P., 1439
Foster, E., *see* Steinrauf, L. K., 1739
Foster, E. L., synthesis and antitumor evaluation of 4-ethoxycarbonyl cyclophosphamide analogs, 709
Foster, R., Hyde, R. M., and Livingstone, D. J., substituent constant for drug design studies based on properties of organic electron donor–acceptor complexes, 1310
Fox, G. G., *see* Maynard, W. R., 1753
Foye, W. O., Lee, Y. J., Shah, K. A., and Kauffman, J. M., pyridinium- and quinolinium-2-dithioacetic acid zwitterions: antiradiation and anticancer activities, 962
Frank, S. G., and Cho, M. J., phase solubility analysis and PMR study of complexing behavior of dinoprostone with β-cyclodextrin in water, 1665
Frankenfeld, J. W., *see* Chiang, C.-W., 63
Fratis, A., *see* Mroszczak, E. J., 920
Frazier, A. G., *see* Chatterji, D. C., 622
Freedman, R., *see* Alaimo, R. J., 281
——*see* Snyder, H. R., Jr., 413
Friedel, R. C., *see* Jenkins, R. G., 17
Frome, E. L., *see* Yakatan, G. J., 252
Fujii, A., Shores, K. E., Buch, J. H., Garascia, R. J., and Cook, E. S., comparison of stationary phases in reversed-phase TLC for correlation between structure and biological response of probiotics, 713
Fujimoto, Y., *see* Nakano, N. I., 1005
Fuller, G. C., *see* Chiang, C.-W., 63
Fung, H.-L., and Cho, M. J., molecular interaction between E-prostaglandins and selected polymers and its potential utilization in oral dosage form design, 971
——*see* Horhota, S. T., 267, 1345
——see Yap, P. S. K., 582, 584
Funke, P. T., Malley, M. F., Ivashkiv, E., and Cohen, A. I., determination of serum nadolol levels by GLC–selected ion monitoring mass spectrometry: comparison with a spectrofluorometric method, 653
——*see* Puar, M. S., 850
Fusari, S. A., *see* Holcomb, I. J., 1099

G

Gadalla, M. A. F., Peng, G. W., and Chiou, W. L., rapid and micro high-pressure liquid chromatographic method for simultaneous determination of procainamide and *N*-acetylprocainamide in plasma, 869
——*see* Chiou, W. L., 182, 292
——*see* Peng, G. W., 710, 1036
Gaines, K., *see* Pikal, M. J., 767
Gallelli, J. F., *see* Chatterji, D. C., 526, 622, 1527
Galpin, D. R., Kandeel, E. M., and Martin, A. R., substituted tetralins VI: tentative assignment of absolute stereochemistry of 1-methyl-1-phenyl-1,2,3,4-tetrahydro-3-naphthoic acid and *N,N,*1-trimethyl-1-phenyl-1,2,3,4-tetrahydro-3-naphthylamine isomers, 1367
Gangarosa, L. P., Park, N. H., Fong, B. C., Scott, D. F., and Hill, J. M., conductivity of drugs used for iontophoresis, 1439
Gangjee, A., Hogenkamp, H. P. C., and Kitzen, J. M., vasodilator activity of adenosine analogs, 121
Garascia, R. J., *see* Fujii, A., 713
Garceau, Y., Davis, I., and Hasegawa, J., fluorometric TLC determination of free and conjugated propranolol, naphthoxylactic acid, and *p*-hydroxypropranolol in human plasma and urine, 826
——Davis, I., and Hasegawa, J., plasma propranolol levels in beagle dogs after administration of propranolol hemisuccinate ester, 1360
Garrett, E. R., and Gürkan, T., pharmacokinetics of morphine and its surrogates I: comparisons of sensitive assays of morphine in biological fluids and application to morphine pharmacokinetics in the dog, 1512
——Daver, J., Desnoyers, P., Kosser, M., and Vincent M., kinetics of plasma coagulation and lysis I: basic kinetic model for time course of coagulation–lysis systems and its potential application to clinical studies, 145
——Gouyette, A. J., and Roseboom, H., stability of tetrahydrocannabinols II, 27
Garth, M. A., *see* Tarcza, E., 1050
Gasco, M. R., and Carlotti, M. E., kinetics and mechanism of oxidation of promazine and promethazine by ferric perchlorate, 168
Gautieri, R. F., *see* Mitala, J. J., 377
Gaylord, J., *see* Weinstein, S. H., 547
Geiszler, A. O., *see* Bopp, B. A., 882
——*see* Dren, A. T., 880
Gelbke, H. P., and Schlicht, H. J., formation of thermally stable derivatives of chlordiazepoxide and its desmethyl metabolite for GLC, 1176
Gelijkens, C. F., *see* De Leenheer, A. P., 417
Geneidi, A. S., Ali, A. A., and Salama, R. B., solid dispersions of nitrofurantoin, ethotoin, and coumarin with polyethylene glycol 6000 and their coprecipitates with povidone 25,000, 114
Genua, I., *see* Monge, A., 1025
Gerhart, B. B., *see* Kingston, D. G. I., 249
Gershon, H., and Shanks, L., antifungal properties of halofumarate esters, 578
——Shanks, L., and Clarke, D. D., amino acid analogs IV: 4-fluoroisoleucine, 715
Ghanekar, A. G., and Gupta, V. D., applications of paired ion high-pressure liquid chromatography to catecholamines and phenylephrine, 1247
——and Gupta, V. D., quantitative determinations of two decongestants and an antihistamine in combination using paired ion high-pressure liquid chromatography, 873
——Gupta, V. D., and Gibbs, C. W., Jr., stability of furosemide in aqueous systems, 808
——*see* Gupta, V. D., 889
Ghirardi, P., *see* Marcucci, F., 1470
Ghosal, S., Biswas, K., and Chaudhuri, R. K., chemical constituents of Gentianaceae XXIV: anti-*Mycobacterium* tuberculosis activity of naturally occurring xanthones and synthetic analogs, 721
——Biswas, K., Srivastava, R. S., Chakrabarti, D. K., and Basu Chaudhary, K. C., toxic substances produced by *Fusarium* V: occurrence of zearalenone, diacetoxyscirpenol, and T-2 toxin in moldy corn infected with *Fusarium moniliforme* Sheld., 1768
——Sharma, P. V., and Jaiswal, D. K., chemical constituents of Gentianaceae XXIII: tetraoxygenated and pentaoxygenated xanthones and xanthone *O*-glucosides of *Swertia angustifolia* Buch.-Ham., 55
——*see* Chaudhuri, R. K., 1321
Gibaldi, M., *see* Colburn, W. A., 574, 891
——*see* Lalka, D., 591
Gibbs, C. W., Jr., *see* Ghanekar, A. G., 808
Gibson, T. P., and Atkinson, A. J., Jr., effect of changes in intercompartment rate constants on drug removal during hemoperfusion, 1178
Giles, H. G., *see* Khouw, V., 1329
Gillette, J. R., *see* Pang, K. S., 703
Gilroy, M. L., *see* Yung, D. K., 900
Girgis, E. H., *see* Abu-Shady, H., 618
Gladigau, V., *see* Hengy, H., 1765
Glamkowski, E. J., Reitano, P. A., and Woodward, D. L., synthesis and evaluation of 3-substituted 1-[4-(2-indol-3-ylethyl)piperazinyl]ureas as potential antihypertensive agents, 1773
Glennon, R. A., Rogers, M. E., Bass, R. G., and Ryan, S. B., mesoionic xanthine analogs as inhibitors of cyclic AMP phosphodiesterase, 1762
Goehl, T. J., Mathur, L. K., Strum, J. D., Jaffe, J. M., Pitlick, W. H., Shah, V. P., Poust, R. I., and Colaizzi, J. L., simple high-pressure liquid chromatographic determination of trisulfapyrimidines in human serum, 404
——*see* Strum, J. D., 1399
Goldenberg, M. M., *see* Alaimo, R. J., 1183
——*see* Schwan, T. J., 548, 718
Goldreyer, B. N., *see* Ludden, T. M., 371
Gomeni, R., *see* Marcucci, F., 705
Gomez, R., *see* Philip, C. E., 1752
Gonzalez, E. M., *see* Squella, J. A., 1466
Gorodetzky, C. M., *see* Yeh, S. Y., 878
Goswami, D. D., *see* Thakar, K. A., 587
Gottschalk, L. A., Dinovo, E., Biener, R., and Nandi, B. R., plasma concentrations of thioridazine metabolites and ECG abnormalities, 155
Gouda, M. W., *see* El-Banna, H. M., 1112
——*see* Naggar, V. F., 1029
Gouyette, A. J., *see* Garrett, E. R., 27
Graham, R. E., Biehl, E. R., and Kenner, C. T., analysis of betamethasone and its organic esters in pharmaceutical products, 360
——Biehl, E. R., and Kenner, C. T., rapid blue tetrazolium procedure for analysis of corticosteroids in pharmaceutical preparations, 792
——*see* Biehl, E. R., 927
Gray, J. E., *see* Schwan, T. J., 863
Grebow, P. E., Treitman, J. A., Yeung, A. K., fluorometric assay for urinary indapamide, 1117
Greenberg, A. J., and Ketcham, R., determination of urinary indolic metabolites, 478
Greenblatt, D. J., determination of desmethyldiazepam in plasma by electron-capture GLC: application to pharmacokinetic studies of clorazepate, 427
Greene, D. S., Quintiliani, R., and Nightingale, C. H., physiological perfusion model for cephalosporin antibiotics I: model selection based on blood drug concentrations, 191
Greene, R. F., see Chatterji, D. C., 1527
Griggs, S. C., and King, J. A., synthesis and preliminary anti-inflammatory evaluation of 17β-amino-3β-methoxy-5-androstene hydrochloride and related derivatives, 1215
Grisafe, J. A., and Hayton, W. L., effects of short and medium chain fatty acids on absorption of lipophilic drugs from perfused rat intestine, 1211
——and Hayton, W. L., intestinal absorption of griseofulvin from a triolein digestion mixture in rats, 895
Guideri, G., *see* Barletta, M. A., 1390
Gupta, S. P., *see* Singh, P., 706
Gupta, V. D., effect of vehicles and other active ingredients on stability of hydrocortisone, 299
——modified NF method for quantitative determination of pentaerythritol tetranitrate, 717
——and Ghanekar, A. G., stability-indicating methods for quantitative determination of spironolactone using high-pressure liquid chromatography and blue tetrazolium reaction, 889

——*see* Ghanekar, A. G., 808, 873, 1247
Gürkan, T., *see* Garrett, E. R., 1512
Guttman, D. E., *see* Ravin, L. J., 1523
Guvenir, L., *see* Himmelstein, K. J., 603

H

Hackman, M. R., and Brooks, M. A., noninvasive polarographic measurement of drug dissolution, 842
Hadzija, B. W., and Mattocks, A. M., quantitative TLC determination of propranolol in human plasma, 1307
Haegele, K. D., *see* Ludden, T. M., 371
Hagel, R. B., *see* Philip, C. E., 1752
Haggerty, W. J., *see* Lakings, D. B., 831
Hainsworth, F. T., III, *see* Oliveri-Vigh, S., 1035
Hall, I. H., Lee, K.-H., and ElGebaly, S. A., antitumor agents XXIX: effects of eupahyssopin on nucleic acid, protein, anaerobic, and aerobic metabolism of Ehrlich ascites tumor cells, 1232
——Lee, K. H., and ElGebaly, S. A., antitumor agents XXVII: effects of helenalin on anaerobic and aerobic metabolism of Ehrlich ascites cells, 552
——Lee, K.-H., Starnes, C. O., ElGebaly, S. A., Ibuka, T., Wu, Y.-S., Kimura, T., and Haruna, M., antitumor agents XXX: evaluation of α-methylene-γ-lactone-containing agents for inhibition of tumor growth, respiration, and nucleic acid synthesis, 1235
——Sajadi, Z., and Loeffler, L. J., antineoplastic agents III: effects of dibromoethyl and vinyl esters of *N*-benzyloxycarbonyl-L-phenylalanine on Ehrlich ascites tumor cell metabolism, 1726
——*see* Imakura, Y., 1228
Hall, L. H., and Kier, L. B., molecular connectivity and substructure analysis, 1743
——*see* Kier, L. B., 725, 1408
Hallmark, M. R., *see* Albert, K. S., 1582
Hallquist, S. L., *see* Koch, P. A., 1533
Hamano, S., *see* Tsuji, A., 1059
Hamon, N. W., Bassendowski, D. L., Wright, D. E., Dimmock, J. R., and Noble, L. M., effect of antineoplastic and cytotoxic Mannich bases derived from conjugated styryl ketones on mitochondrial respiration in rat liver cells, 1539
——*see* Hindmarsh, K. W., 1547
Hanke, H. E., *see* Kupchik, E. J., 576
Hanna, S., Diana, F., Slevinski, J., Veronich, K., and Lachman, L., differential pulse polarographic determination of clorazepate monopotassium and dipotassium, 1723
——Rosen, M., Eisenberger, P., Rasero, L., and Lachman, L., GLC determination of warfarin in human plasma, 84
Hansen, A. B., Kreilgård, B., Huang, C.-H., and Repta, A. J., analysis of the product 7-acetylacroninium perchlorate in presence of the parent compound acronine, 237
Hansen, C. S., *see* Schuppan, D., 1720
Hara, Y., Sato, E., Miyagishi, A., Aisaka, A., and Hibino, T., synthesis and β-adrenergic blocking action of a new thiazolylthiopropanolamine derivative, 1334
Hardwidge, E. A., Sarapu, A. C., and Laughlin, W. C., comparison of operational characteristics of different dissolution testing systems, 1732
Harmon, R. E., *see* Shiau, G. T., 394
Hartmann, V., Rödiger, M., Ableidinger, W., and Bethke, H., dihydroergotoxine: separation and determination of four components by high-performance liquid chromatography, 98
Haruna, M., *see* Hall, I. H., 1235
Hasan, F., see Deslauriers, R., 1187
Hasegawa, J., *see* Garceau, Y., 826, 1360
Hashimoto, N., *see* Tsuji, A., 1705
Haslam, J., *see* Stella, V., 1375
Hassan, A. M. M., *see* Shafik, R. M., 991
Hayton, W. L., *see* Grisafe, J. A., 895, 1211
——*see* Kaka, J. S., 1558
Herbert, T. J., *see* Snyder, H. R., Jr., 413
Heikius, B., see Lövgren, T., 1419
Helms, R. J., Muni, I. A., and Leeling, J. L., high-pressure liquid chromatographic analysis of a tetrazolylchromone in biological fluids, 1185
——*see* Muni, I. A., 289
Hem, S. L., *see* Jemal, M., 302
——*see* Porubcan, L. S., 1081
——*see* Serna, C. J., 324, 1144, 1179
Henderson, W. M., *see* Barrett, M. J., 1332
Hengy, H., Vollmer, K.-O., and Gladigau, V., GLC determination of tilidine, nortilidine, and bisnortilidine in biological fluids with a nitrogen-sensitive detector, 1765
Henry, J. P., *see* Cohen, J. L., 1093
Herman, E., *see* Balazs, T., 1355
Hewitt, P. F., *see* Welling, P. G., 764
Hibino, T., *see* Hara, Y., 1334
Higuchi, T., *see* Bodor, N., 1045
——*see* Rytting, J. H., 615
——*see* Stella, V., 1375
Higuchi, W. I., *see* Ando, H. Y., 606
——*see* Kwan, K. H., 1711
Hill, D. L., *see* Finkel, J. M., 1331
Hill, J. M., *see* Gangarosa, L. P., 1439
Himmelstein, K. J., Guvenir, T., and Patton, T. F., preliminary pharmacokinetic model of pilocarpine uptake and distribution in the eye, 603
Hindmarsh, K. W., Hamon, N. W., LeGatt, D. F., and Wallace, S. M., effect of diphenhydramine on methaqualone metabolism: an *in vitro* study, 1547
Hinkle, G. H., Born, G. S., Kessler, W. V., and Shaw, S. M., preferential localization of radiolabeled liposomes in liver, 795
Hirata, T., Peng, G., and Driscoll, J. S., potential CNS antitumor agents—phenothiazines II: fluphenazine analogs, 157
Hirsch, C. A., Messenger, R. J., and Brannon, J. L., fenoprofen: drug form selection and preformulation stability studies, 231
Hite, G. J., *see* Lazer, E. S., 1656
Ho, N. F. H., *see* Ando, H. Y., 606
Hobbs, D. C., *see* Twomey, T. M., 1468
Hoffman, D. J., *see* Sun, S. R., 1647
Hoffmann, J. J., Jolad, S. D., Torrance, S. J., Luzbetak, D. J., Wiedhopf, R. M., and Cole, J. R., odoratin and paucin: cytotoxic sesquiterpene lactones from *Baileya pauciradiata* (Compositae), 1633
Hofmann, A. F., *see* Kwan, K. H., 1711
Hogenkamp, H. P. C., *see* Gangjee, A., 121
Holcomb, I. J., Luers, R. B., and Fusari, S. A., chromatographic separation and assay of morphine in tablets, 1099
Holland, J. B., *see* Dren, A. T., 880
Hollenbeck, R. G., Peck, G. E., and Kildsig, D. O., application of immersional calorimetry to investigation of solid–liquid interactions: microcrystalline cellulose–water system, 1599
——Peck, G. E., and Kildsig, D. O., nonisothermal aqueous calorimetry: computation of process-dependent temperature change and aspects of calorimeter design, 1592
Hollenberg, J. S., *see* Unger, S. H., 1364
Holmes, D. G., *see* Walkling, W. D., 948
Hong, C. O., Mittelman, A., and Chheda, G. B., synthesis and biological activity of N^6-(*n*-alkylureido)-purine ribonucleosides and their 5′-phosphates, 569
Honigberg, I. L., Stewart, J. T., and Smith, M., liquid chromatography in pharmaceutical analysis IX: determination of muscle relaxant–analgesic mixtures using normal phase chromatography, 675
Honkomp, L. J., *see* Schwan, T. J., 421, 1022
Hooper, S. N., and Chandler, R. F., quantitative GLC analysis of sterols in biological samples, 1157
Horhota, S., and Fung, H.-L., site dependence for topical absorption of nitroglycerin in rats, 1345
——and Fung, H.-L., validity of oral bioavailability estimates of phenolsulfonphthalein based on total urinary excretion from rats, 267
Horlock, E., *see* Roberts, M. S., 1685
Horr, G. B., determination of phytonadione in elemental diets by TLC–spectrophotodensitometry, 834
Horrom, B. W., *see* Dren, A. T., 880
Howard, S. A., Mauger, J. W., Khwangsopha, A., and Lee, P., separation of multisized drug suspensions into narrow distributions by centrifugal elutriation, 673
Hoyt, H. J., *see* Stoll, R. G., 1328
Huang, C.-H., *see* Hansen, A. B., 237
Huang, H., *see* Welling, P. G., 764
Hubbard, J. W., Midha, K. K., Cooper, J. K., and Charette, C., radioimmunoassay for psychotropic drugs II: synthesis and properties of haptens for tricyclic antidepressants, 1571
——Midha, K. K., McGilveray, I. J., and Cooper, J. K., radioimmunoassay for psychotropic drugs I: synthesis and properties of haptens for chlorpromazine, 1563
——*see* Midha, K. K., 975
Huber, H. E., *see* DeYoung, J. L., 320
——*see* Streng, W. H., 384
Huber, R. C., Niedermayer, A. O., and Weiss, A. L., lyophilization of sincalide and correlation of headspace relative humidity with product stability, 1239
Hulshoff, A., *see* Calvert, R. T., 205
Hurwitz, A., *see* Liu, S.-T., 636
Hurwitz, A. R., and Carney, C. F., enhancement of ampicillin partition behavior, 138
Hussain, A., Kulkarni, P., and Perrier, D., prodrug approaches to enhancement of physicochemical properties of drugs IX: acetaminophen prodrug, 545
——Wahner, H., and Triplett, J., unusual reversible attack by sodium bisulfite on physostigmine, 742
Hussey, R. L., and Newlon, W. M., high-performance liquid chromatographic and TLC determinations of desacetylvinblastine amide (vindesine) and its monosulfate salt, 1319
Huston, L. P., *see* Rytting, J. H., 615
Huynh-Ngoc, T., Chabot, M., and Sirois, G., bioavailability of three commercial sustained-release tablets of quinidine in maintenance therapy, 1456
Hwang, B., Konicki, G., Dewey, R., and Miao, C., GLC determination of tricrynafen and its metabolites in urine, serum, and plasma of humans and animals, 1095
Hyde, R. M., *see* Foster, R., 1310

I

Ibuka, T., *see* Hall, I. H., 1235
Iga, K., *see* Kitamori, N., 1436, 1674
Ilse, A. C., *see* Schwan, T. J., 718
Imakura, Y., Lee, K.-H., Sims, D., and Hall, I. H., antitumor agents XXVIII: structural elucidation of the novel antitumor sesquiterpene lactone, microlenin, from *Helenium microcephalum*, 1228
Inouye, H., *see* Matsuda, Y., 196
Ionescu, F., *see* Kingston, D. G. I., 249
Iranloye, T. A., and Parrott, E. L., effects of compression force, particle size, and lubricants on dissolution rate, 535
Israili, Z. H., *see* Cunningham, R. F., 434
Ivanson, D. D., *see* Cardinal, J. R., 854
Ivashkiv, E., colorimetric determination of nadolol in tablets, 1024
——*see* Funke, P. T., 653
Iwuagwu, M., *see* Khalil, S. A. H., 287

J

Jacoby, H. I., *see* Walkling, W. D., 945
Jaffe, J. M., *see* Goehl, T. J., 404
——*see* Strum, J. D., 568, 1399
Jaiswal, D. K., *see* Ghosal, S., 55
Jamali, F., and Axelson, J. E., griseofulvin–phenobarbital interaction: a formulation-dependent phenomenon, 466
James, K. C., *see* Evans, B. K., 277
Jani, R. K., *see* Madan, P. L., 409
Jee, J., Yoshikawa, F., Pont, L., Cheung, A., and Lim, P., assay of amygdalin dosage forms from Mexico, 438
——see Culcasi, M., 1190
Jemal, M., Hem, S. L., and Knevel, A. M., demonstration of penicillamine as a product in benzylpenicillenic acid degradation in neutral media using differential pulse polarography, 302
Jenkins, H. J., *see* Viswanath, D. V., 1275
Jenkins, R. G., and Friedel, R. O., analysis of tricyclic antidepressants in human plasma by GLC–chemical-ionization mass spectrometry with selected ion monitoring, 17
Jensen, A. F., *see* Peterson, J. E., 1425

Jindal, S. P., and Vestergaard, P., quantitation of *cocaine and its principal metabolite, benzoylecgonine,* by GLC–mass spectrometry using stable isotope labeled analogs as internal standards, 811
——and Vestergaard, P., quantitation of etorphine in urine by selective ion monitoring using tritiated *etorphine as an internal standard,* 260
——Vestergaard, P., and Lutz, T., mass fragmentographic determination of methadyl acetate in urine *using stable isotope labeled analog as internal* standard, 1483
Johansen, H., and Møller, N., solvent deposition *method for enhancement of dissolution rate:* importance of drug-to-excipient ratio, 134
Johnson, N., Jr., *see* Muni, I. A., 289, 1423
Johnson, N. F., *see* Owerbach, J., 1250
Johnson, R. N., Masserano, R. P., Kho, B. T., and *Adams, W. P., steady-state urinary excretion* method for determining bioequivalence of conjugated estrogen products, 1218
***Jolad, S. D.,** see Hoffmann, J. J., 1633*
Jones, R. H., *see* Solomons, W. E., 314
Jonkman, J. H. G., *see* Neef, K., 1147
Joullié, M. M., *see* Abou-Gharbia, M. A., 953
Jun, H. W., and Ruenitz, P. C., interaction of tricyclic *antipsychotic and antidepressant drugs with* 1-anilino-8-naphthalenesulfonic acid, 861
——*see* Midha, K. K., 975
***Juneau, R.,** and Taber, C., quaternary acetate and* propionate esters of 3-hydroxyquinolizidine, 1759
Jurgens, R. W., Jr., Lacz, J. P., and Welco, A. D., color analysis of dextrose solutions using a color *difference meter, 1485*
Jurs, P. C., *see* Stuper, A. J., 745
Jusko, W. J., see Owerbach, J., 1250

K

Kabasakalian, P., Kalliney, S., and Magatti, A. W., dc polarographic determination of hydroxylaminoev*erninomicin D, 719*
Kagami, I., *see* Tsuji, A., 1701
Kaiser, D. G., and Martin, R. S., electron-capture GLC determination of ibuprofen in serum, 627
Kaka, J. S., and Hayton, W. L., temperature and surfactant *dependence of accumulation of 4-ami*noantipyrine and ethanol in fish, 5558
Kakumoto, Y., *see* Caldwell, J. H., 415
***Kalliney, S.,** see Kabasakalian, P., 719*
Kandeel, E. M., *see* Galpin, D. R., 1367
Kanumuri, R. R., *see* Mendes, R. W., 1613, 1616
Kaplan, H. R., Commarato, M. A., and Lattime, E. C., I-bunolol and propranolol: oral and intravenous β-*adrenoceptor blocking activity in rats compared to* dogs and humans, 132
Kates, R. E., McKennon, D. W., and Comstock, T. J., *rapid high-pressure liquid chromatographic deter*mination of quinidine and dihydroquinidine in plasma samples, 269
——*see* McKennon, D. W., 1756
Kauffman, J. M., see Foye, W. O., 962
***Kaul, P. N.,** and Kulkarni, S. K., new drug metabolism* inhibitor of marine origin, 1293
——Whitfield, L. R., and Clark, M. L., quantitative *determination of amitriptyline in blood, 60*
Kaye, B., and Wood, P. R., analysis of cefazolin in serum or urine, 1170
Kazmi, S. J. A., and Mitchell, A. G., preservation of solubilized and emulsified systems I: correlation of *mathematically predicted preservative availability* with antimicrobial activity, 1260
——and Mitchell, A. G., preservation of solubilized and emulsified systems II: theoretical development of capacity and its role in antimicrobial activity of chlorocresol in cetomacrogol-stabilized systems, 1266
Kelleher, R. T., see Lazer, E. S., 1656
***Keller, W. J.,** and Zelenski, S. G., alkaloids from Lupinus argenteus* var. *stenophyllus,* 430
Kenner, C. T., see Biehl, E. R., 927
——*see Graham, R. E., 360, 792*
Kenyhercz, T. M., and Kissinger, P. T., high-performance liquid chromatographic assay of isoquinoline alkaloid formation from reaction of biogenic amines and aldehydes, 112
Kessler, W. V., *see* Hinkle, G. H., 795
***Ketcham, R.,** see Greenberg, A. J., 478*
Khalil, S. A., *see* El-Banna, H. M., 1112
——*see* Naggar, V. F., 1029
Khalil, S. A. H., and El-Masry, S., instability of digoxin in acid medium using a nonisotopic method, *1358*
——and Iwuagwu, M., *in vitro* uptake of oral contraceptive steroids by magnesium trisilicate, 287
***Kho, B. T.,** see Johnson, R. N., 1218*
Khorrami, J., *see* Lalezari, I., 1336
Khouw, V., Giles, H. G., and Sellers, E. M., binding of *drugs to ion-exchange resins in simulated gastric* fluid, 1329
***Khoyi, A.,** see Shafiee, A., 125*
Khwangsopha, A., see Howard, S. A., 673
Kier, L. B., and Hall, L. H., molecular connectivity study *of muscarinic receptor affinity of acetylcholine* antagonists, 1408
——Simons, R. J., and Hall, L. H., structure–activity *studies on mutagenicity of nitrosamines using mo*lecular connectivity, 725
——*see* Hall, L. H., 1743
Kildsig, D. O., see Hollenbeck, R. G., 1592, 1599
Kim, S. W., see Zentner, G. M., 1347, 1352
***Kimura, T.,** see Hall, I. H., 1235*
King, J. A., see Griggs, S. C., 1215
King, M. E., *see* Peterson, J. E., 1425
Kingston, D. G. I., plant anticancer agents *VI: isolation* of voacangine, voacamine, and epivoacorine from *Tabernaemontana arborea* sap, 271
——plant anticancer agents VII: structural effects on cytotoxicity of bisindole alkaloids of voacamine *type, 272*
——Gerhart, B. B., Ionescu, F., Mangino, M. M., and Sami, S. M., plant anticancer agents V: new bisindole alkaloids from *Tabernaemontana johnstonii* stem bark, 249
***Kinsun, H.,** Moulin, M. A., and Savini, E. C., simulta*neous GLC determination of phenylpropanolamine and chlorpheniramine in urine using a nitrogen se*lective detector, 118*
Kirchmeier, R. L., and Upton, R. P., simultaneous determination of niacin, niacinamide, pyridoxine, thiamine, and riboflavin in multivitamin blends by ion-pair high-pressure liquid chromatography, *1444*
Kirschbaum, J., differential borohydride assay for conjugated ketosteroids: improvement with propylene glycol, *275*
Kish, N. G., see Repke, D. B., 485
Kissinger, P. T., *see* Kenyhercz, T. M., 112
Kitamori, N., and Iga, K., dissolution of nonspherical powders, 1674
——*and Iga, K., dissolution profiles of drugs from* tablets, 1436
Kitzen, J. M., see Gangjee, A., 121
Klasen, H. B., *see* Bult, A., *284*
Kline, B. J., and Martin, M. F., simplified GLC assay for *lidocaine in plasma, 887*
Knapp, J. E., *see* Dwuma-Badu, D., 433
——see Elsohly, M. A., 124
***Knappe, W.-R.,** flavin-catalyzed photooxidation of an* acridan drug: a reinvestigation, 318
Knevel, A. M., see Jemal, M., 302
Kober, A., Ekman, B., and Sjöholm, I., direct and indirect determination of binding constants of drug–*protein complexes with microparticles, 107*
Koch, P. A., Schultz, C. A., Wills, R. J., Haliquist, S. L., and Welling, P. G., influence of food and fluid *ingestion on aspirin bioavailability, 1533*
Kohn, H., *see* Arceneaux, J. H., 600
Kolasinski, H., *see* Matsui, F., 646
Kolb, V. M., new opiate–receptor model, 999
Konicki, G., see Hwang, B., 1095
Konishi, M., *dose-dependent pharmacokinetics of* 7-chloro-1, 3-dihydro-5-(2′-chlorophenyl)-2*H*-1,4-benzodiazepin-2-one in dogs, 1777
***Konning, G. H.,** and Mital, H. C., sheabutter V: effect* of particle size on release of medicament from ointment, 374
Korany, M. A., *see* Wahbi, A. M., 140
Kornet, M. J., synthesis of 1-methyl-2-phenylcarba*moylpyrazolidines as potential anticonvulsant* agents, 1471
Korp, J. D., see Parker, G. R., 239
Korytnyk, W., *see* Paul, B., 642
***Kosegarten, D. C.,** and Maher, T. J., use of guinea pigs* as model to study galactose-induced cataract formation, 1478
Kosser, M., *see* Garrett, E. R., 145
Kossoy, A. D., and Cooke, G. C., characterization of *products derived from aprindine hydrochloride* photolysis, 722
Kostenbauder, H. B., see Calvert, R. T., 205
***Kotzan, J. A.,** effect of diazepam on cognition via* pupillometry, 956
——*see* Needham, T. E., 1070
***Kowal, D. K.,** see Dimmock, J. R., 401*
Kowarski, A. A., see Kowarski, C. R., 875
***Kowarski, C. R.,** and Kowarski, A. A., constant blood* withdrawal method for area under plasma concentration–time curve, 875
***Kramer, P. A.,** see Chapron, D. J., 1018*
Kramer, W. G., and Reuning, R. H., use of area under the curve to estimate absolute bioavailability of *digoxin, 141*
Krebs, H. A., *see* Yeh, S. Y., 878
Kreilgård, B., *see* Hansen, A. B., 237
Kriesel, D. C., see Rippie, E. G., 1121
Kronberg, G. H., Leard, R. S., Meymaris, E., and Tak*man, B. H., synthesis and local anesthetic properties* of secondary alkoxyalkylaminoacylanilides, 595
Kubinyi, H., drug partitioning: relationships between forward and reverse rate constants and partition coefficient, 262
Kulkarni, P., *see* Hussain, A., 545
Kulkarni, S. K., *see* Kaul, P. N., 1293
Kumar, S., *see* Chaudhary, S. K., 987
——*see Singh, S. P., 1682*
Kuo, Y.-N., *see* Bodor, N., 1045
Kupchan, S. M., Ashmore, J. W., and Sneden, A. T., structure–activity relationships among *in vivo* active germacranolides, 865
***Kupchik, E. J.,** Pisano, M. A., Hanke, H. E., and Tseng,* W.-C. R., synthesis and antimicrobial activity of ethyl *N*-aryl - S - (triphenylstannyl)isothiocarbamates, *576*
Kustin, K., see Barr, M. L., 1313
Kwan, K. H., Higuchi, W. I., and Hofmann, A. F., dissolution kinetics of cholesterol in simulated bile II: influence of simulated bile composition, 1711

L

Lachman, L., *see* Hanna, S., 84, 1723
Lacombe, P. S., *see* Marcucci, F., 705
Lacz, J. P., *see* Jurgens, R. W., Jr., 1485
Lafontaine, P., see Matsui, F., 646
***Lagas, M.,** see Lerk, C. F., 935*
Lai, A. A., and Levy, R. H., pharmacokinetic profile of clonazepam in rhesus monkeys, 295
Lai, C.-M., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XXXIII: frequency *distribution of dicumarol total clearance in rats,* 337
——and Levy, G., comparative pharmacokinetics of *coumarin anticoagulants XXXVII: simultaneous in vivo* displacement of dicumarol from serum protein and tissue binding sites by tolbutamide in rats, 1492
——*see* Levy, G., 229
——*see Yacobi, A., 1668*
Lai, T. Y.-F., *see* Carstensen, J. T., 1303
Lakings, D. B., Haggerty, W. J., Rehagen, G., and *Barth, H., determination of indoprofen in physio*logical fluids by reversed-phase liquid chromatography, 831
Lalezari, I., Shafiee, A., Khorrami, J., and Soltani, A., selenium heterocycles XXII: synthesis and anti*bacterial and antifungal activities of arylsulfonyl*-1,2,3-selenadiazoles, 1336
Lalka, D., du Souich, P., McLean, A. J., and Gibaldi, *M., absolute drug bioavailability II: evaluation of* renal clearance perturbation method using literature data assuring a fraction absorbed of unity, 591
——*see* Ludden, T. M., 371
Lambert, H. J., *see* Chien, Y. W., 214
——*see* Lee, H. K., 847
Lang, J. E., *see* Pikal, M. J., 767
Lang, S. A., Jr., see Warren, J. D., 1479

Lant, A. F., see Finch, R. E., 1489
Laprade, B., *see Alexander, K. S., 624*
Lattime, E. C., *see* Kaplan, H. R., 132
Lau Cam, C., see Barletta, M. A., 1643
Laughlin, W. C., see Hardwidge, E. A., 1732
Lausier, J. M., *see* Molzon, J. A., 733
Lauwers, A., see Demeester, J., 729
Lawrence, R. C., see Watson, J. R., 950
Lawson, J. W., *see* Solomons, W. E., 314
Lazarevski, T., Radobolja, G., and Djokić, S., *erythromycin VI: kinetics of acid-catalyzed hydrolysis of* erythromycin oxime and erythromycylamine, *1031*
Lazer, E. S., Aggarwal, N. D., Hite, G. J., Nieforth, K. A., Kelleher, R. T., Spealman, R. D., Schuster, C. *R., and Wolverton, W., synthesis and biological* activity of cocaine analogs I: *N*-alkylated norcocaine derivatives, 1656
Leard, R. S., see Kronberg, G. H., *595*
LeBelle, M. J., and Wilson, W. L., problems with iodometric assay of penicillin V benzathine, *1495*
Lee, C. S., and Benet, L. Z., micro and macro GLC determination of ethambutol in biological fluids, *470*
Lee, F. H., Scrime, M., and Edelson, J., perfluorooctyl bromide concentration in plasma and tissues of *beagle dogs, 1038*
Lee, H. K., Chien, Y. W., Lin, T. K., and Lambert, H. J., functional group contribution of *bile salt molecules* to partitioning of a quaternary ammonium *N,N*-dimethyl derivative of propranolol, 847
Lee, K.-H., see Hall, I. H., 552, 1232, 1235
——*see* Imakura, Y., 1228
Lee, P., see Howard, S. A., 673
Lee, R., see Finkelstein, E., 1447
Lee, Y. J., see Foye, W. O., 962
Leeling, J. L., see Helms, R. J., 1185
——*see* Muni, I. A., 289, 1423
LeGatt, D. F., see Hindmarsh, K. W., 1547
Lehr, D., see Barletta, M. A., 1390
Lei, D. M., see Schumacher, G. E., 1715
Leinweber, F.-J., Szpiech, J. M., and Di Carlo, F. J., *l*-bunolol metabolism in rats: identification of urinary metabolites, 129
Lemke, T. L., Cramer, M. B., and Shanmugam, K., heterocyclic tricycles as potential CNS agents I: 4-aminoalkylindeno[1,2-c]pyrazoles, 1377
Leonard, R. G., see Yakatan, G. J., *252*
Lerk, C. F., Lagas, M., Fell, J. T., and Nauta, P., effect of hydrophilization of hydrophobic drugs on release rate from capsules, 935
Leslie, D. T., see Repke, D. B., 485
Levinson, R. S., see Allen, L. V., Jr., 979
Levy, G., Lai, C.-M., and Yacobi, A., comparative pharmacokinetics of coumarin anticoagulants *XXXII: interindividual differences* in binding of warfarin and dicumarol in rat liver and implications for physiological *pharmacokinetic modeling, 229*
——O'Reilly, R. A., and Wingard, L. B., Jr., comparative pharmacokinetics of coumarin anticoagulants *XXXV: examination of possible pharmacokinetic* interaction between (*R*)-(+)- and (*S*)-(−)-warfarin in humans, 867
——*see Lai, C.-M., 337, 1492*
——see Ole, S., 45
Levy, R. H., *see Lai, A. A., 295*
Lewis, A. R., *see* Tsuji, K., 50
Lewis, G. S., and Turner, C. E., constituents of *Cannabis sativa L. XIII: stability of dosage form prepared* by impregnating synthetic (−)-Δ^9-*trans*-tetrahydrocannabinol on placebo *Cannabis* plant material, *876*
Libeer, J.-C., and Schepens, P., GLC determination of *pemoline in biological fluids, 419*
Liberti, L. E., and Der Marderosian, A., evaluation of commercial ginseng products, 1487
Lim, J. K., see Suphajettra, P., 1394
Lim, P., *see* Culcasi, M., 1190
——*see* Jee, J., 438
Lin, S. K., Moss A. A., Motson, R., and Riegelman, S., pharmacokinetics of iodoxamic acid in rhesus *monkey: biliary excretion, plasma protein binding,* and enterohepatic circulation, 930
Lin, T. K., see Lee, H. K., 847
Linardi, M. C. F., see de Oliveira, M. M., 562
Lindebaum, S., *see* Stella, V., 1375
Lindup, W. E., see Bowmer, C. J., 1193
Ling, W. C., thermal degradation of gelatin as applied to processing of gel mass, 218
Linn, E. E., *see* Schumacher, G. E., 1717
Liu, S.-T., and Hurwitz, A., effect of enantiomeric purity on solubility determination of dexclamol hydrochloride, 636
Livingstone, D. J., *see* Foster, R., 1310
Lock, A., see Walker, R. B., 558
Lockwood, T., see Barnett, G., 224
Lodge, B. A., *see* Deslauriers, R., 1187
Loeffler, L. J., see Hall, I. H., 1726
Loh, A., see Zuleski, F. R., 1138
Lohman, F. H., *see* Winder, W. C., 492
Long, J. P., *see* Sharabi, F. M., 1639
Look, Z. M., see Yacobi, A., 1668
Lopez, S., see Strahl, N. R., 1041
Lordi, N. G., see Timko, R. J., 496
Lougheed, G. S., see Schwan, T. J., 1022
Lovati, M. R., see De Simone, R., 1695
Lovering, E. G., see Butterfield, A. G., 650
——*see* Matsui, F., 646
——*see* McErlane, K. M., 958
——*see Watson, J. R., 950*
Lövgren, T., Heikius, B., Lundberg, B., and Sjöblom, L., simultaneous solubilization of steroid hormones *I*: estrogens and C_{21} steroids, 1419
Ludden, T. M., Lalka, D., Wyman, M. G., Goldreyer, B. *N., Haegele, K. D., Brooks, D. T., Davila, I., and* Wallace, J. E., microdetermination of procainamide in human serum, 371
Luers, R. B., see Holcomb, I. J., 1099
Lukes, A. L., see Pikal, M. J., 767
Lundberg, B., *see* Lövgren, T., 1419
Lundberg, J. B., *see* Palermo, P. J., 1627
Lundblad, J. L., *see* Ng, P. K., 431
Luscombe, D. K., see Evans, B. K., 277
Lutz, T., *see* Jindal, S. P., 1483
Luzbetak, D. J., *see* Hoffmann, J. J., 1633
Lynch, V. D., *see* Barletta, M. A., 1643
Lyons, L. L., see Welling, P. G., 764

M

Ma, J. K. H., see Day, S. T., 1518
Mabadeje, A. F. B., *see* Meyer, M. C., 1659
Madan, P. L., effect of intensity of agitation on disintegration time of tablets, 210
——*Jani, R. K., and Bartilucci, A. J., new method of* preparing gelatin microcapsules of soluble pharmaceuticals, 409
Magatti, A. W., see Kabasakalian, P., 719
Maghssoudi, R. H., and Fawzi, A. B., direct spectrophotometric determination of *thebaine in arya* II population capsules of *Papaver bracteatum* Lindl, 32
Maher, T. J., see Kosegarten, D. C., 1478
Mahony, D. E., *see* Yung, D. K., 900
Maienthal, M., see Doherty, R., 1698
Maksay, G., Tegyey, Z., and Ötvös, L., stereospecificity of esterase hydrolyzing oxazepam acetate, 1208
Malley, M. F., *see* Funke, P. T., 653
Manalili, F. S., see Philip, C. E., 1752
Mangino, M. M., see Kingston, D. G. I., 249
Manion, C. V., see Wolshin, E. M., 1692
Mann, D. E., Jr., see Mitala, J. J., 377
Manno, J. E., see Brown, R. D., 1687
Marcucci, F., Mussini, E., Cotellessa, L., Ghirardi, P., *Parenti, M., Riva, R., and Salva, P., distribution of* camazepam in rats and mice, 1470
——Riva, R., Gomeni, R., Zavattini, G., Lacombe, P. *S., and Mussini, E., pharmacokinetic studies on* ditazole, a novel inhibitor of platelet aggregation, 705
Marfil, F., *see* Sioufi, A., 243
Maronde, R. F., see Wan, S. H., 1340
Marsico, J. W., *see* Warren, J. D., 1479
Martin, A., *see* Thurston, G. B., 1499
Martin, A. R., see Galpin, D. R., 1367
Martin, G., see DeLong, A. F., 1171
Martin, G. E., Shambhu, M. B., and Digenis, G. A., polymer-bound carbonic anhydrides in *N*-acylation *of 7-aminocephalosporanic acid, 110*
Martin, M. F., see Kline, B. J., 887
Martin, R. P., *see* Fink, D. W., 1415
Martin, R. S., see Kaiser, D. G., 627
Martinelli, L. C., *see* Day, S. T., 1518
Martinez, M. T., see Monge, A., 1025
Martono, D. D., see Allen, L. V., Jr., 979
Marx, D. B., see Blanchard, J., 340
Maryanoff, B. E., and Zelesko, M. J., stereochemical considerations in structural comparison of enkephalins and endorphins with exogenous opiate *agents, 590*
Marzilli, L. G., *see* Burns, H. D., 1434
Masih, S. Z., see Mendes, R. W., 1613, 1616
Mason, W. D., see Weddle, O. H., 1033
Masserano, R. P., *see* Johnson, R. N., 1218
Masters, R. E., and Rost, W. J., *secondary disulfonamides* and secondary tetrasulfondiamides as proposed new biological alkylating agents, 857
Mather, L. E., see Austin, K. L., 1510
Mathison, I. W., *see* Solomons, W. E., 314
Mathur, L. K., see Goehl, T. J., 404
Matin, S. B., and Amos, B., quantitative determination of prednisone and prednisolone in human plasma using GLC and chemical-ionization mass spectrometry, *923*
——see Nerenberg, C., 1553
——*see* Wan, S. H., 1340
Matsuda, Y., Inouye, H., and Nakanishi, R., stabilization of sulfisomidine tablets by use of film coating con*taining UV absorber: protection of coloration and* photolytic degradation from exaggerated light, 196
Matsui, F., Robertson, D. L., Lafontaine, P., Kolasinski, H., and Lovering, E. G., stability studies of phenyl*butazone and phenylbutazone–antacid oral for*mulations, 646
——*see* McErlane, K. M., 958
Mattocks, A. M., see Jadzija, R. W., 1307
Mauger, J. W., see Alexander, K. S., 624
——*see* Howard, S. A., 673
Maulding, H. V., solid-state dispersions employing urethan, 391
Mayersohn, M., see Yung, S., 1491
Maynard, W. R., Bruce, R. B., and Fox, G. G., determination of carbocysteine from human plasma, *1753*
McDonald, R., see Woodard, G. D., 1403
McDowell, A. E., *and Pardue, H. L., simultaneous* multicomponent drug determinations with a vidicon spectrometer, 822
McErlane, K. M., Wood, R. J., Matsui, F., and Lovering, E. G., impurities in drugs II: meperidine and its formulations, 958
McGilveray, I. J., *see* Hubbard, J. W., 1563
——see Midha, K. K., 279
*McGregor, M. A., and Barnes, G. T., equilibrium pen*etration of monolayers IV: dipalmitoyllecithin–cetrimonium bromide systems, 364
——*and Barnes, G. T., equilibrium penetration of* monolayers VI: cholesterol–cetrimonium bromide system, 1054
McGuire, J. L., *see* Abrams, L. S., 1287
——see Weintraub, H. S., 1406
McKennon, D. W., and Kates, R. E., high-pressure liquid chromatographic determination of plasma dobutamine concentrations, 1756
——*see Kates, R. E., 269*
Mc Lean, A. J., see Lalka, D., 592
McNiff, E. F., *see* Yap, P. S. K., 582
McQuinn, R. L., *see* Yeh, S. Y., 878
McRae, J. D., and Tadros, L. M., hydrolysis kinetics of *the monophosphate ester triclofos sodium, 631*
Mehta, A., Zoglio, M. A., and Carstensen, J. T., ball milling as a measure of crushing strength of gran*ules, 905*
Meijer, D. K. F., see Neef, K., 1147
Meliklan, A. P., *see* Meyer, M. C., 1290
Melnick, L. R., *see* Chang, S. Y., 679, 682
Mendes, R. W., Masih, S. Z., and Kanumuri, R. R., ef*fect of formulation and process variables on bioe*quivalency of nitrofurantoin I: preliminary studies, 1613
——Masih, S. Z., and Kanumuri, R. R., effect of formulation and process variables on bioequivalency of nitrofurantoin II: *in vivo–in vitro* correlation, 1616
Messenger, R. J., see Hirsch, C. A., 231

Meyer, M. B., *see* Wolshin, E. M., 1692
Meyer, M. C., Melikian, A. P., and Straughn, A. B., *relative bioavailability of meprobamate tablets in humans*, 1290
——Straughn, A. B., Ramachander, G., Cavagnol, J. C., *and Mabadeje, A. F. B., bioavailability of sulfadiazine solutions, suspensions, and tablets in humans*, 1659
Meyer, R. C., *and Cohn, L. B., thimerosal determination by high-pressure liquid chromatography*, 1636
Meymaris, E., see Kronberg, G. H., 595
Miao, C., see Hwang, B., 1095
***Midha, K. K.,** Hubbard, J. W., Charette, C., and Jun, H. W., formation of a cyclic derivative of ethacrynic acid with diazomethane*, 975
——*McGilveray, I. J., and Cooper, J. K., GLC determination of plasma concentrations of γ-oxo metabolite of phenylbutazone*, 279
——*see* Butterfield, A. G., *839*
——see Hubbard, J. W., 1563, 1571
***Mierzwa, R. A.,** see Chib, J. S., 264*
Mikhail, E. A., see Abdel-Monem, M. M., 1174
Milano, E., see Wolshin, E. M., 1692
***Miles, D. H.,** see Bhattacharyya, J., 1325*
Miles, N. J., *see* Schwan, T. J., 548
Miller, A. K., Adir, J., and Vestal, R. E., tolbutamide *binding to plasma proteins of young and old human subjects*, 1192
Milman, H. A., *see* Brynes, S., 1550
Milo-Goldzweig, I., *see* Segal, R., 1169, 1589
Mital, H. C., see Konning, G. H., 375
***Mitala, J. J.,** Mann, D. E., Jr., and Gautieri, R. F., influence of cobalt (dietary), cobalamins, and inorganic cobalt salts on phenytoin- and cortisone-induced teratogenesis in mice*, 377
Mitchell, A. G., *see* Kazmi, S. J. A., 1260, 1266
***Mitra, C.,** see Banerjee, S., 480*
Mitra, G., *see* Ng, P. K., 431
Mittelman, A., see Hong, C. I., 569
***Miyagishi, A.,** see Hara, Y., 1334*
Miyamoto, E., *see* Tsuji, A., 1701, 1705
Mizrahi, L. M., *see* Richards, R. M. E., 380
Mizutani, A., *see* Mizutani, T., 1102
Mizutani, T., and Mizutani, A., estimation of adsorption of drugs and proteins on glass surfaces with controlled pore glass as a reference, 1102
Mobley, A., see Day, J. L., 1027
***Mody, N. V.,** see Bhattacharyya, J., 1325*
Møller, N., *see* Johansen, H., 134
Mollica, J. A., Ahuja, S., and Cohen, J., stability of *pharmaceuticals*, *443*
Molzon, J. A., Lausier, J. M., and Paruta, A. N., solubility of calcium oxalate in 1-alkanols and ethanol–water *mixtures*, *733*
Momirović-Čuljat, J., *see* Bonevski, R., 1474
Monge, A., Genua, I., Palop, J. A., Martinez, M. T., Roldan, F., and Fernández, J., new 5-hydroxy-2-indolecarbohydrazides as platelet aggregation inhibitors *in ethylene glycol*, *1025*
Moreaux, C., *see* Bouche, R., 1019
Morishita, S.-I., Baba, S., and Nagase, Y., studies on *drug metabolism by use of isotopes XX: ion cluster* technique for detection of urinary metabolites of 1-butyryl-4-cinnamylpiperazine by mass chromatography, 757
Moros, S., see Rucki, R., 1297
***Mosher, A. H.,** see Walkling, W. D., 948*
Moss, A. A., *see* Lin, S. K., 930
Motson, R., *see* Lin, S. K., 930
Motycka, S., *and Nairn, J. G., influence of wax coatings on release rate of anions from ion-exchange* resin beads, 500
Moulin, M. A., *see* Kinsun, H., 118
Mowery, P. J., see Tan, H. S. I., 1142
Mroszczak, E. J., Runkel, R., Strand, L. J., Tomlinson, R. V., Fratis, A., and Segre, E., cloprednol bioavailability in humans, 920
***Muni, I. A.,** Leeling, J. L., and Johnson, N., Jr., fate of* ^{14}C-3-methylamino-1,2,3,4-tetrahydrocarbazole hydrochloride in rats and dogs, 1423
——*Leeling, J. L., Helms, R. J., Johnson, N., Jr.,* Bare, J. J., and Phillips, B. M., improved colorimetric determination *of aspirin and salicylic acid concentrations* in human plasma, 289
——see Helms, R. J., 1185
Munno, N., *see* de Silva, J. A. F., 752
Munro, A. C., Chainey, M. G., and Woroniecki, S. R., *preparation and immunological cross-reactions of* penicilloic and penilloic acids, 1197
Munson, J. W., and Abdine, H., direct determination *of acetaminophen in plasma by differential pulse* voltammetry, 1775
Mussini, E., *see* Marcucci, F., 705, 1470
Musto, J. D., Sane, J. N., and Warner, V. D., high-pressure liquid chromatographic determination of *camphor and parachlorophenol in camphorated* parachlorophenol, 266
Myrick, J. W., see Veng Pedersen, P., 1450

N

***Nagase, Y.,** see Morishita, S.-I., 757*
Naggar, V. F., Khalil, S. A., and Gouda, M. W., effect of concomitant administration of magnesium trisilicate on GI absorption of dexamethasone in humans, 1029
***Naghaway, J. A.,** and Soine, T. O., dequaternization* of curare bases with sodium thiophenoxide and ethanolamine, 1204
——*and Soine, T. O., Hofmann elimination with diazomethane on curare bases and selected quaternary* tetrahydroisoquinoline alkaloids, 473
***Nairn, J. G.,** see Motycka, S., 500*
Nakamura, Y., see Otsuka, A., 151
Nakanishi, R., *see* Matsuda, Y., 196
Nakano, N. I., Oshio, T., Fujimoto, Y., and Amiya, T., study of drug–protein binding by affinity chromatography: *interaction of bovine serum albumin and* salicylic acid, 1005
Nakashima, E., *see* Tsuji, A., 1059
Nandi, B. R., *see* Gottschalk, L. A., 155
Nation, R. L., Peng, G. W., Smith, V., and Chiou, W. L., *simple, rapid, and micro high-pressure liquid* chromatographic determination of plasma griseofulvin levels, 805
***Nauta, P.,** see Lerk, C. F., 935*
Needham, T. E., Shah, K., Kotzan, J., and Zia, H., correlation of aspirin excretion with parameters from different dissolution methods, 1070
——*see* Shams-Eldeen, M. A., 1077
Neef, K., Jonkman, J. H. G., and Meijer, D. K. F., hepatic disposition and biliary excretion of the organic cations thiazinamium and thiazinamium sulfoxide *in rats*, *1147*
Nelson, K. G., and Wang, L. Y., determination of time course of tablet disintegration II: method using *continuous functions*, *86*
Nerenberg, C., Runkel, R. A., and Matin, S. B., radioimmunoassay of oxfendazole in bovine, equine, or *canine plasma or serum*, *1553*
Nerenberg, S. T., *see* Chiou, W. L., 293
Nesbitt, R. U., Jr., and Sandmann, B. J., solubility studies of silver sulfonamides, 1012
Neu, C., see Tan, H. S. I., 1142
***Neumann, M. G.,** and De Groote, A. M. C., reaction of* sodium hydroxymethanesulfonate with substituted anilines, 1283
***Newlon, W. M.,** see Hussey, R. L., 1319*
Newton, B. N., structure–toxicity relationships of iodinated aromatic carbonates and related compounds, 1154
Newton, D. W., potential source of error in official *diazepam assays*, *550*
Ng, P. K., Mitra, G., and Lundblad, J. L., simultaneous salt and ethanol removal from human serum albumin, 431
Niazi, S., thermodynamics of mercaptopurine dehydration, 488
——see Bakar, S., 141
——see El-Rashidy, R., 967
Niedermayer, A. O., *see* Huber, R. C., 1239
Nieforth, K. A., see Lazer, E. S., 1656
Niemann, R., see Day, J. L., 1027
***Nightingale, C. H.,** see Finkelstein, E., 1447*
——*see* Greene, D. S., 191
——*see* Schneider, H., 1620
***Nigrelli, R. F.,** see Chib, J. S., 264*
Noble, L. M., *see* Dimmock, J. R., 401, 1536
——*see* Hamon, N. W., 1539
Nonemaker, W. S., see Prince, H. N., 1629
Norgard, R. C., see Prince, H. N., 1629
Nuñez-Vergara, L. J., *see* Squella, J. A., 1466
Nyathi, C. B., see Dimmock, J. R., 1543

O

***Ober, R. E.,** see Schuppan, D., 1720*
Ohno, K., *see* Abdel-Monem, M. M., 1671
Ole, S., and Levy, G., frequency distribution of bilirubin *intrinsic clearance in adult male Sprague–Dawley* rats, 45
Okada, H., *see* Stella, V., 1375
Oles, P. J., high-pressure liquid chromatographic separation and determination of anomeric forms of *streptozocin in a powder formulation*, *1300*
Oliveri-Vigh, S., and Hainsworth, F. T., III, benzoyl peroxide assay using high-pressure liquid chro*matography*, *1035*
Omar, N. M., improved spectrophotometric determination of antazoline, 1610
——*see* El-Rabbat, N. A., *779*
O'Reilly, R. A., see Levy, G., 867
***Oroshnik, W.,** and Soldati, G., synthesis of anticho*linergic agents: *N*-methyl-4-piperidinyl α-benzoyloxy-α-cyclopentylphenylacetate salts, 701
***Oshio, T.,** see Nakano, N. I., 1005*
Otani, T. T., and Briley, M. R., effect of acylated amino acids and acylated amino acid analogs on microbial *antitumor screen*, *520*
Otsuka, A., Yonezawa, Y., and Nakamura, Y., *physiochemical properties of glycyrrhizic acid in* aqueous media II: effect of flocculation–deflocculation behavior of suspensions of sulfathiazole and *graphite*, *151*
Ötvös, L., *see* Maksay, G., 1208
Owerbach, J., Johnson, N. F., Bates, T. R., Pieniaszek, H. J., Jr., and Jusko, W. J., high-performance liquid chromatographic assay of sulfapyridine and *acetylsulfapyridine in biological fluids*, *1250*

P

Palement, J., effect of local anesthetics on electrically excitable bilayer lipid membranes, 965
Palagyi, L., *see* Chowhan, Z. T., 1385
Palermo, P. J., and Lundberg, J. B., simultaneous *programmed temperature GLC assay of phenol,* chloroxylenol, and lidocaine hydrochloride in topical antiseptic cream, 1627
Palmieri, A., III, *effect of dissolved oxygen levels on* oxidative degradation of pyrogallol, 1338
Palop, J. A., see Monge, A., 1025
***Pandey, B. R.,** see Singh, S. P., 1682*
Pang, K. S., and Gillette, J. R., theoretical relationships between area under the curve and route of administration of drugs and their precursors for evaluating sites and pathways of metabolism, 703
Pannekoek, W. J., *see* Dimmock, J. R., 401, 1536
Papageorgiu, A., *see* Catsoulacos, P., 1342
Pardue, H. L., see McDowell, A. E., 822
***Parenti, M.,** see Marcucci, F., 1470*
Park, N. H., *see* Gangarosa, L. P., 1439
Parker, G. R., correlation of log *P* with molecular *connectivity in hydroxyureas: influence of confor*mational system on log *P*, 513
——and Korp, J. D., comparison of solid and solution conformations of hydroxyurea and 3-ethyl-1-hydroxyurea utilizing IR–X-ray method, 239
Parmar, S. S., *see Chaudhary, S. K., 987, 1507*
——*see* Singh, S. P., 1682
Parrot, E. L., *see* Iranloye, T. A., 535
Parsons, D. L., and Vallner, J. J., Scatchard plot analysis of ligand-erythrocyte interactions, 1344
Paruta, A. N., *see* Alexander, K. S., 624
——see Breon, T. L., 67, 73
——see Molzon, J. A., 733
Patel, D. M., *see* Zalipsky, J. J., 256, 387
Patel, M. A., see Devani, M. B., 661
Patrick, J. E., see Abrams, L. S., 1287
——*see Alton, K. B., 985*
——*see* Weintraub, H. S., 1406
Patton, T. F., *see* Himmelstein, K. J., 603
***Paul, B.,** and Korytnyk, W., alanine derivatives with* reactive groups, 642
***Peck, C. C.,** and Benet, L. Z., general method for de*termining macrodissociation constants of polyprotic, amphoteric compounds from solubility

measurements, 12
Peck, G. E., see Hollenbeck, R. G., 1592, 1599
***Peeters, J.,** determination of ionization constants in mixed aqueous solvents of varying composition by a single titration, 127*
***Pelletier, W. T.,** see Briggs, F. H., 735*
Pelosi, S. S., see Alaimo, R. J., 281
Pelsor, F. R., Allen, L. M., and Creaven, P. J., multicompartment pharmacokinetic model of 4′-demethylepipodophyllotoxin 9-(4,6-*O*-ethylidene-β-*D*-glucopyranoside) in humans, *1106*
Peng, A., *see* Peng, G. W., 710
Peng, G., see Hirata, T., 157
***Peng, G. W.,** Gadalla, M. A. F., and Chiou, W. L., rapid* and micro high-pressure liquid chromatographic determination of chloramphenicol in plasma, *1036*
——Gadalla, M. A. F., Smith, V., Peng, A., and Chiou, W. L., *simple and rapid high-pressure liquid chromatographic* simultaneous determination of aspirin, salicylic acid, and salicyluric acid in plasma, 710
——*see Chiou, W. L., 182, 292*
——*see* Gadalla, M. A. F., 869
——*see* Nation, R. L., 805
——*see Slonek, J. E., 1462*
Perdue, G. P., and Blomster, R. N., South American plants III: isolation of fulvoplumierin from *Himatanthus sucuuba* (M. Arg.) Woodson (Apocynaceae), 1322
***Perrier, D.,** see Hussain, A., 545*
Petersen, H., Jr., *see* Breon, T. L., 67, 73
Peterson, A., *see* Ravin, L. J., 1523
***Peterson, J. E.,** King, M. E., Banks, W. F., Baker, J. F.,* Jensen, A. F., Ross, R. W., Jr., Clemans, S., and Edelson, J., radioimmunoassay for danazol in human and monkey plasma, 1425
Philip, C. E., Manalili, F. S., Umagat, H. J., Hagel, R. B., *and Gomez, R., limit test for determination of* free ferricyanide and ferrocyanide in sodium nitroferricyanide, 1752
***Phillips, B. M.,** see Muni, I. A., 289*
Phillips, E. W., see Vilallonga, F. A., 773
Phoebe, C. H., Jr., *see* Elsohly, M. A., 124
Piccirilli, R. M., Snoke, E. O., Watts, R. F., and Popp, F. D., new compounds: isoquinoline derivatives as *simple emetine models, 740*
Pieniaszek, H. J., Jr., *see* Owerbach, J., 1250
Pifferi, G., see Pinza, M., 120
Pikal, M. J., Lukes, A. L., Lang, J. E., and Gaines, K., quantitative crystallinity determinations for β-lactam antibiotics by solution calorimetry: correlations with *stability, 767*
Pillersdorf, A., *see* Donbrow, M., 1676
Pinza, M., and Pifferi, G., convenient synthesis of (*RS*)-4-amino-3-hydroxybutyric acid, 120
Piperno, E., see Walkling, W. D., 948
Pipkin, J. D., and Stella, V. J., thiamine whole blood pharmacokinetics in rats using both a specific ^{35}S-thiamine liquid scintillation assay and the *thiochrome fluorescence assay, 818*
Pisano, M. A., *see* Kupchik, E. J., 576
Pitlick, W. H., *see* Goehl, T. J., 404
——*see* Strum, J. D., 1399
Plakogiannis, F. M., and Saad, A. M., quantitative determination of acetaminophen in plasma, 581
Plourde, J. R., *see* Vinh, C. T., 731
Politis, D., *see* Catsoulacos, P., 1342
***Polk, A.,** see DeLong, A. F., 1171*
Pont, L., *see* Jee, J., 438
Popp, F. D., and Watts, R. F., synthesis of potential antineoplastic agents XXVI: 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2*H*-benzo[a]2-quinolizinone derivatives, 871
——see Piccirilli, R. M., 740
Porubcan, L. S., Serna, C. J., White, J. L., and Hem, S. L., mechanism of adsorption of clindamycin and tetracycline by montmorillonite, 1081
Post, A., see Warren, R. J., 1481
Poust, R. I., see Goehl, T. J., 404
——*see* Strum, J. D., 568, 1399
Prasad, V. K., *see* Carstensen, J. T., 1303
Princr, D. L., see Prince, H. N., 1629
Prince, H. N., Nonemaker, W. S., Norgard, R. C., and *Prince, D. L., drug resistance studies with topical* antiseptics, 1629
Pritchard, R., see Chowhan, Z. T., 1272, 1645
Puar, M. S., Funke, P. T., and Cohen, A. I., hydrolysis and subsequent cyclization of etazolate hydrochloride *and related compounds in aqueous solutions:* application of PMR and mass spectrometry in accelerated stability studies, 850

Q

Quintiliani, R., *see* Finkelstein, E., 1447
——see Greene, D. S., 191
——*see Schneider, H., 1620*

R

Radobolja, G., *see* Lazarevski, T., 1031
Rahman, A., Cradock, J. C., and Davignon, J. P., dissolution and absorption of the antineoplastic agent ellipticine, 611
Rahn, P. D., see Allen, P. V., 1087
Ramachander, G., Bapatla, K. R., and Emele, J. F., sex differences in plasma half-life of dextrorphan in rats *administered dextromethorphan, 1326*
——Williams, F. D., and Emele, J. F., effect of salicylamide and acetaminophen on dextromethorphan *hydrobromide metabolism: possible* pharmacological implications, 761
——*see Meyer, M. C., 1659*
Rasero, L., *see* Hanna, S., 84
Rattie, E. S., *see* Ravin, L. J., 1523
Ravin, L. J., Rattie, E. S., Peterson, A., and Guttman, D. E., degradative behavior of a new bronchodilator, carbuterol, in aqueous solution, 1523
Ravis, W. R., and Feldman, S., effect of enzyme-inducing and enzyme-inhibiting agents on drug absorption I: 3-*O*-methylglucose transport *in rats,* 245
Reardon, C. R., *see* Wolshin, E. M., 1692
Reavey-Cantwell, N. H., see DeLong, A. F., 1171
——*see* Zalipsky, J. J., 256, 387
Redalieu, E., Tipnis, V. V., and Wagner, W. E., Jr., determination of plasma hydrochlorothiazide levels in humans, 726
Reece, P. A., Stanley, P. E., and Zacest, R., interference in assays for hydralazine in humans by a major plasma metabolite, hydralazine pyruvic acid hydrazone, *1150*
Rehagen, G., *see* Lakings, D. B., 831
Reitano, P. A., *see* Glamkowski, E. J., 1773
Repke, D. B., Bates, D. K., and Ferguson, W. J., synthesis of dextroamphetamine sulfate and methamphetamine hydrochloride from D-phenyl*alanine, 1167*
——Leslie, D. T., and Kish, N. G., GLC–mass spectral *analysis of fungal metabolites, 485*
Repta, A. J., *see* Hansen, A. B., 237
Rettig, H., see Rippie, E. G., 1121
Reuning, R. H., see Kramer, W. G., 141
Rezvani, A., *see* Shafiee, A., 125
Rhodes, C. T., *see* Chiang, C.-W., 63
Richards, R. M. E., and Mizrahi, L. M., differences in antibacterial activity of benzalkonium chloride, 380
Riegelman, S., *see* Lin, S. K., 930
Rippere, R. A., effects of paper on performance of *antibiotic-impregnated disks, 367*
Rippie, E. G., Kriesel, D. C., and Rettig, H., electronic monitoring of events within dynamic particulate beds: conductance and capacitance measurements, 1121
Ritschel, W. A., *see* Tan, H. S. I., 1142
Riva, R., *see* Marcucci, F., 705, 1470
Roberts, M. S., and Horlock, E., effect of repeated skin application on percutaneous absorption of salicylic acid, 1685
Robertson, D. L., *see* Matsui, F., 646
Robinson, J. B., see Yung, S., 1491
Rödiger, M., *see* Hartmann, V., 98
Roehrs, R. E., *see* Schoenwald, R. D., 1280
Rogers, M. E., see Glennon, R. A., 1762
Roldan, F., *see* Monge, A., 1025
Roller, R. G., see Bodor, N., 685
Roman, D. P., *see* Bachman, G. L., 1323
Rooks, W. H., II, see Chowhan, Z. T., 1645
Roos, R. W., high-pressure liquid chromatographic analysis of estrogens in pharmaceuticals by measurement of their dansyl derivatives, 1735
Roseboom, H., *see* Garrett, E. R., 27
Rosen, M., *see* Hanna, S., 84
Rosenberg, L. S., and Schulman, S. G., tautomerism of singly protonated chloroquine and quinacrine, 1770
——*see* Schulman, S. G., 334
Ross, A., see Rucki, R., 1297
Ross, R. W., Jr., see Peterson, J. E., 1425
Rosseel, M. T., Bogaert, M. G., and Claeys, M., quantitative GLC determination of *cis*- and *trans*-isomers *of doxepin and desmethyldoxepin, 802*
Rost, W. J., *see* Masters, R. E., 857
Rowell, P. P., *see* Chaturvedi, A. K., 657
Rozek, L. F., see Chien, Y. W., 214
Rucker, G., see Taha, A. M., 775
Rucki, R., Ross, A., Donahue, J., *and Moros, S., effect* of amitriptyline on polarography of chlordiazepoxide, 1297
Ruenitz, P. C., see Jun, H. W., 861
Ruggieri, G. D., *see* Chib, J. S., 264
Runkel, R., *see* Mroszczak, E. J., 920
——*see Nerenberg, C., 1553*
Ryan, A. J., Ashley, J. J., and Upton, R. A., pharmacokinetics of aryldihydro-*s*-triazines with antifolate activity I: metabolism and excretion by rats, 306
——see Upton, R. A., 310
Ryan, S. B., see Glennon, R. A., 1762
Rytting, J. H., Huston, L. P., and Higuchi, T., thermodynamic group contributions for hydroxyl, amino, *and methylene groups, 615*

S

Saad, A. M., *see* Plakogiannis, F. M., 581
Safwat, S., see Youssef, M. K., 556
Sajadi, Z., *see* Hall, I. H., 1726
Sakaguchi, H., *see* Tsuji, A., 1701
Sakmar, E., see Albert, K. S., 1582
Salama, R. B., see Geneidi, A. S., 114
Salmon, S. E., *see* Chang, S. Y., 679, 682
Salva, P., *see* Marcucci, F., 1470
Sami, S. M., see Kingston, D. G. I., 249
Sampaio, M. R. P., see de Oliveira, M. M., 562
Sancillio, F. D., *see* Upton, L. M., 913
Sandmann, B. J., *see* Nesbitt, R. U., Jr., 1012
Sane, J. N., see Musto, J. D., 266
Sanvordeker, D. R., ditheophylline succinate: transfer of theophylline across everted rat intestinal sacs, *1459*
Sarapu, A. C., *see* Allen, P. V., 1087
——*see* Hardwidge, E. A., 1732
Sastry, B. V. R., *see* Chaturvedi, A. K., 657
Sato, E., see Hara, Y., 1334
Sato, R. I., see Sinha, B. K., 407
Sattar, A., see Steinrauf, L. K., 1739
Savabi, F., see Shafiee, A., 125
Savini, E. C., see Kinsun, H., 118
Schepens, P., *see* Libeer, J. C., 419
Schiff, P. L., Jr., *see* Dwuma-Badu, D., 433
——*see* Elsohly, M. A., *124*
Schjønsby, H., *see* Andersen, K.-J., 1626
Schlicht, H. J., see Gelbke, H. P., 1176
Schneider, H., Nightingale, C. H., Quintiliani, R., and Flanagan, D. R., evaluation of an oral prolonged-*release antibiotic formulation, 1620*
Schoenwald, R. D., and Ward, R. L., relationship between steroid permeability across excised rabbit cornea and octanol–water partition coefficients, 786
——Ward, R. L., DeSantis, L. M., and Roehrs, R. E., influence of high-viscosity vehicles on miotic effect of pilocarpine, 1280
——*see* DeSantis, L. M., 1189
Schroeder, H. G., Bivins, B. A., Sherman, G. P., and DeLuca, P. P., physiological effects of subvisible *microspheres administered intravenously to beagle* dogs, 508
——Dakkuri, A., and DeLuca, P. P., sustained release from inert wax matrixes I: drug–wax combinations, 350
——*Simmons, G. H., and DeLuca, P. P., distribution* of radiolabeled subvisible microspheres after intravenous administration to beagle dogs, 504
——*see Dakkuri, A., 354*
Schulman, S. G., Rosenberg, L. S., and Sturgeon, R. J., spectroscopic approach to estimation of mi-

croequilibrium constants of prototropic reactions of aminobenzoic acids, 334
——*see* Capomacchia, A. C., 89
——*see* Rosenberg, L. S., 1770
Schultz, C. A., *see* Koch, P. A., 1533
Schultz, J. S., and Armstrong, W., permeability of interstitial space of muscle (rat diaphragm) to solutes of different molecular weights, 696
Schumacher, G. E., and Lei, D. M., kinetic and thermodynamic aspects of *in vitro* interphase transfer of tetracyclines I: influence of hydroxyl group substitution, 1715
——and Linn, E. E., kinetic and thermodynamic aspects of *in vitro* interphase transfer of tetracyclines II: influence of divalent metal salts, 1717
Schuppan, D., Hansen, C. S., and Ober, R. E., GLC determination of nanogram quantities of a new analgesic, nefopam, in human plasma, 1720
Schuster, C. R., *see* Lazer, E. S., 1656
Schwan, T. J., and Gray, J. E., synthesis of antifungal 2-substituted phthalimidines, 863
——Goldenberg, M. M., and Ilse, A. C., synthesis of an anti-inflammatory 10,10a-dihydro-1*H*,5*H*-imidazo[1,5-*b*]isoquinoline-1,3(2*H*)-dione, 718
——Goldenberg, M. M., and Miles, N. J., anti-inflammatory 1-substituted 2-imidazolidinones, 548
——Honkomp, L. J., Davis, C. S., and Lougheed, G. S., synthesis and hypotensive activity of a series of 2-substituted 5,6-dimethoxyindazoles, 1022
——Honkomp, L. J., Snyder, H. R., Jr., and Watson, E. J., synthesis of 4,5-dimethoxykynuramine and its *in vivo* conversion to 6,7-dimethoxy-4-quinolinol, 421
Schwartz, J. A., *see* Blanchard, J., 340
Schwartzman, G., recommendations to eliminate subjective olfactory methods from compendial identification tests, 539
——Asher, I., Folen, V., Brannon, W., and Taylor, J., ambiguities in IR and X-ray characterization of amphotericin B, 398
Sciarra, J. J., and Cutie, A., simulated respiratory system for *in vitro* evaluation of two inhalation delivery systems using selected steroids, 1428
Scott, D. F., *see* Gangarosa, L. P., 1439
Scrime, M., *see* Lee, F. H., 1038
Sears, R. W., *see* Butterfield, A. G., 650
Segal, R., Breuer, A., and Milo-Goldzweig, I., solasodine stability under conditions of saponin hydrolysis, 1169
——Shud, F., and Milo-Goldzweig, I., hemolytic properties of synthetic glycosides, 1589
Segre, E., *see* Mroszczak, E. J., 920
Selk, S. J., *see* Bodor, N., 685
Sellers, E. M., *see* Khouw, V., 1329
Serna, C. J., White, J. L., and Hem, S. L., factors affecting homogeneous precipitation of aluminum hydroxide gel, 1179
——White, J. L., and Hem, S. L., nature of amorphous aluminum hydroxycarbonate, 1144
——White, J. L., and Hem, S. L., structural survey of carbonate-containing antacids, 324
——*see* Porubcan, L. S., 1081
Shaffer, R. D., *see* Sternson, L. A., 327
Shafiee, A., Savabi, F., Rezvani, A., Farrokhsiar, M., and Khoyi, A., synthesis and local anesthetic activity of benzo[*b*]furan derivatives, 125
——*see* Lalezari, I., 1336
Shafik, R. M., Soliman, R., and Hassan, A. M. M., new biphenyl derivatives I: 1-(4-biphenylyl)-2-phenylethylamines as potential antispasmodic and cardiovascular agents, 991
——*see* Soliman, F. S. G., 411
Shah, A. C., *see* Yakatan, G. J., 252
Shah, K., *see* Needham, T. E., 1070
Shah, K. A., *see* Foye, W. O., 962
Shah, V. P., *see* Goehl, T. J., 404
——*see* Strum, J. D., 1399
Shahi, V., and Zatz, J. L., effect of formulation factors on penetration of hydrocortisone through mouse skin, 789
Shambhu, M. D., *see* Martin, G. E., 110
Shams-Eldeen, M. A., Vallner, J. J., and Needham, T. E., interaction of sulindac and metabolite with human serum albumin, 1077
Shani, J., Berman, J. A., and Wolf, W., autoradiographic distribution studies of 2-^{14}C-fluorouracil following oral or intravenous administration in mice bearing solid sarcoma-180, 344
Shankle, L. L., determination of phenylpropanolamine salts in dosage forms through fluorescent derivative formation, 1635
Shanks, L., *see* Gershon, H., 578, 715
Shanmugam, K., *see* Lemke, T. L., 1377
Sharabi, F. M., Long, J. P., and Cannon, J. G., hypotensive effect induced by a cyclic dopamine analog, *trans*-4-methyl -7,8- dihydroxy-1,2,3,4,4a,5,6,-10b-octahydrobenzo[*f*]quinoline, 1639
Sharma, P. V., *see* Ghosal, S., 55
Shaw, J. E., *see* Chandrasekaran, S. K., 1370
Shaw, S. M., *see* Hinkle, G. H., 795
Shen, D. D., Fixley, M., and Azarnoff, D. L., theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms, 916
Sheridan, J., *see* Carstensen, J. T., 48, 982
Sherman, G. P., *see* Schroeder, H. G., 508
Shiau, G. T., De, K. K., and Harmon, R. E., synthesis and evaluation of *N*-deacetyl-*N*-glycosylalkylthiocolchicines as antileukemic agents, 394
Shingal, E., *see* Culcasi, M., 1190
Shipman, C., Jr., *see* Ando, H. Y., 606
Shishoo, C. J., *see* Devani, M. B., 661
Shores, K. E., *see* Fujii, A., 713
Shud, F., *see* Segal, R., 1589
Simmons, G. H., *see* Schroeder, H. G., 504
Simons, R. J., *see* Kier, L. B., 725
Sims, D., *see* Imakura, Y., 1228
Singh, P., and Gupta, S. P., electronic structure–activity relationships of antibacterial acridines, 706
Singh, S. P., Pandey, B. R., Kumar, S., and Parmar, S. S., anticonvulsant activity and inhibition of respiration in rat brain homogenates by substituted trimethoxybenzamides, 1682
Sinha, B. K., and Sato, R. I., synthesis and biological activities of 10-substituted benzo[*b*][1,5]naphthyridines, 407
Sioufi, A., Caudal, F., and Marfil, F., GLC determination of phenylbutazone in human plasma, 243
Sirois, G., *see* Huynh-Ngoc, T., 1456
Sirtori, C. R., *see* De Simone, R., 1695
Sirtori, M., *see* De Simone, R., 1695
——*see* Kober, A., 107
Sjöholm, I., *see* Ekman, B., 693
Sjöblom, L., *see* Lövgren, T., 1419
Slatkin, D. J., *see* Dwuma-Badu, D., 433
——*see* Elsohly, M. A., 124
Slevinski, J., *see* Hanna, S., 1723
Sloan, K. B., *see* Bodor, N., 1045
Slonek, J. E., Peng, G. W., and Chiou, W. L., rapid and micro high-pressure liquid chromatographic determination of plasma phenytoin levels, 1462
Smith, I. C. P., *see* Deslauriers, R., 1187
Smith, L. M., *see* Stratford, E. S., 80
Smith, M., *see* Honigberg, I. L., 675
Smith, P. J., *see* Dimmock, J. R., 401, 1536, 1543
Smith, R. B., *see* Doluisio, J. T., 1586
Smith, V., *see* Nation, R. L., 805
——*see* Peng, G. W., 710
Smyth, R. D., *see* DeLong, A. F., 1171
Sneden, A. T., *see* Kupchan, S. M., 865
Snoke, E. O., *see* Piccirilli, R. M., 740
Snyder, H. R., Jr., Burrous, S. E., Freedman, R., and Herbert, T. J., *S*-(4-chlorophenyl) 3-aryl-3-hydroxypropanethioates as antibacterial agents, 413
——*see* Schwan, T. J., 421
Soine, T. O., *see* Naghaway, J. A., 473, 1204
Soldati, G., *see* Oroshnik, W., 701
Soliman, F. S. G., Shafik, R. M., and Elnenaey, E. A., synthesis of methaqualone and its diphasic titration in pure and tablet forms, 411
Soliman, R., *see* Shafik, R. M., 991
Solomons, W. E., Mathison, I. W., Jones, R. H., Wojciechowski, N. J., and Lawson, J. W., synthesis, toxicity, and cardiovascular properties of *N*-aralkyl- and *N*-acyl-5-aminoethylindans, 314
Soltani, A., *see* Lalezari, I., 1336
Sowa, D. T., *see* Burns, H. D., 1434
Spealman, R. D., *see* Lazer, E. S., 1656
Spikes, C., *see* Day, J. L., 1027
Spillane, W. J., and Benson, G. A., metabolic studies of the nonnutritive sweeteners cyclopentylmethylsulfamate and cyclopentylsulfamate: determination of metabolites in rat urine, 226
Spino, M., *see* Teare, F. W., 1641
Squella, J. A., Nuñez-Vergara, L. J., and Gonzalez, E. M., polarographic analysis of cephalexin, 1466
Srivastava, R. S., *see* Ghosal, S., 1768
Staab, R., *see* Barletta, M. A., 1643
Stagg, D., *see* Bhattacharyya, J., 1325
Staiger, D. B., *see* Warren, R. J., 1481
Stambaugh, J. E., *see* Wainer, I. W., 116
Stanley, P. E., *see* Reece, P. A., 1150
Starnes, C. O., *see* Hall, I. H., 1235
Stedman, R. J., *see* Burns, L. B., 258
Steenberg, M. L., *see* Arceneaux, J. H., 600
Steinrauf, L. K., Cox, B., Foster, E., Satter, A., and Blickenstaff, R. T., synthesis and evaluation of sulfur-containing steroids against methylmercuric chloride toxicity, 1739
Stella, V., Haslam, J., Yata, N., Okada, H., Lindenbaum, S., and Higuchi, T., enhancement of bioavailability of a hydrophobic amine antimalarial by formulation with oleic acid in a soft gelatin capsule, 1375
——*see* Pipkin, J. D., 818
Stempien, M. F., Jr., *see* Chib, J. S., 264
Sternson, L. A., and Shaffer, R. D., kinetics of digoxin stability in aqueous solution, 327
Stewart, J. M., *see* Doherty, R., 1698
Stewart, J. T., *see* Bouwsma, O. J., 1224
——*see* Honigberg, I. L., 675
Stoll, R. G., Chao, G. C., Hoyt, H. J., and Yacobi, A., comparison of *in vitro* dissolution and *in vivo* bioavailability of methaqualone tablets in humans, 1328
——*see* Albert, K. S., 1582
Strahl, N. R., and Lopez, S., influence of partition coefficient on intestinal absorption of alkylamine antihistamines, 1041
Strand, L. J., *see* Mroszczak, E. J., 920
Stratford, E. S., Smith, L. M., and Tomecko, G. W., potential hypocholesteremic derivatives of styrylacetic acid II: *cis*- and *trans*-3-methyl-4-phenyl-3-butenoic acid analogs, 80
Straughn, A. B., *see* Meyer, M. C., 1290, 1659
Streng, W. H., microionization constants of commercial cephalosporins, 666
——Huber, H. E., and Carstensen, J. T., relationship between osmolality and osmolarity, 384
Strohl, J. H., *see* Suphajettra, P., 1394
Strojny, N., *see* de Silva, J. A. F., 752
Strum, J. D., Colaizzi, J. L., Goehl, T. J., Jaffe, J. M., Pitlick, W. H., Shah, V. P., and Poust, R. I., bioavailability of sulfonamide suspensions I: dissolution profiles of sulfamethizole using paddle method, 1399
——Ebersole, J. W., Jaffe, J. M., Colaizzi, J. L., and Poust, R. I., correlation of quinidine absorption with disintegration and dissolution rates, 568
——*see* Goehl, T. J., 404
Stuper, A. J., and Jurs, P. C., structure–activity studies of barbiturates using pattern recognition techniques, 745
Sturgeon, R. J., *see* Schulman, S. G., 334
Su, T. T., *see* Abou-Gharbia, M. A., 953
Summers, M. P., glass formation in barbiturates and solid dispersion systems of barbiturates with citric acid, 1606
Sun, S.-R., fluorescence–TLC densitometric determination of diazepam and other 1,4-benzodiazepines in serum, 1413
——quantitative determination of chlordiazepoxide and its metabolites in serum by fluorescence TLC–densitometry, 639
——and Hoffman, D. J., rapid GLC determination of chlordiazepoxide and metabolite in serum using on-column methylation, 1647
Suphajettra, P., Strohl, J. H., and Lim, J. K., nitroglycerin stability in polyethylene glycol 400 and povidone solutions, 1394
Svendsen, A. B., *see* Verpoorte, R., 171
Swinyard, E. A., and Woodhead, J. E., drug contamination of mortars and pestles, 1758
Sýkora, S., *see* Bartošek, I., 1160
Szpiech, J. M., *see* Leinweber, F.-J., 129

T

Taber, C., *see* Juneau, R., 1759
Tadros, L. M., *see* McRae, J. D., 631

Taha, A. M., and Rücker, G., ^{13}C-NMR spectroscopy of tropane alkaloids, 775
Takman, B. H., *see* Kronberg, G. H., 595
Tam, Y. K., and Axelson, J. E., sensitive electron-capture GLC determination of metoclopramide in biological fluids, 1073
Tan, H. G. H., *see* DeYoung, J. L., 320
Tan, H. S. I., Mowery, P. J., Ritschel, W. A., and Neu, C., spectrophotofluorometric analysis of 3′,4′,7-tris[*O*-(β-hydroxyethyl)]rutoside in urine, 1142
Tao, I. Y. C., and Blickenstaff, R. T., total synthesis of 1,11- and 3,11-diazasteroids, 283
Tarcza, E., and Garth, M. A., assays and statistical analyses for antibiotic standards, 1050
Taylor, J., *see* Schwartzman, G., 398
Teare, F. W., Yadav, R. N., and Spino, M., determination of flucytosine in tablets by differential pulse polarography, 1641
——*see* Yadav, R. N., 436
Tegyey, Z., *see* Maksay, G., 1208
Temple, A. R., *see* Chen, C. N., 38
Thakar, K. A., Goswami, D. D., and Choudhari, S. R., synthesis of 2-(substituted anilino) 4-substituted phenyl)thiazoles, 587
Thomford, N. R., *see* Caldwell, J. H., 415
Thompson, C. C., *see* Webb, N. E., 165
Thompson, E. B., and Anderson, C. C., cardiovascular effects of *Azadirachta indica* extract, 1476
Thurston, G. B., and Martin, A., rheology of pharmaceutical systems: oscillatory and steady shear of non-newtonian viscoelastic liquids, 1499
Timko, R. J., and Lordi, N. G., *in vitro* evaluation of three commercial sustained-release papaverine hydrochloride products, 496
Timmermans, P. J. A., *see* Driessen, O., 1494
Tipnis, V. V., *see* Redalieu, E., 726
Toama, M. A., El Fatatry, H. M., and El Falaha, B., *in vitro* studies on drug–antibiotic interactions I: analgesics, antipyretics, antimalarials, and tranquilizers, 23
Tolan, J. W., *see* Fink, D. W., 837
Tomecko, G. W., *see* Stratford, E. S., 80
Tomlinson, R. V., *see* Mroszczak, E. J., 920
Tomolonis, A., *see* Chowhan, Z. T., 1645
Torde, R. F., *see* Winder, W. C., 492
Torkelson, A. R., *see* Weaver, F. A., 1009
Torrance, S. J., *see* Hoffmann, J. J., 1633
Toultou, E., *see* Donbrow, M., 95
Townley, E. R., *see* Upton, L. M., 913
Treitman, J. A., *see* Grebow, P. E., 1117
Triplett, J., *see* Hussain, A., 742
Trzeciakowski, J., and Chiou, C. Y., pharmacological studies on *N*-demethylated carbachol, 531
Tsai, W., *see* Belmonte, A. A., 517
Tseng, W.-C. R., *see* Kupchik, E. J., 576
Tsuji, A., Miyamoto, E., Hashimoto, N., and Yamana, T., GI absorption of β-lactam antibiotics II: deviation from pH-partition hypothesis in penicillin absorption through *in situ* and *in vitro* lipoidal barriers, 1705
——Miyamoto, E., Kagami, I., Sakaguchi, H., and Yamana, T., GI absorption of β-lactam antibiotics I: kinetic assessment of competing absorption and degradation in GI tract, 1701
——Nakashima, E., Hamano, S., and Yamana, T., physicochemical properties of amphoteric β-lactam antibiotics I: stability, solubility, and dissolution behavior of amino penicillins as a function of pH, 1059
Tsuji, K., and Lewis, A. R., evaluation of acceptance criteria for particulate limits for small-volume parenteral products, 50
Tterlikkis, L., *see* Day, J. L., 1027
Tuckerman, M. M., *see* Burns, L. B., 258
Turner, C. E., *see* Elsohly, M. A., 124
——*see* Lewis, G. S., 876
Turner, W. A., *see* Dimmock, J. R., 401
Twomey, T. M., and Hobbs, D. C., analysis of prazosin in plasma by a sensitive high-performance liquid chromatograhic–fluorescence method, 1468

U

Umagat, H. J., *see* Philip, C. E., 1752
Underberg, W. J. M., oxidative degradation of pharmaceutically important phenothiazines I: isolation and identification of oxidation products of promethazine, 1128
——oxidative degradation of pharmaceutically important phenothiazines II: kinetics and mechanism of promethazine oxidation, 1133
——oxidative degradation of pharmaceutically important phenothiazines II: quantitative determination of promethazine and some degradation products, 1131
Underwood, F. L., and Cadwallader, D. E., automated potentiometric procedure for studying dissolution kinetics of acidic drugs under sink conditions, 1163
Unger, S. H., Cook, J. R., and Hollenberg, J. S., simple procedure for determining octanol–aqueous partition, distribution, and ionization coefficients by reversed-phase high-pressure liquid chrromatography, 1364
Upton, L. M., Townley, E. R., and Sancilio, F. D., analysis of steroid phosphates by high-pressure liquid chromatography: betamethasone sodium phosphate, 913
Upton, R. A., Ashley, J. J., and Ryan, A. J., pharmacokinetics of aryldihydro-*s*-triazines with antifolate activity II: blood levels and their relevance to antineoplastic activity in rats, 310
——*see* Ryan, A. J., 306
Upton, R. P., *see* Kirchmeier, R. L., 1444

V

Vallner, J. J., *see* Capomacchia, A. C., 1042
——*see* Parsons, D. L., 1344
——*see* Shams-Eldeen, M. A., 1077
Vanderwielen, A. J., *see* Allen, P. V., 1087
Van Lear, G. E., Chiccarelli, F. S., Bonenfant, P. A., and Barr, A., quantitation of the anti-inflammatory agent fenbufen and its metabolites in human serum and urine using high-pressure liquid chromatography, 1662
Van Meerssche, M., *see* Bouche, R., 1019
Vaughan, D. P., and Dennis, M., mathematical basis of point–area deconvolution method for determining *in vivo* input functions, 663
Veng Pedersen, P., general treatment of competitive binding of small molecules to macromolecules as applied to dynamic dialysis: theoretical analysis, 908
——general treatment of linear pharmacokinetics, 187
——and Myrick, J. W., versatile kinetic approach to analysis of dissolution data, 1450
Venkataramanan, R., and Axelson, J. E., electron-capture detector GLC technique for estimating tocainide in biological fluids, 201
Veronich, K., *see* Hanna, S., 1723
Verpoorte, R., and Svendsen, A. B., alkaloids of *Strychnos dolichothyrsa* Gilg ex Onochie et Hepper, 171
Vestal, R. E., *see* Miller, A. K., 1192
Vestergaard, P., *see* Jindal, S. P., 260, 811, 1483
Villalonga, F. A., and Phillips, E. W., interaction of doxorubicin with phospholipid monolayers, 773
Vincent, M., *see* Garrett, E. R., 145
Vinh, C. T., Braun, J., and Plourde, J. R., determination of clonazepam in tablets by dc polarography, 731
Viswanath, D. V., and Jenkins, H. J., neuromuscular block of the polymyxin group of antibiotics, 1275
Vochten, R., *see* Demeester, J., 729
Vollmer, K.-O., *see* Hengy, H., 1765

W

Wagner, J. G., *see* Albert, K. S., 1582
Wagner, R. J., *see* Winder, W. C., 492
Wagner, W. E., Jr., *see* Redalieu, E., 726
Wahbi, A. M., Abdine, H., Korany, M. A., and El-Yazbi, F. A., spectrophotometric analysis of binary mixtures of antazoline and naphazoline, 140
Wahner, H., *see* Hussain, A., 742
Wainer, I. W., and Stambaugh, J. E., GLC determination of meperidinic and normeperidinic acids in urine, 116
Walker, R. B., Ayres, J. W., Block, J. H., and Lock, A., *tert*-butoxycarbonyl as a convenient protecting group in synthesis of potential centrally active dopamine derivatives, 558
Walkling, W. D., Bonfilio, A. C., and Jacoby, H. I., possible ion-pair-mediated absorption of mixidine I: partitioning and lethality studies, 945
——Holmes, D. G., Cressman, W. A., Dix, R. K., Piperno, E., and Mosher, A. H., possible ion-pair-mediated absorption of mixidine II: plasma levels and histology, 948
Wallace, J. E., *see* Ludden, T. M., 371
Wallace, S. M., *see* Hindmarsh, K. W., 1547
Waller, C. W., *see* Craig, J. C., 483
Walson, P. D., *see* Chang, S. Y., 679, 682
Wan, S. H., Maronde, R. W., and Matin, S. B., GLC determination of atenolol and β-blocking agents in biological fluids, 1340
Wang, L. Y., *see* Nelson, K. G., 86
Ward, R. L., *see* Schoenwald, R. D., 786, 1280
Warner, V. D., *see* Musto, J. D., 266
Warren, J. D., Lang, S. A., Jr., Chan, P. S., and Marsico, J. W., quinazolinylformamidines and quinazolinediylbisformamidines as antihypertensive agents, 1479
Warren, R. J., Zarembo, J. E., Staiger, D. B., and Post, A., quantitative determination of cephalexin in cepharadine by NMR spectroscopy, 1481
Watson, E., and Chan, K. K., GLC–mass spectrometry of several important anticancer drugs I: pertrimethylsilylation and *O*-methoxime formation, 1243
——*see* Chan, K. K., 1748
Watson, E. J., *see* Schwan, T. J., 421
Watson, J. R., Lawrence, R. C., and Lovering, E. G., simple GLC analysis of anticonvulsant drugs in commercial dosage forms, 950
Watts, R. F., *see* Piccirilli, R. M., 740
——*see* Popp, F. D., 871
Weaver, F. A., Torkelson, A. R., Zygmunt, W. A., and Browder, H. P., tissue culture cytotoxicity assay for cyclophosphamide metabolites in rat body fluids, 1009
Webb, N. E., and Thompson, C. C., molecular complexing ability of quinoline and its simple derivatives, 165
Weddle, O. H., Amick, E. N., and Mason, W. D., rapid determination of atenolol in human plasma and urine by high-pressure liquid chromatography, 1033
Weidler, D. J., *see* Albert, K. S., 1582
Weinstein, S. H., Alteras M., and Gaylord, J., quantitative determination of nalbuphine in plasma using electron-capture detection, 547
Weintraub, H. S., Abrams, L. S., Patrick, J. E., and McGuire, J. L., disposition of norgestimate in the presence and absence of ethinyl estradiol after oral administration to humans, 1406
——*see* Abrams, L. S., 1287
Weiss, A. L., *see* Huber, R. C., 1239
Welch, R. D., *see* Albert, K. S., 1579
Welco, A. D., *see* Jurgens, R. W., Jr., 1485
Welling, P. G., and Craig, W. A., pharmacokinetics of intravenous erythromycin, 1057
——Huang, H., Hewitt, P. F., and Lyons, L. L., bioavailability of erythromycin stearate: influence of food and fluid volume, 764
——*see* Koch, P. A., 1533
Wen, L.-F. L., *see* Bohannon, T. E., 815
White, J. L., *see* Porubcan, L. S., 1081
——*see* Serna, C. J., 324, 1144, 1179
Whitfield, L. R., *see* Kaul, P. N., 60
Wiedhopf, R. M., *see* Hoffmann, J. J., 1633
Williams, F. D., *see* Ramachander, G., 761
Wills, R. J., *see* Koch, P. A., 1533
Wilson, W. L., *see* LeBelle, M. J., 1495
Winder, W. C., Lohman, F. H., Torde, R. F., and Wagner, R. J., ultrasonic method for direct and simultaneous determination of alcohol and soluble solids content of mouthwash, 492
Wingard, L. B., Jr., *see* Levy, G., 867
Wishousky, T. I., *see* Zacchei, A. G., 162
Wojciechowski, N. J., *see* Solomons, W. E., 314
Wolf, W., *see* Shani, J., 344
Wolshin, E. M., Cavanaugh, M. H., Manion, C. V., Meyer, M. B., Milano, E., Reardon, C. R., and Wolshin, S. M., assay of tocainide in blood by high-pressure liquid chromatography, 1692
Wolshin, S. M., *see* Wolshin, E. M., 1692
Wolverton, W., *see* Lazer, E. S., 1656

Wood, P. R., *see* Kaye, B., 1170
Wood, R. J., *see* McErlane, K. M., 958
Woodard, G. D., McDonald, R., and Cox, J. S. G., interaction of cromolyn sodium in aqueous solution with magnesium ions, 1403
Woodhead, J. H., *see* Swinyard, E. A., 1758
Woodward, D. L., *see* Glamkowski, E. J., 1773
Wooten, R., *see* Biehl, E. R., 927
Woroniecki, S. R., *see* Munro, A. C., 1197
Wright, D. E., *see* Hamon, N. W., 1539
Wright, J. L., *see* Carstensen, J. T., 48, 982
Wu, Y.-S., *see* Hall, I. H., 1235
Wunderly, S. W., *see* Brochmann-Hanssen, E., 103
Wylie, L. T., *see* Ziegler, V. E., 554
Wyman, M. G., *see* Ludden, T. M., 371

X

Y

Yacobi, A., Look, Z. M., and Lai, C. M., simultaneous determination of pseudoephedrine and chlorpheniramine in pharmaceutical dosage forms, 1668
——*see* Levy, G., 229
——*see* Stoll, R. G., 1328
Yadav, R. N., and Teare, F. W., determination of fluoxymesterone, norethandrolone, prednisolone, and prednisone in tablets by differential pulse polarography, 436
——*see* Teare, F. W., 1641
Yakatan, G. J., Frome, E. L., Leonard, R. G., Shah, A. C., and Doluisio, J. T., bioavailability of acetazolamide tablets, 252
Yamana, T., *see* Tsuji, A., 1059, 1701, 1705
Yap, P. S. K., and Fung, H.-L., pharmacokinetics of nitroglycerin in rats, 584
——McNiff, E. F., and Fung, H.-L., improved GLC determination of plasma nitroglycerin concentrations, 582
Yata, N., *see* Stella, V., 1375
Yeh, S. Y., McQuinn, R. L., Krebs, H. A., and Gorodetzky, C. W., metabolism and excretion of normorphine in dogs, 878
Yeung, A. K., *see* Grebow, P. E., 1117
Yonezawa, Y., *see* Otsuka, A., 151
Yoshikawa, F., *see* Jee, J., 438
Youssef, M. K., Attia, I. A., and Safwat, S., paper chromatographic determination of chlortetracycline, 556
Yung, D. K., Gilroy, M. L., and Mahony, D. E., synthesis and quantitative structure–activity relationships of antibacterial 1-(substituted benzhydryl)-4-(5-nitro-2-furfurylideneamino)piperazines, 900
Yung, S., Mayersohn, M., and Robinson, J. B., ascorbic acid elimination in humans after intravenous administration, 1491

Z

Zacchei, A. G., and Wishousky, T. I., GLC determination of the polyvalent saluretic uricosuric agent (2-cyclopentyl-6,7-dichloro-2-methyl-1-oxo-5-indanyloxy)acetic acid in biological fluids, 162
Zacest, R., *see* Reece, P. A., 1150
Zalipsky, J. J., Patel, D. M., and Reavey-Cantwell, N. H., characterization of impurities in sulfasalazine, 387
——Patel, D. M., and Reavey-Cantwell, N. H., hydrolytic degradation of 2,6-dichlorobenzylthiopseudourea hydrochloride, 256
Zarembo, J. E., *see* Warren, R. J., 1481
——*see* Shahi, V., 789
Zatz, J. L., comparison of adsorbed films of a polyvinylpyrrolidone copolymer with spread monolayers, 1464
Zavattini, G., *see* Marcucci, F., 705
Zelenski, S. G., *see* Keller, W. J., 430
Zelesko, M. J., *see* Maryanoff, B. E., 590
Zentner, G. M., Cardinal, J. R., and Kim, S. W., progestin permeation through polymer membranes I: diffusion studies on plasma-soaked membranes, 1347
——Cardinal, J. R., and Kim, S. W., progestin permeation through polymer membranes II: diffusion studies on hydrogel membranes, 1352
Zia, H., *see* Needham, T. E., 1070
Ziegler, V. E., Wylie, L. T., and Biggs, J. T., intrapatient variability of serial steady-state plasma tricyclic antidepressant concentrations, 554
Zimmerman, J. J., rapid attainment of successively higher steady-state plasma levels using the Wagner two-step infusion method, 1651
Zoglio, M. A., *see* DeYoung, J. L., 320
——*see* Mehta, A., 905
Zuleski, F. R., Loh, A., and Di Carlo, F. J., determination of ethinyl estradiol in human urine by radiochemical GLC, 1138
Zygmunt, W. A., *see* Weaver, F. A., 1009
Zymalkowski, F., *see* Chaudhuri, R. K., 1321

A

Absorption—4-aminoantipyrene and ethanol by goldfish, effect of temperature and surfactant, 1558
—dexamethasone in humans, effect of concomitant administration of magnesium trisilicate, 1029
GI—aspirin in humans, effect of food and fluid volume, 1533
GI—digoxin, effect of kaolin–pectin suspension in humans, 1582
GI—ellipticine, effect of polyvinylpyrrolidone, 611
GI—erythromycin stearate, effect of food and fluid volume, humans, 764
GI—griseofulvin from aqueous phase and aqueous phases containing triolein digestion mixture, rats, 895
GI—β-lactam antibiotics, kinetics in rats, 1701
GI—methotrexate from rat small intestine *in situ*, 560
GI—propicillin, deviation from pH–partition hypothesis rats, 1705
GI—salicylate, effect of ascorbate, rat intestine *in vivo* and *in vitro*, 224
GI—various alkylamine antihistamines, effect of partition coefficient, rats, 1041
GI—various cephalosporins, effect of ionization, rats, 320
—lipophilic drugs from perfused rat intestine, effects of various fatty acids, 1211
—mixidine, effect of intraduodenal administration with various ratios of 2-naphthalenesulfonic acid as counterion, 948
—mixidine in rats, determined by lethality, 945
percutaneous—naproxen, effect of various surfactants, *in vivo* and *in vitro* correlations in rats, 1645
percutaneous—naproxen, effect of various surfactants, rabbit, rat, and human skin compared, 1272
percutaneous—nitroglycerin in rats, effect of application site, 1345
percutaneous—salicylic acid, effect of repeated application, rats, 1685
—quinidine sulfate, four commercial tablets, related to dissolution profiles, 568
rates—pentobarbital from capsules and suppositories in humans, 1586
urinary bladder—saccharin in rats, 1493
Abuse drugs—*N*-ethyl-1-phenylcyclohexylamine identified in street sample by NMR, IR, and mass spectral data, 885
Acetaminophen—differential pulse voltammetric analysis in plasma, 1775
—effect on metabolism of dextromethorphan hydrobromide in rats, 761
prodrug—1-(*p*-acetaminophenoxy) -1- ethoxyethane synthesized, hydrolysis rate and bioavailability studied, dogs, 545
—spectrophotometric analysis in plasma, 581
1-(*p*-Acetaminophenoxy) -1- ethoxyethane—acetaminophen prodrug synthesized, hydrolysis rate and bioavailability studied, dogs, 545
Acetazolamide—bioavailability of various tablet lots compared in humans, 252
17β-Acetoxy-2α-chloro-3-(*p*-nitrophenoxy)imino-5α-androstane—bioavailability from solutions and suspensions in rats and humans, 1287
7-Acetylacroninium perchlorate—two-component spectrophotometric analysis with acronine in parenteral solutions, 237
Acetylation—isoniazid in humans, genetic phenotypes determined using metabolic clearance values, 1018
Acetylcholine analogs, various—synthesized, evaluated as inhibitors of choline acetyltransferase, 657
antagonists, various—molecular connectivity indexes correlated to muscarinic receptor affinity, 1408
***N*-Acetylprocainamide**—high-performance liquid chromatographic analysis simultaneously with procainamide in plasma, 839
—high-pressure liquid chromatographic analysis simultaneously with procainamide in plasma, 869
Acridan, substituted—mechanism of anaerobic flavin-catalyzed photooxidation, 318
Acridines, various—antibacterial activity related to electronic structure, 706
Acronine—two-component spectrophotometric analysis with 7-acetylacroninium perchlorate in parenteral solutions, 237
Acylated amino acids, various—evaluated in microbial antitumor screen, 520
Adduct forming agents—effect on aqueous–octanol partition coefficient of ampicillin, 138
Adenosine analogs, various—evaluated as smooth muscle vasodilators, dog hindlimb preparation, 121
diphosphate—effect on human platelet aggregation with and without various prostaglandins, kinetic study, 939
β-Adrenergic blocking activity—thiazolylthiopropanolamine derivative evaluated in dogs, 1334
Adrenergics—epinephrine, levarterenol, and isoproterenol, colorimetric analyses in bulk drug and dosage forms, 779
—epinephrine, oxidation in alkaline solutions, effect of sodium metabisulfite and cysteine, 1474
—naphazoline nitrate, spectrophotometric analysis simultaneously with antazoline hydrochloride in pharmaceutical formulations, 140
—phenylephrine hydrochloride and phenylpropanolamine hydrochloride, high-pressure liquid chromatographic analyses in dosage forms, 873
—phenylpropanolamine, fluorometric analysis in dosage forms, 1635
—phenylpropanolamine, GLC analysis in presence of chlorpheniramine, human urine, 118
—pseudoephedrine, high-pressure liquid chromatographic analysis, simultaneously with chlorpheniramine, in dosage forms, 1668
β-Adrenoceptor blocking activity—*l*-bunolol and propranolol compared in dogs, rats, and humans, oral and intravenous dosage, 132
Adrenocortical steroids—desoxycorticosterone acetate, subcutaneous release from microsealed drug delivery system in rats, *in vitro–in vivo* correlation, compared to matrix-type silicone device, 214
—fludrocortisone acetate tablets, dissolution, high-pressure liquid chromatographic analysis, 1397
Adsorption—cetrimonium bromide on dipalmitoylecithin monolayers, calculated from surface pressure–area isotherms, 364
—clindamycin and tetracycline to montmorillonite, IR and X-ray analyses of mechanism, 1081
—fluorouracil on glass surfaces, 1494
in vitro—emetine on activated charcoal, 426
in vitro—typical drugs to activated charcoal, effect of pepsin, 1181
in vitro—various progestins, estrogens, and commercial contraceptive tablets by magnesium trisilicate, 287
—polyvinylpyrrolidone copolymer from solution, studied by surface pressure measurement, films compared to spread monolayers, 1464
vapor—combined with immersional calorimetry procedure to characterize solid–liquid interactions of microcrystalline cellulose–water system, 1599
—various drugs and proteins to glass surfaces studied using controlled pore glass, effect of pH, 1102
—various drugs to two ion-exchange resins in simulated gastric fluid, compared to previous results with charcoal, 1329
Aerosol constituents—polyethylene glycol 400, effect on pulmonary dynamics in perfused isolated guinea pig lung, 1002
Age—of subject, effect on plasma protein binding of tolbutamide in humans, 1192
Aggregation, platelet—kinetic study, effect of adenosine diphosphate, various prostaglandins, and arachidonic acid, 939
Agitation intensity—effect on disintegration time of specially fabricated and commercial tablets, 210
Alanine derivatives, various—synthesized, evaluated for cytotoxic activity, 642
Albumin—effect on drug–protein binding, Scatchard plots with positive slopes, 1193
human serum—binding to dantrolene, fluorescence quenching study, mechanism evaluated, 1042
human serum—simultaneous salt and ethanol removal by diafiltration, 431
Alcohol—ultrasonic analysis in pharmaceutical formulations, 492
Alcohols, aliphatic series—hydroxyl group contribution to free energy of transfer from one phase to another, 615
Aldehydes, various—reaction with dopamine, formation rate of isoquinoline alkaloids, 112
Alkaline picrate—analysis, creatinine in human plasma, compared to high-pressure liquid chromatography and automated analysis, 292
Alkaloids—anhydrocannabisativine isolated from ethanol extract of leaves and roots of *Cannabis sativa*, structure determined, 124
Catharanthus—vindesine, high-performance liquid chromatographic and TLC analyses, bulk drug, 1319
—emetine, *in vitro* adsorption on activated charcoal, 426
—from stem bark of *Strychnos dolichothyrsa* isolated and identified, muscle relaxant activity evaluated, 171
—isolated from various *Tabernaemontana* species or synthesized, structural effects on cytotoxicity evaluated, 272
isoquinoline—formation rate by reaction of various catecholamines and aldehydes, 112
morphine—biosynthesis in *Papaver bracteatum*, radiochemical study, 103
—quindoline and CSA-3 isolated from ethanol extract of roots of *Cryptolepis sanguinolenta*, 433
various—isolated from aboveground portions of *Lupinus argenteus* var. *stenophyllus*, 430
various—isolated from *Tabernaemontana arborea* sap, cytotoxic activity evaluated, 271
various—isolated from *Tabernaemontana johnstonii* stem bark, structures elucidated, cytotoxic activity evaluated, 249
various quaternary—Hofmann elimination reaction with diazomethane, 473
various tropane—^{13}C-NMR spectra determined, carbon resonances assigned, 775
Alkoxyacylaminoacylanilides, various—synthesized, evaluated for local anesthetic activity in rats, 595
Allyl alcohols—various 1-phenyl-1-nonen-3-one derivatives synthesized, 1536
Aluminum hydroxide gel—factors affecting homogeneous precipitation in hydrolysis of aluminum nitrate by sodium carbonate, 1179
Aluminum hydroxycarbonate, amorphous—prepared by titration of sodium carbonate with aluminum nitrate, physicochemical nature studied, model for particle surface at solution interface proposed, 1144
Amanita pantherina—GLC–mass spectral analysis of various components, 485
Amines, aliphatic series—amino group contribution to free energy of transfer from one phase to another, 615
Amino acid analogs—4-fluoroisoleucine synthesized and evaluated for antimicrobial activity, 715
Amino acids—tyrosine and tryptophan, simultaneous spectrophotometric analyses in solutions, 729

various acylated—evaluated in microbial antitumor screen, 520
—various alanine derivatives synthesized, evaluated for cytotoxic activity, 642
ω-Amino acids and derivatives, various—reversed-phase TLC for correlation between structure and biological response, various fatty acids and derivatives evaluated as stationary phases, 713
3-Aminoacridinium monocations—binding to double-stranded DNA, equilibrium expressions developed, 89
17β-Aminoandrostenes, substituted—synthesized, evaluated for anti-inflammatory activity in rats, 1215
4-Aminoantipyrine—accumulation by goldfish, effect of temperature and surfactant, 1558
Aminobenzoic acids, various—microequilibrium constants of protolytic dissociation estimated spectrophotometrically, 334
4-Amino-3-hydroxybutyric acid—three-step synthesis from crotonic acid, 120
7-Aminoquinolinium monocations—binding to double-stranded DNA, equilibrium expressions developed, 89
Amitriptyline—effect on polarographic analysis of chlordiazepoxide, commercial products and synthetic mixtures, 1297
—fluorometric analysis, blood and tissues, 60
Amphotericin B—different IR spectra attributed to method of sample preparation, 398
Ampicillin—aqueous-octanol partition coefficient, effect of various ion-pair or adduct forming additives, 138
Amygdalin acid—synthesized, high-pressure liquid chromatographic analysis in amygdalin dosage forms, 1190
Amygdalinamide—synthesized, high-pressure liquid chromatographic analysis in amygdalin dosage forms, 1190
Amygdalin dosage forms—IR and NMR spectral identification and high-pressure liquid chromatographic analysis of components in various products, 438
Anabolic steroids—ethylestrenol impurity, stereochemistry at C-5 assigned, 1187
Analgesics—acetaminophen and salicylamide, effect on metabolism of dextromethorphan hydrobromide in rats, 761
—acetaminophen, differential pulse voltammetric analysis in plasma, 1775
—acetaminophen, prodrug synthesized, hydrolysis rate and bioavailability studied, dogs, 545
—acetaminophen, spectrophotometric analysis in plasma, 581
—aspirin–acetaminophen–urea ternary system, dissolution rates, 1112
—aspirin–acetaminophen–urea ternary system, phase diagram constructed, physical properties evaluated, 1109
—aspirin and salicylic acid, colorimetric analyses in human plasma, 289
—aspirin and salicylic acid, liquid chromatographic analyses in multicomponent tablets, 1066
—aspirin, bioavailability in humans, effect of food and fluid volume, 1533
—aspirin, excretion in humans correlated with parameters from various in vitro dissolution methods, 1070
—aspirin, salicylic acid, and salicyluric acid, simultaneous high-pressure liquid chromatographic analyses in plasma, 710
—aspirin, stability in solid dispersion binary systems with urea or povidone, effect of temperature and humidity, 1631
—1-butyryl-4-cinnamylpiperazine, ion cluster–mass chromatographic analyses of urinary metabolites in mice and guinea pigs, 757
—indoprofen, high-performance liquid chromatographic analysis in biological fluids, 831
—nalbuphine, electron-capture GLC analysis in plasma, 547
narcotic—meperidine metabolites, GLC analyses in humane urine, 116
—nefopam, GLC analysis in plasma, 1720
—suprofen, high-performance liquid chromatographic analysis in plasma, 985
—tilidine and metabolites, GLC analyses in biological fluids, 1765
various—antimicrobial activity, effect of combination with various antibiotics, 12
various—high-pressure liquid chromatographic analyses in mixtures with muscle relaxants, 675
Androgens—fluoxymesterone and norethandrolone, differential pulse polarographic analysis in tablets, 436
Anesthetic activity, local—various alkoxyacylaminoacylanilides evaluated in rats, 595
local—various benzo[*b*]furan derivatives evaluated, 125
Anesthetics, local—effect on electrically excitable bilayer lipid membranes, 965
topical—benzocaine, diffusion from various polyethylene glycol ointment bases through human stratum corneum, 517
topical—lidocaine, GLC analysis in plasma, 887
—various aliphatic ethers, activity related to molecular connectivity indexes, 564
—various aliphatic hydrocarbons, ethers, and ketones, activity related to molecular connectivity indexes, 566
Anhydrocannabisativine—isolated from ethanol extract of leaves and roots of *Cannabis sativa*, structure determined, 124
Anilines, various substituted—kinetics of reaction with sodium hydroxymethanesulfonate, equilibrium and hydrolysis rate constants calculated, 1283
1-Anilino-8-naphthalenesulfonic acid—binding to various antipsychotic and antidepressant drugs, fluorometric study, 861
Antacids—aluminum hydroxide gel, factors affecting homogeneous precipitation in hydrolysis of aluminum nitrate by sodium carbonate, 1179
—amorphous aluminum hydroxycarbonate, prepared by titration of sodium carbonate with aluminum nitrate, physicochemical nature studied, model for particle surface at solution interface proposed, 1144
—magnesium trisilicate, effect on dexamethasone absorption, concomitant administration in humans, 1029
—magnesium trisilicate, *in vitro* adsorption of various progestins, estrogens, and commercial contraceptive tablets, 287
various carbonate containing—IR and X-ray structural analysis, compared to naturally occurring carbonate minerals, 324
Antazoline—spectrophotometric analysis in prepared solutions and dosage forms, 1610
Antazoline hydrochloride—spectrophotometric analysis simultaneously with naphazoline nitrate in pharmaceutical formulations, 140
Anterior pituitary suppressants—danazol, radioimmunoassay in human and monkey plasma, 1425
Anthelmintics—oxfendazole, radioimmunoassay in plasma or serum, 1553
Antiadrenergic agents—atenolol, GLC analysis in biological fluids, 1340
—atenolol, high-pressure liquid chromatographic determination in biological fluids, 1033
—*l*-bunolol, β-adrenoceptor blocking activity compared in dogs, rats, and humans, oral and intravenous dosage, 132
—*l*-bunolol, metabolism in rats, urinary metabolites identified, 129
—dihydroergotoxine, high-performance liquid chromatographic analyses of four components in bulk drug and pharmaceutical formulations, 98
—8-hydroxycarteolol, high-pressure liquid chromatographic analysis in plasma and urine, 1623
—nadolol, colorimetric analysis in tablets, 1024
—nadolol, GLC–mass spectrometric analysis in serum, 653
Antiallergic activity—various spirofluorenes evaluated, 953
Antiallergic compounds, potential—substituted tetrazolylchromone, high-pressure liquid chromatographic analysis in biological fluids, 1185
Antiallergy agents, potential—various heterocyclic oxamates evaluated, 735
Antiarrhythmic agents—quinidine and dihydroquinidine, various cardiac effects compared in isolated heart and *in vivo* in dogs, 1355
—quinidine, pharmacokinetics and bioavailability of three dosage forms compared, humans, 1456
Antiasthmatic agents—cromolyn sodium, interaction with magnesium ions in solution, 1403
Antibacterial activity—3-aryl-3-hydroxypropanethioates evaluated, 413
—evaluated for various substituted benzothiazoles, 281
—evaluated in various commercial solutions of benzalkonium chloride, related to composition, 380
—evaluated in various compounds isolated from methanolic extracts of hard and soft sponge *Verongia archeri*, 264
—evaluated in various substituted piperazines, 900
—various acridines, related to electronic structure, 706
—various isothiocarbamates evaluated, 576
—various 3-substituted 1,2-benzisothiazole 1,1-dioxides evaluated, 1323
—various substituted 1,2,3-selenadiazoles evaluated, 1336
Antibacterial–antirickettsials—chloramphenicol, high-pressure liquid chromatographic analysis in plasma, 1036
Antibacterials—ampicillin, aqueous-octanol partition coefficient, effect of various ion-pair or adduct forming additives, 138
—benzylpenicillenic acid degradation in neutral media, differential pulse polarographic study, penicillamine demonstrated as product, 302
—cefazolin, TLC-densitometric analysis in biological fluids, 1170
—cephalexin, NMR spectroscopic analysis in cephradine bulk drug and dosage forms, 1481
—cephalexin, polarographic analysis in dosage forms, 1466
—cephalexin, prolonged-release tablet compared to capsule and intravenous administration, dissolution *in vitro* and bioavailability in humans, 1620
—cephradine and cephalexin, pharmacokinetics compared, capsules and tablets, in humans, 1447
—chlortetracycline, paper chromatographic analysis in pharmaceutical preparations, 556
—clindamycin and tetracycline, adsorption to montmorillonite, IR and X-ray analyses of mechanism, 1081
—clindamycin base, phosphate, and palmitate, high-pressure liquid chromatographic analyses in bulk drug and dosage forms, 1254
—clindamycin, orally administered, effect of kaolin–pectin suspension on bioavailability in humans, 1579
—effect of paromomycin on R-factor transfer of tetracycline resistance from *Escherichia coli* to *Salmonella pullorum*, 35
—erythromycin oxime and amine, kinetics of acid-catalyzed hydrolysis, 1031
—erythromycin, pharmacokinetics after intravenous administration in humans, 1057
—erythromycin, physical characterization of anhydrate, monohydrate, and dihydrate crystalline solids, dissolution rates in aqueous solution, 1087
—erythromycin stearate, bioavailability, effect of food and fluid volume, humans, 764
—hydroxylaminoeverninomicin D, polarographic analysis, bulk drug, 719
—penicillin V benzathine, iodometric analysis, interference by benzathine molecule, 1495
—polymyxin and colistin, neuromuscular blocking effect in rabbits and cat and frog muscle preparations, 1275
—polymyxin B, complexation with nickel(II) in aqueous media, effect of pH and ligand concentration, 1313
—sulfadiazine, bioavailability of various dosage forms compared in humans, 1659
—sulfadiazine, sulfamethazine, and sulfamerazine,

high-pressure liquid chromatographic analyses *in human serum*, 404
—sulfamethizole, bioavailability in humans and *in vitro* dissolution, two suspensions compared, 1399
—sulfasalazine, various impurities isolated and characterized, 387
—sulfathiazole, flocculation–deflocculation behavior, effect of glycyrrhizic acid, aqueous solutions, various pH values, 151
—tetracycline, complexation with calcium and organic ligands, mechanism of fluorometric analysis, 1518
—tetracyclines, partitioning in aqueous–octanol system, kinetics and thermodynamics, effect of divalent metal salts, 1717
—tetracyclines, partitioning in aqueous–octanol system, kinetics and thermodynamics, effect of hydroxyl group, 1715
topical—pyrogallol, oxidative degradation in aqueous systems, effect of dissolved oxygen levels, 1338
urinary—nitrofurantoin, *in vitro* dissolution rate, effect of formulation and process variables, 1613
urinary—nitrofurantoin, various formulations, bioavailability in humans correlated to dissolution *rate in vitro*, 1616
—various amino penicillins, stability, solubility, and dissolution rates, effect of pH, 1059
—various cephalosporins, GI absorption, effect of ionization, rats, 320
—various cephalosporins, microionization equilibrium constants determined, 666
—various penicilloic and penilloic acids, immunological cross-reactions evaluated *in vitro*, 1197
—various silver sulfonamides, aqueous solubility, effect of pH, 1012
—various sulfonamides, separation from degradation products by liquid–liquid extraction, 1415

Antibiotic reference standards, official—microbiological assays, formulas for simple, quick analysis of data, 1050

Antibiotics—cefaloram, synthesized by *N*-acylation of *tert*-butyl-7-aminocephalosporanate using polystyrene-bound anhydrides, 110
—cycloheximide, high-pressure liquid chromatographic analysis in bulk drug and prepared formulations, 669
β-lactam—crystallinity determined by solution calorimetry, correlated with chemical stability, 767
β-lactam—kinetics of GI absorption and nonenzymatic degradation in rats, 1701
β-lactam—propicillin, GI absorption, deviation from pH–partition hypothesis, rats, 1705
various cephalosporin—pharmacokinetic analysis using two-compartment and perfusion models, 191
various—effect of combination with various analgesics, antipyretics, antimalarials, and tranquilizers, 23

Antibiotic susceptibility disks—effect of various *grades of paper on performance*, 367

Antibodies—to hapten–bovine serum albumin conjugates of various tricyclic antidepressants, developed in rabbits, 1571
—to three chlorpromazine haptens developed in *rabbits*, 1563

Anticholinergic activity—*N*-methyl-4-piperidinyl α-benzoyloxy-α-cyclopentylphenylacetate evaluated *in rabbit eyes*, 701

Anticholinergics—effect of pretreatment on hypothermic response to cobaltous chloride in mice, 799
—scopolamine, cutaneous permeation, mathematical model for pharmacokinetics in human skin, 1370

Anticoagulant effect—(*R*)-(+)- and (*S*)-(−)-warfarin *compared, humans*, 867

Anticoagulants, coumarin—dicumarol, *in vivo* binding to serum proteins and tissues, effect of tolbutamide in rats, 1492
—dicumarol, total clearance in rats, frequency distribution, 337
—warfarin and dicumarol, *in vivo* binding in rat liver, implications for pharmacokinetic modeling, 229
—warfarin, GLC analysis in human plasma, 84

Anticonvulsant activity—evaluated in substituted imidazolidinethiones and various thioimidazolines, 600
—evaluated in various substituted benzo[*a*]-quinolizines, 871
—various oxadiazoles evaluated in mice, 987
—various substituted oxadiazole-2-thiones evaluated in mice, 1507
—various substituted pyrazolidines evaluated in mice, 1471
—various substituted trimethoxybenzamides evaluated in mice, 1682

Anticonvulsants—4-amino-3-hydroxybutyric acid, three-step synthesis under mild reaction conditions, 120
—clonazepam, dc polarographic analysis in tablets, 731
—clonazepam, pharmacokinetics in rhesus monkeys, 295
—ethosuximide, pharmacokinetic parameters during single or divided daily doses compared using MULTDOS and 1969 or 1974 NONLIN *computer program*, 574
—phenytoin, high-pressure liquid chromatographic analysis in plasma, 1462
various—GLC analyses in commercial dosage forms, 950

Anticonvulsant–sedatives—phenobarbital, interaction with griseofulvin, effect of different dosage forms in rats, 466

Antidepressants—amitriptyline, effect on polarographic analysis of chlordiazepoxide, commercial products and synthetic mixtures, 1297
—amitriptyline, fluorometric analysis, blood and tissues, 60
—*cis*- and *trans*-doxepin, simultaneous GLC analyses in human plasma, 802
various—binding to 1-anilino-8-naphthalenesulfonic acid, *fluorometric study*, 861
various—plasma drug levels, intrapatient variability in steady state, 554
various tricyclic—GLC–chemical-ionization mass spectrometric analyses, human plasma, 17
various tricyclic—haptens synthesized, coupled to bovine serum albumin, antibodies developed in rabbits, 1571

Antidiabetic agents—tolbutamide, effect on *in vivo* binding of dicumarol to serum proteins and tissues in rats, 1492
—tolbutamide, plasma protein binding in humans, effect of subject age, 1192

Antidiarrheals—kaolin–pectin suspension, effect of bioavailability of orally administered clindamycin in humans, 1579
—kaolin–pectin suspension, effect on GI absorption and bioavailability of digoxin in humans, 1582

Antiemetics—metoclopramide, electron-capture GLC *analysis is biological fluids*, 1073
—promethazine, oxidative thermal degradation products isolated and identified, 1128
—promethazine, polarographic analysis, prepared samples, 1131
—promethazine, thermal degradation kinetics in acidic medium, effect of anaerobic and aerobic conditions, pH, metal ions, and antioxidants, 1133

Antifungal activity—evaluated in various substituted piperazines, 900
—various halofumarate alkyl esters evaluated, 578
—various isothiocarbamates evaluated, 576
—various 3-substituted 1,2-benzisothiazole 1,1-dioxides evaluated, 1323
—various substituted phthalimidines evaluated, 863
—various substituted 1,2,3-selenadiazoles evaluated, 1336

Antifungal agents—flucytosine, differential pulse polarographic analysis in dosage forms, 1641
—griseofulvin, GI absorption from aqueous phase and aqueous phases containing triolein digestion mixture, rats, 895
—griseofulvin, high-pressure liquid chromatographic analysis in plasma, 805
—griseofulvin, interaction with phenobarbital, effect of different dosage forms in rats, 466
topical—amphotericin B, different IR spectra attributed to method of sample preparation, 398

Antihistaminics—antazoline hydrochloride, spectrophotometric analysis simultaneously with naphazoline nitrate in pharmaceutical formulations, 140
—antazoline, spectrophotometric analysis in prepared solutions and dosage forms, 1610
—brompheniramine maleate, high-pressure liquid chromatographic analysis in dosage forms, 873
—chlorpheniramine, GLC analysis in presence of phenylpropanolamine, human urine, 118
—chlorpheniramine, high-pressure liquid chromatographic analysis, simultaneously with pseudoephedrine, in dosage forms, 1668
—diphenhydramine, effect on methaqualone metabolism in rat liver homogenate, 1547
—tripelennamine hydrochloride, release from inert carnauba or castor wax matrixes, 350
—tripelennamine hydrochloride, release from inert wax matrixes, effect of various surfactants, 354
—tripelennamine hydrochloride, release from inert wax matrix tablets, effect of povidone, 357
various alkylamine—GI absorption, effect of partition coefficient, rats, 1041

Antihypercholesterolemic activity—cholestyramine analog synthesized, *in vitro* binding of sodium cholate and cholesterol lowering effect in humans *evaluated*, 1695

Antihypertensive activity—substituted (indolylethyl)piperazinylureas evaluated in rats and dogs, 1773
—various substituted quinazolinylformamidines evaluated in rats, 1479

Antihypertensives—6,7 - dimethoxy -4- quinolinol, formed *in vivo* from 4,5-dimethoxykynuramine, 421
—hydralazine, interference in published GLC and spectrophotometric analyses in plasma by major metabolite, 1150
—indapamide, fluorometric analysis in urine, 1117
—methyldopa, colorimetric analysis in bulk drug and dosage forms, 779
—prazosin, high-performance liquid chromatographic–fluorescence analysis in plasma, 1468
—reserpine, high-performance liquid chromatographic analysis, simultaneously with hydrochlorothiazide, in tablets, 650
—sodium nitroferricyanide (nitroprusside), prepared solutions, chromatographic separation and *spectrophotometric analyses of free ferricyanide* and ferrocyanide, 1752

Anti-infectives, topical—camphorated parachlorophenol, high-pressure liquid chromatographic analyses of camphor and parachlorophenol, pharmaceutical formulations, 266
—thimerosal, high-pressure liquid chromatographic analysis in aqueous pharmaceutical preparations, 1636
—various silver sulfonamides, coordination properties and structures studied, 284

Anti-inflammatory activity—evaluated in substituted imidazo[1,5-*b*]isoquinolines, 718
—various substituted 17β-aminoandrostenes evaluated in rats, 1215
—various 1-substituted 2-imidazolidinones evaluated, 548

Anti-inflammatory agents—fenbufen, high-pressure liquid chromatographic analysis in serum and *urine*, 1662
—fenclorac, GLC analysis in plasma, 1171
—fenoprofen, various salts synthesized, evaluated as oral dosage forms, stability studies, 231
—ibuprofen, electron-capture GLC analysis in *serum, time course of protein binding in humans*, 627
—naproxen and various salts, solubility as a func-

tion of pH, 1257
—naproxen, percutaneous absorption, effect of various surfactants, *in vivo and in vitro* correlations in rats, 1645
—*naproxen, percutaneous absorption, effect of* various surfactants, rabbit, rat, and human skin compared, 1272
—*sulindac and metabolite, binding to human serum* albumin, 1077
Antileukemic activity—various substituted thiocolchicines evaluated, 394
Antimalarials—chloroquine and quinacrine, protolytic *dissociation, spectrophotometric evaluation,* 1770
—α-(dibutylaminomethyl)-6,8-dichloro - 2 - (3′,4′-*dichlorophenyl)-4-quinolinemethanol, bioavail*ability from two dosage forms compared, dogs, 1375
potential—α-dibutylaminomethyl - 2,6 - bis(*p*-trifluoromethylphenyl)-4-pyridinemethanol, *prototropic species characterized from electronic* absorption and fluorescence spectra at various pH values and in *n*-hexane, 1224
various—antimicrobial activity, effect of combination with various antibiotics, 23
Antimicrobial activity—*chlorocresol in solubilized and* emulsified systems, related to phase distribution with mathematical model, 1260
—*chlorocresol, role of capacity in solubilized and* emulsified systems, 1266
—evaluated in diastereoisomeric 4-dimethylamino-3-phenyl-2-butanols and related esters, 401
—*evaluated in various analgesics, antipyretics,* antimalarials, and tranquilizers, effect of combination with various antibiotics, 23
—*4-fluoroisoleucine evaluated, 715*
—various 1-phenyl-1-nonen-3-one derivatives evaluated *in vitro,* 1543
Antimicrobial data sets—analyzed by molecular connectivity method, structure-activity relationships *produced, 1743*
Antimicrobial effectiveness test inoculum organisms, various—storage below freezing, effect of various *solutions, 815*
Antimicrobials—chloramphenicol and others, effect *on in vitro activity of rat liver mitochondrial* monoamine oxidase, 480
—effect of paromomycin on R-factor transfer of *tetracycline resistance from Escherichia coli to Salmonella pullorum,* 35
Antineoplastic activity—evaluated in various sub*stituted benzo[a]quinolizines, 871*
—fulvoplumierin isolated from *Himatanthus sucuuba bark, evaluated, 1322*
—germacranolides isolated from *Eupatorium* semiserratum and Eriophyllum confertiflorum *evaluated, 865*
—3β-hydroxy-13α-amino -13,17- seco-5α-androstan-17-oic-13,17-lactam ester of chlorambucil evaluated in mice and rats, 1342
—substituted phenylalanine esters, effect on tumor *cell metabolism in mice, 1726*
—various isoquinoline derivatives evaluated, 740
—various α-methylene-γ-lactone-containing *agents evaluated, 1235*
—various 1-phenyl-1-nonen-3-one derivatives evaluated in mice, 1543
—various secondary disulfonamides and tetrasulfondiamides evaluated, 857
—*various substituted triazines, related to blood* levels, rats, 310
—various sulfonamides and sulfonyl hydrazides *evaluated in mice, 1550*
Antineoplastic agents—acronine, two-component spectrophotometric analysis with 7-acetylacroninium perchlorate in parenteral solutions, 237
—carmustine, differential pulse polarographic *analysis in biological samples, 1160*
—cyclophosphamide, *in vitro* analysis of metabolites in rat body fluids, 1009
—*daunorubicin and doxorubicin, binding to DNA,* direct and difference spectroscopic methods compared, 688
—daunorubicin, doxorubicin, and hydroxyl metabolites, organic–aqueous distribution, self-association in aqueous phase, 782
—doxorubicin and daunorubicin, various glycone analogs, GLC–mass spectral analyses, prepared samples, 1748
—*doxorubicin, energy of interaction with phos*pholipid monolayers at air–water interface, 773
—*ellipticine, dissolution and GI absorption, effect* of polyvinylpyrrolidone, 611
—fluorouracil, adsorption on glass surfaces, 1494
—fluorouracil, nitrogen-detector GLC analysis in *plasma, 1489*
—2-^{14}C-fluorouracil, tissue distribution in mice after oral or intravenous administration, autoradi*ographic determination, 344*
—hydroxyurea and 3-ethyl analog, comparison of *solid and solution conformations, 239*
—melphalan, high-pressure liquid chromatographic analysis in plasma, 679
—*melphalan, hydrolysis, effect of bovine serum* albumin, various temperatures, 682
—mercaptopurine, high-performance liquid chromatographic analysis in plasma, 1027
—mercaptopurine, thermodynamics of dehydration, *stability of hydrate and anhydrate forms under* various thermal conditions, 488
—methotrexate, chromatographic separation, UV, *NMR, and mass spectral analyses of impurities* in various formulations, 622
—methotrexate, GI absorption from rat small intestine *in situ,* 560
—methotrexate, thermal and photolytic decom*position in aqueous solutions, 526*
potential—coralyne sulfoacetate, fluorometric analysis in serum, 1331
potential—eupahyssopin, effects on nucleic acid, protein, anaerobic, and aerobic metabolism of Ehrlich ascites tumor cells, 1232
potential—microlenin, isolated from *Helenium* microcephalum whole plant extract, structure *and stereochemistry determined, 1228*
potential—podophyllotoxin derivative and metabolite, pharmacokinetics in humans, 1106
—*procarbazine hydrochloride, high-pressure liquid* chromatographic analysis of degradation products *in pharmaceutical formulations, 424*
—streptozocin, high-pressure liquid chromatographic analysis and separation of anomers in a *commercial dosage form, 1300*
various—GLC–mass spectral analyses in bulk drug, 1343
Antineoplastic–antiviral agents—floxuridine, GLC analysis in plasma, 417
Antioxidants—*butylated hydroxyanisole, binding to* human albumin studied using membrane filtration equipment, 967
—*sodium bisulfite, effect on physostigmine mole*cule in solution, 742
Antiperspirant activity—*N*-methyl-4-piperidinyl α-benzoyloxy-α-cyclopentylphenylacetate evaluated in humans, 701
Antiproteolytic activity—*various oxadiazoles evalu*ated *in vitro,* 987
—various substituted oxadiazole-2-thiones evalu*ated for effect on trypsin hydrolysis of bovine* serum albumin, 1507
Antipsychotics, various—binding to 1-anilino-8-naphthalenesulfonic acid, fluorometric study, 861
Antipyretic–analgesics—4-aminoantipyrine, accu*mulation by goldfish, effect of temperature and* surfactant, 1558
Antipyretics, various—antimicrobial activity, effect *of combination with various antibiotics, 23*
Antiradiation activity—methylpyridinium-2-dithioacetic acid evaluated *in mice, 962*
Antirheumatic agents—phenylbutazone, GLC analysis in human plasma, 243
—*phenylbutazone, γ-oxo metabolite, GLC analysis* in plasma, 279
—phenylbutazone, various solid oral formulations, *stability, effect of temperature and humidity,* 646
Antiseptics, topical—*chlorhexidine gluconate and* povidone-iodine, resistance by various microorganisms *in vitro,* 1629
Antispasmodic activity—various substituted 1-(4-biphenylyl)-2-phenylethylamines evaluated, 991
Antitumor activity—bromoacetylcholine and bromoacetate, effect on neuroblastoma in mice, 331
CNS—fluphenazine and various analogs evaluated, 157
—*evaluated in cyclophosphamide analogs, 709*
—evaluated in various diazasteroids, 283
—helenalin, effects in anaerobic and aerobic metabolism of Ehrlich ascites cells, 552
—various acetylglycosyl quinone derivatives *evaluated for antitumor activity in mice, 562*
—various acylated amino acids evaluated in microbial screen, 520
—*various benzo[b][1,5]naphthyridines evaluated,* 407
—*various pyridinium- and quinolinium-2-dithioacetic* acids evaluated in mice, 962
Antitussives—dextromethorphan hydrobromide, *metabolism, effect of salicylamide and acet*aminophen, rats, 761
—dextromethorphan, metabolism in male and female rats compared, 1326
Antiulcerogenic activity—various 2-(substituted *phenylimino)-2H-quinolizines evaluated, 1183*
Antiviral activity—various substituted as-triazines evaluated, 737
Antiviral data sets—analyzed by molecular connectivity method, structure–activity relationships produced, 1743
Aplysia dactylomela—sea hare, dactylyne isolated, pharmacological activity in mice, rats, and guinea *pigs, effect on drug metabolism in mice, 1293*
Apparatus, dissolution—hydrodynamics of four different types compared, 1303
testing—three systems compared, suitability for use as production control tools and relation to blood *level studies in dogs evaluated, 1732*
—three types compared, papverine hydrochloride, three commercial sustained-release products, *496*
—USP basket, directly compressed tablet, sigmoid-shaped curve explained, 48
Aprindine hydrochloride—photolysis products identified by GLC and combined GLC–mass spectrom*etry, 722*
Arachidonic acid—effect on human platelet aggregation with and without aspirin, kinetic study, 939
Arylation, homolytic—thiazole with phenylazotriphenylmethane, 2-phenyl-5-triphenylmethylthiazole synthesized, 1432
Ascorbate—effect on GI absorption of salicylate, rat intestine *in vivo* and *in vitro,* 224
Ascorbic acid—effect on galactose-induced cataract formation in guinea pigs, 1478
—elimination in humans after intravenous admin*istration, 1491*
L-Asparagine synthetase activity—effect of various *sulfonamides and sulfonyl hydrazides evaluated in* vitro, 1550
Aspirin—bioavailability in humans, effect of food and *fluid volume, 1533*
—colorimetric analysis in human plasma, 289
—compressed disks alone and equimolar mixture *with salicylic acid, dissolution rate, effects of* compression force, particle size, and lubricants, *535*
—excretion in humans correlated with parameters from various *in vitro* dissolution methods, *1070*
—high-pressure liquid chromatographic analysis in plasma simultaneously with salicylic acid and salicyluric acid, 710
—liquid chromatographic analysis in multicompo*nent tablets, 1066*
—stability in solid dispersion binary systens with urea or povidone, effect of temperature and hu*midity, 1631*
Association, self—sodium cholate in 0.15 *M* NaCl, multiple aggregate model, 854
—sodium cholate, glycocholate, and taurocholate, pattern in aqueous electrolyte solutions, light-*scattering study, 174*
Atenolol—GLC analysis in biological fluids, 1340
—high-pressure liquid chromatographic determi-

nation in biological fluids, 1033
Atomic absorption spectrophotometry—analysis, *gold in whole blood*, 1332
AUC—determined by constant blood withdrawal and *intermittent sampling methods compared, sodium* salicylate and aspirin in dogs, 875
Automated analysis—creatinine in human plasma, *compared to high-pressure liquid chromatography* and alkaline picrate method, 292
Autoradiography—determination, 2-^{14}C-fluorouracil, tissue distribution in mice after oral or intravenous administration, 344
Azadirachta indica—*extract of leaves, cardiovascular* effects evaluated in guinea pigs and rabbits, 1476
Aziridines—*various 1-phenyl-1-nonen-3-one derivatives* synthesized, 1536

B

Bacterial resistance—*to tetracycline, R-factor* transfer from *Escherichia coli* to *Salmonella pullorum*, effect of paromomycin, 35
Balleya pauciradiata—whole plant ethanol extract, odoratin and paucin isolated and identified, 1633
Barbiturates, various—*glass formation and solid* dispersion systems evaluated, 1606
—*in vitro* removal by liquid membranes from pH 2 *donor solutions, effect of temperature, phase* ratio, and bile salts, 63
—prediction of duration of depressant effects using pattern recognition system based on structural descriptors, 745
Beckmann-type rearrangement—*in reduction of N*-benzyl-2-cyano-2-(hydroxyimino)acetamide, two diamines formed, 860
Benzalkonium chloride—various commercial solutions, antibacterial activity evaluated and related to composition, 380
Benzathine molecule—interference in iodometric analysis of penicillin V benzathine, 1495
1,2-Benzisothiazole 1,1-dioxides, *3-substituted*—synthesized, evaluated for antibacterial and antifungal activity, 1323
Benzoate anions—*release from ion-exchange resin* beads, effect of coating with various waxes, 500
Benzocaine—*diffusion from various polyethylene* glycol ointment bases through human stratum corneum, 517
1,4-Benzodiazepine, *substituted—chlorodesmethyldiazepam*, pharmacokinetics in dogs, 1777
Benzo[*b*]furan derivatives—synthesized, local anesthetic activity evaluated, 125
Benzo[*b*][1,5]naphthyridines, substituted—*synthesized, binding with DNA studied, antitumor activity* evaluated, 407
Benzo[*a*]pyrene—effect of preadministration on *transfer of 3-O-methylglucose across everted rat* small intestine, 245
Benzo[*f*]quinoline, substituted—hypotensive activity evaluated in dogs and spontaneous hypertensive rats, 1639
Benzo[a]quinolizines, *various substituted—synthesized*, evaluated for antineoplastic and anticonvulsant activity, 871
Benzothiazoles, *various substituted—synthesized*, evaluated for antibacterial activity, 281
Benzoylecgonine—GLC–*mass spectrometric analysis* in human urine, 811
Benzoyl peroxide—high-pressure liquid chromato*graphic analysis in bulk drug and commercial* preparations, 1035
***N*-Benzyl-2-cyano-2-(hydroxyimino)acetamide**—*reduced, two diamines formed by* Beckmann-type rearrangement, 860
***N*-Benzyloxycarbonyl-L-phenylalanine esters**—effect on tumor cell metabolism in mice, 1726
Benzylpenicillenic acid—degradation in neutral *media, differential pulse polarographic study*, penicillamine demonstrated as product, 302
Betamethasone and various esters—spectrophotometric *analyses in pharmaceutical products*, 360
Betamethasone sodium phosphate—high-pressure liquid chromatographic *analysis in dosage forms*, 913
Bile acid salts—pattern of association in aqueous electrolyte solutions, light-scattering study, 174
composition—effect on dissolution kinetics of cholesterol in simulated bile, 1711
salt molecules—functional group contribution to ion-pair partitioning of quaternary ammonium derivative of propranolol, 847
salts, dihydroxy—self-association in aqueous electrolyte solutions, turbidimetric study, 994
salts—*sodium cholate, solubilization of naphthalene* and self-association in 0.15 *M* NaCl, 854
Bilirubin—intrinsic body clearance, frequency distri*bution, rats*, 45
—kinetics of formation, distribution, and elimination in rats, effect of phototherapy, 205
Binding—3-aminoacridinium and 7-aminoquinolinium monocations to double-stranded DNA, equilibri*um expressions developed*, 89
—1-anilino-8-naphthalenesulfonic acid to various antipsychotics and antidepressants, fluorometric *study*, 861
—butylated hydroxyanisole to human albumin, studied using membrane filtration equipment, 967
capacities—use in Scatchard plots constructed *from ligand interaction data evaluated*, 1344
competitive—small molecules to macromolecules, mathematical analysis of dynamic dialysis process, 908
constants—daunorubicin and doxorubicin to DNA, *direct and difference spectroscopic methods* compared, 688
—dantrolene to human serum albumin, fluores*cence quenching study, mechanism evaluated*, 1042
—DNA to various substituted benzo[*b*][1,5]-naphthyridines, 407
intrinsic factor mediated—cyanocobalamin to *cholestyramine in vitro, effect of pH, added* electrolyte and bile salt, 1626
—opiate agonists and antagonists to receptor, new *model proposed*, 999
plasma protein—diazepam, effect of sodium oleate in rats, 891
plasma protein—iodoxamic acid in rhesus monkeys, 930
plasma protein—tolbutamide in humans, effect of subject age, 1192
protein—salicylic acid to bovine serum albumin, *affinity chromatographic study*, 1005
protein—salicylic acid, warfarin, and tryptophan to albumin in free solution and in microparticles, direct and indirect determination of constants, 107
protein—sulindac and metabolite to human serum albumin, 1077
protein—various drugs, Scatchard plots with pos*itive slopes, effect of albumin concentration*, 1193
serum protein and tissue—dicumarol in vivo, effect of tolbutamide in rats, 1492
—various drugs to two ion-exchange resins in *simulated gastric fluid, compared to previous* results with charcoal, 1329
Bioavailability, absolute—evaluation of renal clear*ance perturbation method using literature data* assuring a fraction absorbed of unity, 591
—*acetaminophen prodrug studied, dogs*, 545
—acetazolamide, various tablet lots compared in humans, 252
—*aspirin in humans, effect of food and fluid volume*, 1533
—cloprednol, various dosage forms in humans, 920
—digoxin, effect of kaolin–pectin suspension in *humans*, 1582
—digoxin, estimated using area under the curve from 0 to 24 and 0 to 72 hr and 0 to infinity, *141*
—erythromycin stearate, effect of food and fluid volume, humans, 764
in vivo—methaqualone, two tablets in humans, compared to *in vitro* dissolution, 1328
—*meprobamate, 11 commercial products in humans*, 1290
—orally administered clindamycin, effect of kaolin–pectin suspension in humans, 1579
oral—phenolsulfonphthalein *in rats, based on urinary excretion data*, 267
—pentobarbital from capsules and suppositories *in humans*, 1586
—prolonged-release cephalexin tablet compared to capsule and intravenous administration in humans, 1620
—quinidine, three dosage forms compared, hu*mans*, 1456
—quinolinemethanol antimalarial from two dosage forms compared, dogs, 1375
—*substituted androstane from solutions and suspensions* in rats and humans, 1287
—sulfadiazine, various dosage forms compared in humans, 1659
—sulfamethizole, two suspensions compared, *1399*
—theophylline, commercial elixir and two tablets compared, chronic dosing in humans, 916
—*various formulations of nitrofurantoin* in humans, correlated to dissolution rate *in vitro*, 1616
Biosynthesis—*morphine alkaloids in Papaver bracteatum*, radiochemical study, 103
Biphenyl derivatives, various—synthesized, evaluated *for antispasmodic and cardiovascular activity*, 991
Bisnoryangonin—GLC–mass spectral analysis in mushrooms, 485
Blood levels—various substituted triazines, related *to antineoplastic activity, rats*, 310
Blue tetrazolium—reaction with various corticosteroids, spectrophotometric analyses in pharma*ceutical preparations*, 792
—reaction with various phenylhydrazines, kinetics and mechanism, 927
Books
Actinomycetes: The Boundary Microorganisms, *144*
Actualites Pharmacologiques, 1650
Advances in Chromatography, Vol. 14, 144
Advances in Chromatography, Vol. 16, 1650
Advances in General and Cellular Pharmacology, Vol. 1, 1195
Affinity Chromatography. Journal of Chromatography Library, Vol. 12, 1778
Alcoholism. New Knowledge and New Responses, 894
Alicyclic Chemistry, Vol. 5. A Specialist Periodical *Report*, 143
The Alkaloids, Vol. 7. A Specialist Periodical Report, 892
Aminergic Hypotheses of Behavior: Reality or Cliche? NIDA Research Monograph 3, 294
Analytical Profiles of Drug Substances, Vol. 6. 442
Antibiotics in Clinical Practice, Third Ed., 144
Anticonvulsants. Medicinal Chemistry: A Series of Monographs, Vol. 15, 894
Antifungal Compounds, Vol. 1, 442
Antifungal Compounds, Vol. 2: Interactions in Biological and Ecological Systems, 744
Applications of Ion-Selective Membrane Electrodes in Organic Analysis, 1497
Aromatic and Heteroaromatic Chemistry, Vol. 5, *744*
Aspirin and Related Drugs: Their Actions and Uses, *293*
Assay of Drugs and Other Trace Compounds in Biological Fluids. Methodological Developments *in Biochemistry. Vol. 5, 441*
Atlas of Cell Biology, 144
Behavioral Neurology. 2nd Ed., 1650
Behavioral Tolerance: Research and Treatment Implications. NIDA Research Monograph 18, *1650*
The Biochemical Basis of Neuropharmacology. 3rd Ed., 1650
Biochemistry, 1196
Biological Bases of Psychiatric Disorders, 744
Biomedical Applications of Immobilized Enzymes and Proteins, Vol. 2., 894
Biopharmaceutics and Clinical Pharmacokinetics, *1195*
Biosynthesis, Vol. 5. A Specialist Periodical Report, 1196

Blood Policy: Issues and Alternatives, 894
British Pharmacopoeia 1973 Addendum 1977, *144*
Cannabinoid Assays in Humans. NIDA Research Monograph 7, 294
Case Studies in Medical Physiology, 594
Catecholamines of Developing Brain. Preconditioning of Behavior (Aggression? Anxiety?), 1196
Chemical Process Industries, 4th Ed., 894
The Chemistry of Pyrroles, 744
Chemotherapy of Infection, 594
Chemotherapy of Solid Tumors. Report on a WHO *Expert Committee, 594*
Cholesterol, 442
Clinical Pharmacokinetics. Proceedings of an International Symposium at Salzgitter-Ringelheim (Germany), June 20 and 21, 1975, 894
Clinical Psychopharmacology, 1196
Clinical Toxicology, Vol. XVIII, 144
Clofibrate and Related Analogs. A Comprehensive *Review, 593*
Cosmetics: What the Ads Don't Tell You, 894
Current Chemotherapy Vols. I and II. Proceedings of the 10th International Congress of Chemotherapy, 1650
Current Developments in Psychopharmacology, Vol. 4, 744
Design of Biopharmaceutical Properties through *Prodrugs and Analogs, 293*
Drug and Chemical Toxicology: An International Journal for Rapid Communication, 144
Drug Dependence. *Current Problems and Issues,* 594
Drug Design and Adverse Reactions, 594
Drug Discrimination and State Dependent Learning, 1196
Drug Disposition and Pharmacokinetics, 2nd Ed., 441
Drug Disposition During Development, 1778
Drugs and Driving. NIDA Research Monograph 11, 594
The Economics of Medical Malpractice, 1650
Effectors of Thermogenesis, Proceeding of a Symposium Held at Geneva (Switzerland) 14–16 *July 1977, 1650*
Effects of Labeling the "Drug-Abuser": An Inquiry. NIDA Research Monograph 6, 294
Entwicklung der Hypertoniemortalität und des Antihypertensiva-Verbrauchs in der Schweiz, 1498
Environmental Cancer. Advances in Modern Toxicology, Vol. 3, 442
Epidemiological Evaluation of Drugs, 1196
The Epidemiology of Drug Abuse: Current Issues. NIDA Research Monograph 10, 442
The Epidemiology of Heroin and Other Narcotics. NIDA Research Monograph 16, 1498
Essays in Neurochemistry and Neuropharmacology, Vol. 2, 1498
The Essential Guide to Prescription Drugs: What You *Need to Know for Safe Drug Use, 144*
The Ethical Pharmaceutical Industry and Some of Its Economic Aspects. An Annotated Bibliography, 894
The Fetus and Birth. Ciba Foundation Symposium *47 (new series), 442*
Fiches de Dosages des Medicaments dans les Millieux Biologiques, 1778
Findings of Drug Abuse Research, Vols. 1 and 2. NIDA Research Monograph 1, 442
Fluorescence and Phosphorescence Spectroscopy: Physiochemical Principles and Practice, 592
Fluorescent Antibody Techniques and Their Applications, *2nd Ed., 894*
Foreign Compound Metabolism in Mammals, Vol. 4. A Specialist Periodical Report, 143
The Freezing of Mammalian Embryos. Ciba Foundation Symposium 52 (new series), 1498
Further Perspectives in Organic Chemistry. Ciba Foundation Symposium 53 (new series), 1650
Gaddum's Pharmacology, 8th Ed., 1650
Gas Chromatography with Glass Capillary Columns, 1498
Glucagon: Its Role in Physiology and Clinical Medicine, 1497
Guide des Plantes Dangereuses, 1498
Haemostatic Drugs: A Critical Appraisal, 594
Hagers Handbuch der Pharmazeutischen Praxis, 1196
Handbook of Clinical Drug Data, 4th Ed., 1650
Handbook of Clinical Pharmacology, 1650
Handbook of Injectable Drugs, 294
Health and Disease in Tribal Societies, Ciba Foundation Symposium 49 (new series), 1196
Health Needs of Society: A Challenge for Medical *Education. 10th CIOMS Round Table Conference* and Report of the Scientific Session of the 10th General Assembly of CIOMS, Geneva, 1498
Health Organizations of the United States, Canada, and Internationally. 4th Ed., 594
Herbicides and Fungicides—Factors Affecting Their Activity, 594
How to Form Your Own Professional Corporation, *894*
Hypertension. Mechanisms, Diagnosis & Management, 1497
IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man, Volumes 1–15, 1778
Iatrogenic Carcinogenesis, 1498
Identifizierung von Arzneistoffen, 894
Immunology: A Programmed Text, 442
Immunology of The Gut. Ciba Foundation Symposium 46 (new series), 442
Industrial Bioavailability and Pharmacokinetics: Guidelines, Regulations, and Controls, 1497
Infection Control in Health Care Facilities: Micro*biological Surveillance, 894*
Inflammation and Antiinflammatories, 1649
Inflammation: Mechanisms and Their Impact on Therapy, Proceedings of an Advanced Teaching Course Held in Rotterdam, November 1976, *1497*
Infrared Absorption Spectroscopy, Second Ed., 144
International Nonproprietary Names (INN) for Pharmaceutical Substances. Cumulative List No. *5,* 1196
International Symposium on Marine Natural Products, 143
An Introduction to Clay Colloid Chemistry. 2nd Ed., 442
An Introduction to Organic Chemistry, 894
Iron Metabolism. Ciba Foundation Symposium 51 (new series), 1498
Kinetics of Drug Action. Handbook of Experimental Pharmacology, Vol. 47, 744
Leukemia Research, 144
The Lymphocyte: Structure and Function, Part II, 744
Major Medicinal Plants: Botany, Culture and Uses, 1649
Manual of Anesthesia, 1196
Manual of Medical Therapeutics, 22nd Ed., 894
Mass Spectrometry in Drug Metabolism, 893
Medical Botany: Plants Affecting Man's Health, *593*
Medication Guide for Patient Counseling. 1st Ed., 594
Medicinal Chemistry V. Proceedings of the 5th International Symposium on Medical Chemistry. *Paris, July 19–22, 1976, 441*
Membranous Elements and Movement of Molecules. Methodological Surveys, Vol. 6., 894
*Methods in Prenatal Toxicology. Evaluation of Em*bryotoxic Effects in Experimental Animals. *Teratology Workshop,* April 1977, Berlin, 1498
Microbiology—1977, 592
Microemulsions: Theory and Practice, 744
Microsomes and Drug Oxidations. Proceedings of the Third International Symposium, Berlin, July 1976, 894
Modern Practice of Gas Chromatography, 144
Molecular Biology, Biochemistry, and Biophysics 23: Secondary Metabolism and Cell Differentiation, 594
The Molecular Biology of Animal Viruses, Vol. 1, 144
The Molecular Biology of Animal Viruses, Vol. 2, 1650
Mycotoxic Fungi, Mycotoxins, Mycotoxicoses: An Encyclopedic Handbook, Vol. 1., 894
Mycotoxic Fungi, Mycotoxins, and Mycotoxicoses: *An Encyclopedic Handbook, Vol. 2, 1650*
Narcotic Antagonists: Naltrexone Progress Report. NIDA Research Monograph 9, 294
Neisseria gonorrhoeae and Gonococcal Infections, 1650
New Drugs: Discovery and Development (Drugs and the Pharmaceutical Sciences Series, Vol. 5), 1778
NMR: An Introduction to Proton Nuclear Magnetic Resonance Spectroscopy, 144
Noncatecholic Phenylethylamines, Part I, Phenyl*ethylamine: Biological Mechanisms and Clinical* Aspects, 1498
Nursing Pharmacology: A Systems Approach to Drug Therapy and Nursing Practice, 1650
Operational Definitions in Socio-Behavioral Drug Use Research 1975. NIDA Research Monograph 2, 294
Ophthalmica, Band II, Pharmazeutische Grundlagen *ihrer Zubereitung, 1650*
Organic Syntheses, Vol. 57, 1196
Origins of Human Cancer, Book A, Incidence of *Cancer in Humans; Book B, Mechanisms of* Carcinogenesis; Book C, Human Risk Assessment, 1497
Peptide Transport and Hydrolysis. Ciba Foundation Symposium 50 (new series), 1196
Perspectives in Pharmacy, 1196
Pharmaceutical Microbiology, 893
Pharmacie. 5th Ed., 594
Pharmacological and Biochemical Properties of Drug Substances, Vol. 1, 1196
Pharmacology of Steroid Contraceptive Drugs (Monographs of the Mario Negri Institute for Pharmacological Research, Milan, Italy), 1044
pH Measurements, 1650
Phenomenology and Treatment of Schizophrenia, 1650
Physical Chemistry for Students of Pharmacy and Biology, 3rd Ed., 1196
Plasma Proteins: Analytical and Preparative Techniques, 1498
Plasmids: Medical and Theoretical Aspects. Third *International Symposium on Antibiotic Resis*tance, Castle of Smolenice, Czechoslovakia, 1976, 894
Polymeric Drugs, 1650
Practical Clinical Pharmacy, 293
Predicting Dependence Liability of Stimulant and Depressant Drugs, 894
Predicting the Properties of Mixtures: Mixture Rules *in Science and Engineering, 1650*
Prevention and Detection of Cancer. Part I. Prevention, Vol. 1: Etiology, 894
Problems of Clinical Pharmacology in Therapeutic Research: Phase 1, 1196
Proceedings of the First Cleveland Symposium on Macromolecules, 144
Progress in Drug Metabolism, Vol. 2, 1649
Progress in Drug Research, Vol. 21, 1498
Prolactin and Human Reproduction, 144
Protein Crosslinking: Biochemical and Molecular Aspects. Advances in Experimental Medicine and Biology, Vol. 86A, 894
*Protein Crosslinking: Nutritional and Medical Con*sequences. Advances in Experimental Medicine and Biology, Vol. 86B, 894
*Psychodynamics of Drug Dependence. NIDA Re*search Monograph 12, 894
Psychopharmacology: A Biochemical and Behavioral Approach, 442
Quality Control in the Clinical Laboratory: A Pro*cedural Text, 894*
Quality Control in Toxicology, 894
Radiotracer Techniques and Applications, Vol. 2, *744*
Rational Management of Diabetes, 442
Reagents for Organic Synthesis. Vol. 6, 442
Recent Advances in the Chemistry of β-Lactam Antibiotics, 1650
*Recent Developments in the Pharmacology of In*flammatory Mediators, 894
Receptors and Recognition, Series A, Vol. 3, 744
Receptors in Pharmacology (Modern Pharmacol-

ogy–Toxicology Series, Vol. 11), 1650
Research on Smoking Behavior. NIDA Research Monograph 17, 1498
Respiratory Tract Mucus. Ciba Foundation Symposium 54 (new series), 1650
Review of Inhalants: Euphoria to Dysfunction, NIDA Research Monograph 15, 1498
Reviews of Physiology, Biochemistry and Pharmacology 79, *1497*
Reviews of Physiology, Biochemistry, and Pharmacology 80, 1498
Rx: 3X/Week LAAM: Alternative to Methodone. NIDA Research Monograph 8, 294
The Science and Technology of Gelatin, 594
The Selection of Essential Drugs. Report of a WHO Expert Committee, 1498
Serotonin in Health and Disease, Vol. II: Physiological Regulation and Pharmacological Action, 1498
The SI for the Health Professions, 1498
The Specific Treatment of Virus Diseases, 894
Survey of Organic Syntheses, Vol. 2, 1043
The Synthesis of Prostaglandins, 1196
Synthesis of Prostaglandins, Recent Developments in the Chemistry of Carbon Compounds, Vol. 8, 1498
Terpenoids and Steroids, Vol. 7. A Specialist Periodical Report, *593*
Testing and Screening for Drugs of Abuse: Techniques, Issues and Clinical Implications, 294
Textbook of Adverse Drug Reactions, 1497
Topics in Antibiotic Chemistry, Vol. 1, 594
The Total Synthesis of Natural Products, Vol. 3, 894
Toxicologic Emergencies. A Handbook in Problem Solving, 1196
USAN and the USP Dictionary of Drug Names, 144
Venoms: Chemistry and Molecular Biology, 893
Water, Wastes and Health in Hot Climates, 744
WHO Expert Committee on Specifications for Pharmaceutical Preparations. Twenty-Sixth Report, 1196
Workplace Safety and Health. The Role of Workers' Compensation, 1196
Young Men and Drugs—A Nationwide Survey. NIDA *Research Monograph 5, 294*
Zinc and Copper in Clinical Medicine, 1650
Bromoacetate—effect on neuroblastoma in *mice,* 331
Bromoacetylcholine—effect on neuroblastoma in *mice,* 331
Bromopheniramine maleate—high-pressure liquid chromatographic analysis in dosage forms, 873
Bronchodilators—*carbuterol, degradation kinetics in* aqueous solution, pH effect, 1523
l-Bunolol—β-adrenoceptor blocking activity compared in dogs, rats, and humans, oral and intravenous dosage, 132
—*metabolism in rats, urinary metabolites identified,* 129
Butylated hydroxyanisole—binding to human albumin *studied using membrane filtration equipment,* 967
1-Butyryl-4-cinnamylpiperazine—ion cluster–mass chromatographic analyses of urinary metabolites in mice and guinea pigs, 757

C

Caffeine—formation of charge transfer complexes with *p*-cresol, UV absorption study, 1381
—*GLC analysis in plasma, 1093*
Calcium oxalate—solubility in various 1-alkanols and ethanol–water mixtures, 733
Calorimetry, *immersional*—*combined with vapor* adsorption procedure to characterize solid–liquid interactions of microcrystalline cellulose–water system, 1599
nonisothermal—general method for determining *process-dependent temperature change, aspect* of calorimeter design, 1592
solution—determinations of crystallinity of β-lactam antibiotics, correlated with chemical stability, 767
Camazepam—blood and brain distribution in rats and *mice,* 1470
Camphor—high-pressure liquid chromatographic analysis in pharmaceutical formulations of camphorated parachlorophenol, 266
Cannabinoids—Δ9-tetrahydrocannabinol, kinetics of biphasic degradation in acidic solution, 27
Cannabis sativa—ethanol extract of leaves and roots, anhydrocannabisativine isolated, structure *determined,* 124
—stability of dosage form prepared by impregnating synthetic (−)-Δ^9-tetrahydrocannabinol on *placebo Cannabis plant material,* 876
Capacity—theoretical development, role in antimicrobial activity of chlorocresol in solubilized and emulsified systems, 1266
Caracurine V and N-oxides—isolated from stem bark *of Strychnos dolichothyrsa, muscle relaxant activity* evaluated, 171
Carbachol, *N*-demethylated—synthesized, cholinergic *activity evaluated in vivo and in vitro,* 531
Carbocysteine—GLC analysis in plasma, 1753
Carbonate-containing antacids, various—IR and X-ray structural analysis, compared to naturally occurring carbonate minerals, 324
Carbonic anhydrase inhibitors—*acetazolamide,* bioavailability of various tablet lots compared in humans, 252
Carboxymethylcellulose—*oscillatory and steady* shear rate measurements compared, effect of concentration and viscosity grade, 1499
Carbuterol—*degradation kinetics in aqueous solution,* pH effect, 1523
Cardiac arrhythmias—isoproterenol induced, effect of hemodynamic alterations, rats treated with desoxycorticosterone acetate, 1390
Cardiac depressants—*aprindine hydrochloride,* photolysis products identified by GLC and GLC–mass spectrometry, 722
—*procainamide, electron-capture GLC analysis in* human serum, 371
—procainamide, high-performance liquid chromatographic analysis simultaneously with *N*-acetylprocainamide in plasma, 839
—*procainamide, high-pressure liquid chromatographic* analysis simultaneously with *N*-acetylprocainamide in plasma, 869
—*propranolol and major metabolites, fluorometric* TLC analyses in human plasma and urine, 826
—propranolol, *plasma levels after administration* of hemisuccinate in dogs, 1360
—propranolol, TLC analysis in plasma, 1307
—*quinidine, crystal and molecular structure de*termined by X-ray diffraction, 1698
—quinidine, high-pressure liquid chromatographic *analysis in plasma, 269*
—quinidine sulfate, four commercial tablets, dissolution *profiles determined and related to dis*integration and absorption, 568
—tocainide, electron-capture GLC analysis in bi*ological fluids, 201*
—tocainide, high-pressure liquid chromatographic analysis in blood, 1692
Cardiac effects, various—quinidine and dihydroquinidine compared in isolated heart and *in vivo* in dogs, 1355
Cardiotonic agents—digoxin, biliary excretion measured by enterohepatic circulation minimal in*terruption technique,* rats, 415
—digoxin, bioavailability estimated using area under *the curve from 0 to 24 and 0 to 72 hr and 0 to* infinity, 141
—digoxin, GI absorption and bioavailability, effect *of kaolin–pectin suspension in humans, 1582*
—digoxin, hydrolysis at gastric pH, colorimetric analysis, 1358
—digoxin, hydrolysis, kinetic study, effect of pH, 327
—dobutamine, *high-pressure liquid chromato*graphic analysis in plasma, 1756
Cardiovascular activity—various substituted 1-(4-*biphenylyl)-2-phenylethylamines evaluated, 991*
Cardiovascular effects—*Azadirachta indica* extract of leaves, evaluated in guinea pigs and rabbits, 1476
Cardiovascular properties—various substituted indans evaluated, 314
Carminative activity—*various classes of compounds,* related to solubility, 277
Carmustine—differential pulse polarographic analysis in biological samples, 1160
Catecholamines, various—colorimetric analyses in *bulk drug and dosage forms,* 779
—paired ion high-pressure liquid chromatographic analyses in prepared solutions and dosage forms, *1247*
—reaction with acetaldehyde, formation rate of isoquinoline alkaloids, 112
Cefaloram—synthesized by *N*-aceylation of *tert*-butyl 7-aminocephalosporanate using polystyrene-bound *anhydrides,* 110
Cefazolin—TLC–densitometric analysis in biological fluids, 1170
Cellulose, *microcrystalline–water system—solid–*liquid interactions characterized by immersional calorimetry–vapor absorption procedure, 1599
Central depressants—various barbiturates, glass formation and solid dispersion systems evaluated, 1606
Centrifugal elutriation—used to separate suspensions into distinct particle-size fractions, 673
Cephalexin—*NMR spectroscopic analysis in* cephradine bulk drug and dosage forms, 1481
—pharmacokinetics compared to cephradine, *capsules and tablets, in humans, 1447*
—polarographic analysis in dosage forms, 1466
—prolonged-release tablet compared to capsule *and intravenous administration,* dissolution *in vitro,* and bioavailability in humans, 1620
Cephalosporins—*cefaloram synthesized by N-acyl*ation of *tert*-butyl 7-aminocephalosporanate using polystyrene-bound anhydrides, 110
—*cephradine and cephalexin, pharmacokinetics* compared, capsules and tablets, in humans, 1447
various—GI absorption, effect of ionization, rats, 320
various—*microionization equilibrium constants* determined, 666
various—pharmacokinetic analysis using two-*compartment and perfusion models, 191*
Cephradine—pharmacokinetics compared to cephalexin, capsules and tablets, in humans, *1447*
Cetrimonium bromide—equilibrium penetration of *dipalmitoyllecithin monolayers, surface pres*sure–area isotherms measured, 364
—penetration of cholesterol monolayers, equilib*rium surface pressure–area isotherms obtained,* 1054
Charcoal, activated—adsorption of typical drugs, effect of pepsin *in vitro,* 1181
—*in vitro* adsorption of emetine, 426
Chelating agents—*various sulfur-containing steroids* synthesized, evaluated in treatment of methylmercuric chloride toxicity in mice, 1739
Chlorambucil, *3β-hydroxy-13α-amino-13,17-seco-*5α-androstan-17-oic-13,17-lactam ester—synthesized, antineoplastic activity evaluated, mice and rats, 1342
Chloramphenicol—effect on *in vitro* activity of rat liver *mitochondrial monoamine oxidase, 480*
—high-pressure liquid chromatographic analysis in plasma, 1036
Chlordiazepoxide—and desmethyl metabolite, derivatization and GLC analyses, bulk drug, 1176
—and *metabolites, fluorescence TLC–densito*metric analyses in serum, 639
—electron-capture GLC analysis in serum, 1647
—*polarographic analysis, effect of amitriptyline,* commercial products and synthetic mixtures, 1297
Chlorhexidine gluconate—resistance by various microorganisms *in vitro,* 1629
Chlorocresol—*in solubilized and emulsified systems,* mathematical model relating phase distribution to antimicrobial activity, 1260
—*in solubilized and emulsified systems, role of* capacity in antimicrobial activity, 1266
Chlorodesmethyldiazepam—pharmacokinetics in dogs, 1777
Chloroquine—protolytic dissociation, spectrophotometric evaluation, 1770

Chloroxylenol—GLC analysis simultaneously with other active ingredients in commercial preparations, 1627
Chlorpheniramine—GLC analysis in presence of phenylpropanolamine, human urine, 118
—high-pressure liquid chromatographic analysis, simultaneously with pseudoephedrine, in dosage forms, 1668
Chlorpromazine—three haptens synthesized and characterized, antibodies developed in rabbits, antiserum titers determined, 1563
Chlortetracycline—paper chromatographic analysis in pharmaceutical preparations, 556
Cholesterol biosynthesis—effect of 2-indeneacetic acid and substituted 2-naphthoic acids and chloro derivatives, rat liver homogenates, 80
—dissolution kinetics in simulated bile, effect of bile composition, 1711
monolayers—penetration by cetrimonium bromide, equilibrium surface pressure–area isotherms obtained, 1054
Cholestyramine analog—cholpor synthesized, *in vitro* binding of sodium cholate and cholesterol lowering effect in humans evaluated, 1695
—intrinsic factor-mediated binding of cyanocobalamin, effect of pH, added electrolyte, and bile salt, 1626
Choline acetyltransferase activity—various acetylcholine analogs evaluated as inhibitors, 657
Cholinergic activity—*N*-demethylated carbachol evaluated *in vivo* and *in vitro*, 531
—various 3-hydroxyquinolizidine esters evaluated *in vitro*, 1759
Cholinergics, ophthalmic—pilocarpine, uptake and distribution in rabbit eye, preliminary pharmacokinetic model, 603
Cholpor—cholestyramine analog synthesized, *in vitro* binding of sodium cholate and cholesterol lowering effect in humans evaluated, 1695
Chromatography, affinity—study of binding of salicylic acid to bovine serum albumin, 1005
—analysis, morphine sulfate in tablets, 1099
ion exchange—separation of theophylline and hydroxyethyl derivative in pharmaceutical syrup, 572
paper—analysis, chlortetracycline in pharmaceutical preparations, 556
Chromone, substituted—high-pressure liquid chromatographic analysis in biological fluids, 1185
Clays—montmorillonite, adsorption of clindamycin and tetracycline, IR and X-ray analyses of mechanism, 1081
Clearance, intrinsic body—bilirubin, frequency distribution, rats, 45
rates, intercompartment—effect of changing on drug removal during hemoperfusion, computer simulation, 1178
total body drug—rapid estimation during constant-rate intravenous infusion, equation derived, 1776
total—dicumarol in rats, frequency distribution, 337
Clindamycin—adsorption to montmorillonite, IR and X-ray analyses of mechanism, 1081
—base, phosphate, and palmitate, high-pressure liquid chromatographic analyses in bulk drug and dosage forms, 1254
—orally administered, effect of kaolin–pectin suspension on bioavailability in humans, 1579
Clonazepam—dc polarographic analysis in tablets, 731
—pharmacokinetics in rhesus monkeys, 295
Cloprednol—bioavailability of various dosage forms in humans, 920
Clorazepate monopotassium and dipotassium—differential pulse polarographic analyses in pharmaceutical preparations, 1723
—pharmacokinetic study by GLC analysis of desmethyldiazepam in plasma, 427
CNS activity—evaluated in substituted imidazolidinethiones and various thioimidazolines, 600
—evaluated in substituted indenopyrazoles in mice, 1377
—various dopamine derivatives synthesized with *tert*-butoxycarbonyl as protecting group, evaluated in mice, 558
Coagulation and coagulation–lysis—time courses after addition of thrombin or thrombin–streptokinase to plasma, kinetic model developed, 145
Cobalt-containing agents, various—effect on phenytoin- and cortisone-induced teratogenesis in mice, 377
Cobaltous chloride—mechanism of hypothermic response in mice, effect of pretreatment with anticholinergics, 799
Cocaine analogs, various—synthesized, evaluated for effect on milk intake in rats, behavorial modifications in monkeys, and effect on ^{3}H-serotonin uptake by rat synaptosomes, 1656
—GLC–mass spectrometric analysis in human urine, 811
Colistin—neuromuscular blocking effect in rabbits and cat and frog muscle preparations, 1275
Color—analysis, dextrose solutions, color difference meter compared to standard measurements, 1485
Coloration—sulfisomidine tablets, effect of film coating containing UV absorber, 196
Colorimetry—analyses, aspirin and salicylic acid in human plasma, 289
—analyses, epinephrine, levarterenol, isoproterenol, and methyldopa in bulk drug and dosage forms, 779
—analysis based on blue tetrazolium reaction, spironolactone in tablets, 889
—analysis, digoxin, using xanthydrol reagent, aqueous acidic solutions, 1358
—analysis, nadolol in tablets, 1024
—analysis, pentaerythritol tetranitrate in dosage forms, NF method modified, 717
Compendial odor identification tests—substitution of IR and UV spectroscopic methods recommended, 539
Complexation—dinoprostone with β-cyclodextrin, phase solubility and PMR analyses, 1665
—polymyxin B and nickel (II) in aqueous media, effect of pH and ligand concentration, 1313
—tetracycline with calcium and organic ligands, mechanism of fluorometric analysis, 1518
Complexes, charge transfer—formed by caffeine and theophylline with *p*-cresol, UV absorption study, 1381
electron donor–acceptor—as model system for structure–activity relationships, 1310
—salicylamide and caffeine, dissolution rates estimated using theoretical diffusion model, compared to experimental results, 95
—various silver sulfonamides, coordination properties and structures studied, 284
Complexing, molecular—various quinoline and naphthalene derivatives with 9-(dicyanomethylene)-2,4,7-trinitrofluorene, mechanism of π-electron donation, 165
Compression force—effect on dissolution rate of compressed disks of salicylic acid, aspirin, and equimolar mixture, 535
Computer analyses—MULTDOS and 1969 or 1974 NONLIN program, pharmacokinetic parameters of ethosuximide during single or divided daily doses compared, 574
Computer programs—ESTRIP for calculation of initial polyexponential parameter estimates, 1687
Conductivity, electrical—various drugs measured *in vitro*, suitability for iontophoresis, 1439
Conformations—solid and solution compared, hydroxyurea and 3-ethyl analog, 239
Contamination—in pharmaceutical formulations, various origins, prevention methods, and detection procedures, review, 1
—mortars and pestles washed by usual procedures, demonstrated by pentylenetetrazol seizure threshhold test, 1756
Content uniformity—noninvasive polarographic assessment of various capsules and tablets, 842
Contraceptives, oral—commercial product, *in vitro* adsorption by magnesium trisilicate, 287
Coprecipitates—nitrofurantoin, ethotoin, and coumarin with povidone, effect on dissolution rate, 114
Coralyne sulfoacetate—fluorometric analysis in serum, 1331
Corticosteroids, various—blue tetrazolium spectrophotometric analyses in pharmaceutical preparations, 792
Cortisone-induced teratogenesis—effect of various cobalt-containing agents in mice, 377
Coumarin anticoagulants—dicumarol, total clearance in rats, frequency distribution, 337
anticoagulants—warfarin and dicumarol, *in vivo* binding in rat liver, implications for pharmacokinetic modeling, 229
—solid dispersions with polyethylene glycol 6000, coprecipitates with povidone, effect on dissolution rate, 114
Creatine phosphokinase myocardial band—correlated with infarct size and myocardial tissue damage, rats with induced myocardial infarctions, 1643
Creatinine—analyses by high-pressure liquid chromatography, automated analysis, and alkaline picrate method compared, human plasma, 292
—high-pressure liquid chromatographic analysis in biological fluids, 182
***p*-Cresol**—formation of charge transfer complexes with caffeine and theophylline, UV absorption study, 1381
Cromolyn sodium—interaction with magnesium ions in solution, 1403
Cryptolepis sanguinolenta—ethanol extract of roots, quindoline and CSA-3 isolated, 433
Crystallinity—determination by solution calorimetry, β-lactam antibiotics, correlated with chemical stability, 767
Curare bases, various—Hofmann elimination reaction with diazomethane, 473
various—syntheses by dequaternization procedures compared, mechanisms evaluated, products identified, 1204
Cyanocobalamin—intrinsic factor-mediated binding to cholestyramine *in vitro*, effect of pH, added electrolyte, and bile salt, 1626
Cyclic AMP phosphodiesterase—effect of various thiazolo- and thiadiazolo[3,2-*a*]pyrimidines *in vitro*, 1762
Cyclobarbital—oxidation products isolated and identified, 1019
β-Cyclodextrin—complexation with dinoprostone, phase solubility and PMR analyses, 1665
Cycloheximide—high-pressure chromatographic analysis in bulk drug and prepared formulations, 669
(2-Cyclopentyl -6,7- dichloro-2-methyl-1-oxo-5-indanyloxy)acetic acid—GLC analysis in biological fluids, 162
Cyclopentylsulfamate and cyclopentylmethylsulfamate—metabolism in rats, 226
Cyclophosphamide analogs—synthesized, antitumor activity evaluated, 709
metabolites—*in vitro* cytotoxicity analyses in rat body fluids, 1009
Cysteine—effect on oxidation of epinephrine in alkaline solutions, 1474
Cytotoxic activity—fluphenazine and various analogs evaluated, 157
—various alanine derivatives evaluated, 642
—various alkaloids isolated from *Tabernaemontana arborea* sap evaluated, 271
—various alkaloids isolated from *Tabernaemontana johnstonii* stem bark evaluated, 249
—various substituted purine ribonucleosides and 5′-phosphates evaluated *in vitro*, 569
—various substituted thiocolchicines evaluated, 394
Cytotoxicity—alkaloids isolated from various *Tabernaemontana* species or synthesized, structural effects evaluated, 272
—*in vitro* analyses of cyclophosphamide metabolites in rat body fluids, 1009
Cytotoxic sesquiterpene lactones—odoratin and paucin, isolated from whole plant ethanol extract of *Baileya pauciradiata*, 1633

D

Dactylyne—isolated from *Aplysia dactylomela* sea hare, pharmacological activity in mice, rats, and guinea pigs, effect on drug metabolism in mice, 1293

Danazol—radioimmunoassay in human and monkey plasma, 1425
Dansyl derivatives—various estrogens, high-pressure liquid chromatographic analyses, pharmaceutical preparations, 1735
Dantrolene—binding to human serum albumin, fluorescence quenching study, mechanism evaluated, 1042
Daunorubicin—binding to DNA, direct and difference spectroscopic methods compared, 688
—GLC–mass spectral analysis, bulk drug, 1243
glycone analogs, various—GLC–mass spectral analyses, prepared samples, 1748
—organic–aqueous distribution, self-association in aqueous phase, 782
dc Polarography—analysis, clonazepam in tablets, 731
Decomposition—thermal and photolytic, methotrexate in aqueous solutions, 526
Deconvolution—point–area and area–area methods for determining *in vivo* input functions compared, 663
Degradation—benzylpenicillenic acid in neutral media, differential pulse polarographic study, penicillamine demonstrated as product, 302
hydrolytic—2,6-dichlorobenzylthiopseudourea in basic medium, products isolated and identified, 256
kinetics—carbuterol in aqueous solution, pH effect, 1523
nonenzymatic GI—β-lactam antibiotics, kinetics in rats, 1701
oxidative—pyrogallol in aqueous systems, effect of dissolved oxygen levels, 1338
oxidative thermal—promethazine, products isolated and identified, 1128
—pharmaceutical formulations, rates, mechanisms and pathways, review, 443
—phenylbutazone, various solid oral formulations, effect of temperature and humidity, 646
photolytic—sulfisomidine tablets, effect of film coating containing UV absorber, 196
products—of procarbazine hydrochloride, high-pressure liquid chromatographic analysis in pharmaceutical formulations, 424
products of various sulfonamides—separated from parent compounds by liquid–liquid extraction, 1415
products, various—of promethazine, spectrophotometric analyses, prepared samples, 1131
—Δ9-tetrahydrocannabinol in acidic solution, kinetics, 27
thermal—gelatin solution and gel mass, rigidity and viscosity, applied to processing predictions, 218
thermal—promethazine, kinetics in acidic medium, effect of anaerobic and aerobic conditions, pH, metal ions, and antioxidants, 1133
—various polysorbates, autoxidation on storage, effect of light, temperature, and copper sulfate, 1676
Dehydration—thermodynamics, mercaptopurine, stability of hydrate and anhydrate under various thermal conditions, 488
Delivery devices, controlled release—various hydrogel membranes evaluated, permeability to progesterone, 1352
—various polymer membranes evaluated, permeability to progesterone, effect of soaking in plasma, 1347
Delivery systems, inhalation—evaluated *in vitro* using simulated respiratory system, 1428
***N*-Demethylated carbachol**—synthesized, cholinergic activity evaluated *in vivo* and *in vitro*, 531
Demethylation, selective—various polymethoxyxanthones with aqueous piperidine, 1321
4′-Demethylepipodophyllotoxin 9-(4,6-*O*-ethylidene-β-D-glucopyranoside)—and metabolite, pharmacokinetics in humans, 1106
Densitometry–fluorescence TLC—analyses, chlordiazepoxide and metabolites in serum, 639
Depressants, central—cyclobarbital, oxidation products isolated and identified, 1019
Dequaternization—of various curare bases, different procedures compared, mechanisms evaluated, products identified, 1204
Derivatization—ethacrynic acid with methanol–hydrochloric acid or diazomethane, PMR, IR, and GLC–mass spectral analyses of products, 975
Dermatitis suppressants—sulfapyridine and acetyl metabolite, high-performance liquid chromatographic analyses in biological fluids, 1250
Desmethyldiazepam—electron-capture GLC analysis in plasma, 427
—fluorescence–TLC densitometric analysis in serum, 1413
Desmethyldoxepin, *cis* and *trans*—simultaneous GLC analyses in human plasma, 802
Desoxycorticosterone acetate—pretreatment, effect of hemodynamic alterations on isoproterenol-induced cardiac arrhythmias, 1390
—subcutaneous release from microsealed drug delivery system in rats, *in vitro–in vivo* correlation, compared to matrix-type silicone device, 214
Dexamethasone—absorption in humans, effect of concomitant administration of magnesium trisilicate, 1029
Dexclamol hydrochloride—solubility, effect of enantiomeric purity, 636
Dextroamphetamine sulfate—synthesized from D-phenylalanine, 1167
Dextromethorphan hydrobromide—metabolism, effect of salicylamide and acetaminophen, rats, 761
Dextromethorphan—metabolism in male and female rats compared, 1326
Dextrorphan—plasma half-life in male and female rats compared, 1326
Dextrose solutions—color analysis, color difference meter compared to standard measurements, 1485
Diafiltration—simultaneous salt and ethanol removal from human serum albumin, 431
Diamines—formed by reduction of *N*-benzyl-2-cyano-2-(hydroxyimino)acetamide by Beckmann-type rearrangement, 860
(±)-2,5-Diamino-2-(cyanomethyl)pentanoic acid—synthesized, effect on ornithine decarboxylase activity evaluated, 1174
Diazasteroids, various—synthesized, antitumor activity evaluated, 283
Diazepam—effect on recall ability evaluated by pupillometry, humans, 956
—fluorescence–TLC densitometric analysis in serum, 1413
—plasma protein binding, effect of sodium oleate in rats, 891
—spectrophotometric analysis in dosage forms, official method adapted to correct for potential interference by hydrolysis product, 550
α-(Dibutylaminomethyl -6,8- dichloro-2-(3′,4′-dichlorophenyl) -4- quinolinemethanol—bioavailability from two dosage forms compared, dogs, 1375
2,6 - Dichlorobenzylthiopseudourea — hydrolytic degradation in basic medium, products isolated and identified, 256
Dicumarol—*in vivo* binding in rat liver, implications for pharmacokinetic modeling, 229
—*in vivo* binding to serum proteins and tissues, effect of tolbutamide in rats, 1492
—total clearance in rats, frequency distribution, 337
9-(Dicyanomethylene) -2,4,7- trinitrofluorene—mechanism of π-electron donation by various quinolines and naphthalenes in molecular complexing, 165
Differential pulse polarography—analyses, fluoxymesterone, norethandrolone, prednisolone, and prednisone in tablets, 436
—study of benzylpenicillenic acid degradation in neutral media, penicillamine demonstrated as product, 302
Differential pulse voltammetry—analysis, acetaminophen in plasma, 1775
Diffusion—benzocaine from various polyethylene glycol ointment bases through human stratum corneum, 517
coefficients—for progesterone permeation through various hydrogels, 1352
model, theoretical—used to estimate dissolution rates of salicylamide in water and caffeine solutions, compared to experimental results, 95
—progesterone through various polymer membranes, effect of soaking in plasma, 1347
^{3}H-Digoxin—biliary excretion measured by enterohepatic circulation minimal interruption technique, rats, 415
Digoxin—bioavailability estimated using area under the curve from 0 to 24 and 0 to 72 hr and 0 to infinity, 141
—GI absorption and bioavailability, effect of kaolin–pectin suspension in humans, 1582
—hydrolysis at gastric pH, colorimetric analysis, 1358
—hydrolysis, kinetic study, effect of pH, 327
Dihydroergotoxine—high-performance liquid chromatographic analyses of four components in bulk drug and pharmaceutical formulations, 98
Dihydroquinidine—high-pressure liquid chromatographic analysis in plasma, 269
—various cardiac effects on isolated heart and *in vivo* in dogs, compared to quinidine, 1355
4,5-Dimethoxykynuramine—synthesized, *in vivo* conversion to 6,7-dimethoxy-4-quinolinol, 421
6,7-Dimethoxy-4-quinolinol—formed *in vivo* from 4,5-dimethoxykynuramine, 421
3 - Dimethylaminomethylkhellin—spectrophotometric analyses in bulk drug and dosage forms, various methods compared, 618
4 - Dimethylamino-3-phenyl-2-butanols—diastereoisomers and related esters, synthesized, antimicrobial activity evaluated, 401
***N*-(2,6 - Dimethylphenylcarbamoyimethyl)iminodiacetic acid** and analogs—synthesized, ^{99m}Tc-complexes prepared, 1434
***O,O*-Dimethyl-(+)-tubocurine**—syntheses by dequaternization procedures compared, mechanisms evaluated, products identified, 1204
2,4-Dinitrophenylhydrazine—blue-colored product of reaction with menadione identified, 258
Dinoprostone—complexation with β-cyclodextrin, phase solubility and PMR analyses, 1665
Dipalmitoyllecithin monolayers—equilibrium penetration by cetrimonium bromide, surface pressure–area isotherms measured, 364
Diphenhydramine—effect on methaqualone metabolism in rat liver homogenate, 1547
Disintegration—quinidine sulfate, four commercial tablets, related to dissolution profiles, 568
tablet—effects on dissolution, theoretical equation derived, 1436
tablet—related to dissolution profile of tablet and dissolution rate of primary drug particles, 86
time—tablets, specially fabricated and commercial, effect of intensity of agitation, 210
Disks, paper—effect of various grades on performance in antibiotic susceptibility tests, 367
Disposition—norgestimate after oral administration alone and combined with ethinyl estradiol in humans, 1406
Dissociation constants—polyprotic, amphoteric compounds, determined using solubility and pH measurements, 12
protolytic—chloroquine and quinacrine, spectrophotometric evaluation, 1770
Dissolution—directly compressed tablet in USP basket apparatus, sigmoid-shaped curve explained, 48
drug—noninvasive polarographic study of various capsules and tablets, 842
—ellipticine, effect of polyvinylpyrrolidone, 611
—hydrodynamics of four different types of apparatus compared, 1303
in vitro—compressed tablets, effect of partial moisture loss, 1385
in vitro—fludrocortisone acetate tablets, high-pressure liquid chromatographic analysis, 1397
in vitro—methaqualone, two tablets, compared to *in vivo* bioavailability in humans, 1328
in vitro—prolonged-release cephalexin tablet, 1620
in vitro—sulfamethizole, two suspensions compared, 1399
—kinetically based equation considers polydisperse systems and solid dosage forms, various condi-

tions, 1450
kinetics—cholesterol in simulated bile, effect of bile composition, 1711
kinetics, *in vitro*—acidic drugs, automated potentiometric study, pH-stat method used to establish sink conditions, 1163
methods, various—*in vitro* parameters correlated with human excretion of aspirin, 1070
—papaverine hydrochloride, three commercial sustained-release products, three different apparatuses compared, 496
—profile of tablet and rate of primary drug particles related to tablet disintegration, 86
profiles—nonspherical powders, effect of particle shape, equations derived, 1674
—quinidine sulfate, four commercial tablets, profiles determined and related to disintegration and absorption, 568
—rapidly soluble, finely subdivided substance in directly compressed and wet granulated tablets, compared with previous theoretical models, 982
rate—compressed disks of salicylic acid, aspirin, and equimolar mixture, effects of compression force, particle size, and lubricants, 535
rate—enhanced by solvent deposition method, effect of drug-to-excipient ratio, 134
rate, *in vitro*—nitrofurantoin, effect of formulation and process variables, 1613
rate, *in vitro*—various formulations of nitrofurantoin correlated with bioavailability in humans, 1616
rates—aspirin–acetaminophen–urea ternary system solid dispersions, 1112
rates—erythromycin anhydrate, monohydrate, and dihydrate crystalline solids in aqueous solution, 1087
rates—hydrocortisone and prednisone sugar solid dispersions in tablets, 979
rates—nitrofurantoin, ethotoin, and coumarin, solid dispersions with polyethylene glycol 6000 and coprecipitates with povidone, 114
rates—salicylamide in water and caffeine solutions, estimated using theoretical diffusion model, compared to experimental results, 95
rates—various amino penicillins, effect of pH, 1059
rates—various drug–urethan solid-state dispersions, compared to pure drug substances and physical mixtures, 391
tablet—theoretical equation derived, effects of tablet disintegration and particle dissolution, 1436
testing systems—three apparatus compared, suitability for use as production control tools and relations to blood level studies in dogs evaluated, 1732
Distribution, blood and brain—camazepam in mice and rats, 1470
coefficients—various compounds, high-pressure liquid chromatographic determination, 1364
—^{14}C-3-methylamino-1,2,3,4-tetrahydrocarbazole hydrochloride in rats and dogs, 1423
organ—^{99m}Tc-pentetic acid liposomes in mice, effect of particle size, 795
organic–aqueous—daunorubicin, doxorubicin, and hydroxyl metabolites, 782
phase—chlorocresol in solubilized and emulsified systems, related to antimicrobial activity with mathematical model, 1260
size—particulate matter in six large-volume parenteral solutions, automatic particle counter and microscopic techniques compared, 340
tissue—4-aminoantipyrine and ethanol by goldfish, effect of temperature and surfactant, 1558
tissue—ditazole in rats, GLC analysis, 705
tissue—2-^{14}C-fluorouracil in mice after oral or intravenous administration, autoradiographic determination, 344
tissue—perfluorooctyl bromide in dogs after oral and intratracheal administration, 1038
tissue—radiolabeled microspheres, after intravenous administration to dogs, bolus and infusion compared, 504
tissue—thiazinamium in rats, 1147
Ditazole—GLC analysis, pharmacokinetic study of blood and tissue distribution in rats, 705
Ditheophylline succinate—theophylline transfer rate across everted rat intestinal sacs, 1459
Dithioacetic acids, pyridinium and quinolinium—zwitterions synthesized, antitumor and antiradiation activity evaluated, 962
Diuretics—ethacrynic acid, reaction with methanol–hydrochloric acid or diazomethane, PMR, IR, and GLC–mass spectral analyses of products, 975
—furosemide, high-pressure liquid chromatographic analysis, stability in aqueous solutions and dosage forms, 808
—hydrochlorothiazide, GLC analysis in plasma, 726
—hydrochlorothiazide, high-performance liquid chromatographic analysis, simultaneously with reserpine, in tablets, 650
—spironolactone, high-pressure liquid chromatographic and colorimetric analyses in tablets, 889
—ticrynafen and metabolites, GLC analyses in biological fluids, 1095
DNA—binding to daunorubicin and doxorubicin, direct and difference spectroscopic methods compared, 688
—binding to various substituted benzo[*b*][1,5]-naphthyridines, 407
double stranded—binding to 3-aminoacridinium and 7-aminoquinolinium monocations, equilibrium expressions developed, 89
Dobutamine—high-pressure liquid chromatographic analysis in plasma, 1756
Dopamine analogs, cyclic—hypotensive activity evaluated in dogs and spontaneous hypertensive rats, 1639
derivatives, various—synthesized with *tert*-butoxycarbonyl as protecting group, CNS activity evaluated in mice, 558
Dosage forms—compressed tablets, effect of partial moisture loss on hardness and *in vitro* dissolution, 1385
—controlled-release delivery devices, various hydrogel membranes evaluated, permeability to progesterone, 1352
—controlled-release delivery devices, various polymer membranes evaluated, permeability to progesterone, effect of soaking in plasma, 1347
—directly compressed and wet granulated tablets containing rapidly soluble, finely subdivided substance, dissolution compared with previous theoretical models, 982
—gelatin microcapsules, method of preparation with soluble pharmaceuticals, 409
—hydrocortisone in various types of vehicles, effect of other active ingredients on stability, 299
—inert wax matrixes, release of tripelennamine hydrochloride or tolazoline hydrochloride from mixtures with carnauba or castor wax, 350
—large-volume parenterals, six types, size distribution of particulate matter, automatic particle counter and microscopic techniques compared, 340
—microsealed drug delivery system, subcutaneous release of desoxycorticosterone acetate in rats, *in vitro–in vivo* correlation, compared to matrix-type silicone device, 214
oral—various fenoprofen salts evaluated, stability studies, 231
—prepared by impregnating synthetic (−)-Δ^9-tetrahydrocannabinol on placebo *Cannabis* plant material, stability, 876
—solid dispersion binary systems, aspirin with urea or povidone, effect of temperature and humidity on stability, 163
—solid dispersions, aspirin–acetaminophen–urea ternary system, dissolution rates, 1112
—solid dispersions, aspirin–acetaminophen–urea ternary system, phase diagram constructed, physical properties evaluated, 1109
solid—enhancement of dissolution rate by solvent deposition method, effect of drug-to-excipient ratio, 134
—suspensions, separated into distinct particle-size fractions by centrifugal elutriation, 673
—tablets containing inert wax matrix, effect of povidone in tripelennamine hydrochloride release, 357
—tablets of tripelennamine hydrochloride in inert wax matrixes, effect of various surfactants on drug release, 354
—tablets, specially fabricated and commercial, effect of intensity of agitation on disintegration time, 210
—transdermal therapeutic system for scopolamine delivery, mathematical model for pharmacokinetics, 1370
various—griseofulvin, effect on interaction with phenobarbital in rats, 466
—various small-volume parenterals, particle content determinations, USP membrane filtration–microscopic and instrumental methods compared, 50
various—stability, review, 443
Doxepin, *cis* and *trans*—simultaneous GLC analyses in human plasma, 802
Doxorubicin—binding to DNA, direct and difference spectroscopic methods compared, 688
—energy of interaction with phospholipid monolayers of air–water interface, 773
—GLC–mass spectral analysis, bulk drug, 1243
glycone analogs, various—GLC–mass spectral analyses, prepared samples, 1748
—organic–aqueous distribution, self-association in aqueous phase, 782
Drug–antibiotic interactions—various analgesics, antipyretics, antimalarials, and tranquilizers, effect of combination with various antibiotics, 23
Drug delivery systems, microsealed—subcutaneous release of desoxycorticosterone acetate in rats, *in vitro–in vivo* correlation, compared to matrix-type silicone device, 214
partitioning—relationship of partition coefficients to forward and reverse rate constants and number of CH_2 groups in a homologous series, 262
release—hydrophobic drugs from capsules, effect of hydrophilization, 935
release—sheabutter ointment compared to others, effect of particle size, 374
removal—during hemoperfusion, effect of changing intercompartment clearance rates, computer simulation, 1178
transport kinetics—evaluated in suspension cultures of mammalian cells, equations derived, 606
Dyes—phenolsulfonphthalein, urinary excretion from rats, validity of oral bioavailability estimates, 267
Dynamic dialysis—mathematical analysis, competitive binding of small molecules to macromolecules studied, 908

E

ECG abnormalities—relationship to plasma concentrations of thioridazine and metabolites evaluated, humans, 155
Editorials
Devious Routes to Governmental Regulation (May)
Fruitless Numbers Games (April)
Information Release: Raw Data or Summary? (July)
IRS's Myopic View of Research (October)
Look What They Say About Us! (September)
Moment of Truth for OTA (January)
A Problem and a Solution (June)
A Profession in Transition (March)
Proposition 13 and Pharmaceutical Scientists (August)
Research Frontiers Remain Ripe (November)
Toward a Uniform Level of Performance (December)
Why a Consideration Fee? (February)
Electron donor–acceptor complexes—as model system for structure–activity relationships, 1310
Electronic absorption spectroscopy—used to characterize prototropic species of substituted pyridinemethanol at various pH values and in *n*-hexane, 1224
Electronic monitoring—mechanical events in dynamic particulate beds, conductance and capacitance characteristics evaluated, 1121

Electronic structure—various acridines, related to antibacterial activity, 706
Electrostatic potential energy—considered in depicting three-dimensional illustrations of molecular structure of narcotic molecules, 73
contours—considered in depicting three-dimensional illustrations of molecular structure sensitive to small electronic perturbations, 67
Elimination—ascorbic acid in humans after intravenous administration, 1491
kinetics—(*R*)-(+)- and (*S*)-(−)-warfarin compared, humans, 867
rate—substituted quaternary pyridinium salt and prodrug from brain, mice, 685
reactions, Hofmann—various curare bases and tetrahydroisoquinoline alkaloids with diazomethane, 473
Ellipticine—dissolution and GI absorption, effect of polyvinylpyrrolidone, 611
Emetine—*in vitro* adsorption on activated charcoal, 426
Enantiomeric purity—dexclamol hydrochloride, effect on solubility, 636
Enantiomers—(*R*)-(+)- and (*S*)-(−)-warfarin, elimination kinetics and anticoagulant effect compared, humans, 867
Enkephalins—stereochemistry compared to exogenous opiates, 590
Enterohepatic circulation—iodoxamic acid in rhesus monkeys, 930
—minimal interruption technique used to measure biliary excretion of ^{3}H-digoxin, rats, 415
Enzyme activity—cyclic AMP phosphodiesterase, effect of various thiazolo- and thiadiazolo[3,2-*a*]pyrimidines *in vitro*, 1762
—effect of 1-phenyl-1-penten-3-one derivatives in rat liver mitochondria, 1539
—effect of various oxadiazoles evaluated in rat brain homogenates, 987
—effect of various sulfonamides and sulfonyl hydrazides on L-asparagine synthetase evaluated *in vitro*, 1550
—effects of helenalin on anaerobic and aerobic metabolism of Ehrlich ascites cells, 552
—Ehrlich ascites tumor cells, effects of eupahyssopin, 1232
—NAD dependent and independent oxidations in rat brain homogenates, effect of various substituted trimethoxybenzamides, 1682
—ornithine decarboxylase, effect of (±)-2,5-diamino-2-(cyanomethyl)pentanoic acid, 1174
—rat liver mitochondrial monoamine oxidase, effect of chloramphenicol and 2-amino-1-*p*-nitrophenylpropane-1,3-diol *in vitro*, 480
tumor—effect of various α-methylene-γ-lactone-containing agents evaluated, 1235
—various acetylcholine analogs evaluated as inhibitors of choline acetyltransferase, 657
Enzyme inducers—phenobarbital, benzo[*a*]pyrene, and proadifen hydrochloride, effect on transfer of 3-*O*-methylglucose across everted rat small intestine, 245
Enzymes—esterases hydrolyzing oxazepam acetate *in vivo* and *in vitro*, stereospecificity determined, 1208
Epinephrine—colorimetric analysis in bulk drug and dosage forms, 779
—oxidation in alkaline solutions, effect of sodium metabisulfite and cysteine, 1474
Equilibrium constants, microionization—determined for various cephalosporins, 666
Equipment, laboratory—contamination of mortars and pestles washed by usual procedures demonstrated by pentylenetetrazol seizure threshold test, 1756
Eriophyllum confertiflorum—germacranolides isolated, antineoplastic activity evaluated, 865
Erythrocyte–ligand interactions—Scatchard plots constructed from data, use of binding capacities evaluated, 1344
Erythromycin oxime and amine—kinetics of acid-catalyzed hydrolysis, 1031
—pharmacokinetics after intravenous administration in humans, 1057
—physical characterization of anhydrate, monohydrate, and dihydrate crystalline solids, dissolution rates in aqueous solution, 1087
stearate—bioavailability, effect of food and fluid volume, humans, 764
Esterases—hydrolyzing oxazepam acetate *in vivo* and *in vitro*, stereospecificity determined, 1208
Estrogens, conjugated—GLC analyses, steady-state urinary excretion in postmenopausal women, 1218
—ethinyl estradiol and mestranol, *in vitro* adsorption by magnesium trisilicate, 287
—ethinyl estradiol, radiochemical GLC analysis in human urine, 1138
various—high-pressure liquid chromatographic analyses of dansyl derivatives, pharmaceutical preparations, 1735
various—simultaneous solubilization in aqueous surfactants, 1419
Etazolate hydrochloride—hydrolysis in aqueous solutions, PMR and mass spectral stability studies, 850
Ethacrynic acid—reaction with methanol–hydrochloric acid or diazomethane, PMR, IR, and GLC–mass spectral analyses of products, 975
Ethambutol—GLC analysis in biological fluids, 470
Ethanol—accumulation by goldfish, effect of temperature and surfactant, 1558
Ethers, various aliphatic—anesthetic activity and toxicity related to molecular connectivity indexes, 564
Ethinyl estradiol—radiochemical GLC analysis in human urine, 1138
Ethosuximide—pharmacokinetic parameters during single or divided daily doses compared using MULTDOS and 1969 or 1974 NONLIN computer program, 574
Ethotoin—solid dispersions with polyethylene glycol 6000, coprecipitates with povidone, effect on dissolution rate, 114
17α-Ethylestran-17β-ol—impurity in ethylestrenol, stereochemistry at C-5 assigned, 1187
Ethylestrenol impurity—stereochemistry at C-5 assigned, 1187
***N*-Ethyl-1-phenylcyclohexylamine**—identified in street sample by NMR, IR, and mass spectral data, 885
Etorphine—GLC-selective ion mass spectrometric analysis in urine, 260
Eupahyssopin—effects on nucleic acid, protein, anaerobic, and aerobic metabolism of Ehrlich ascites tumor cells, 1232
Eupatorium semiserratum—germacranolides isolated, antineoplastic activity evaluated, 865
Excretion—aspirin in humans, correlated with parameters from various *in vitro* dissolution methods, 1070
biliary—^{3}H-digoxin, measured by enterohepatic circulation minimal interruption technique, rats, 415
biliary—iodoxamic acid in rhesus monkeys, 930
biliary—thiazinamium in rats, 1147
—^{14}C-3-methylamino-1,2,3,4-tetrahydrocarbazole hydrochloride in rats and dogs, 1423
—normorphine in dogs, 878
urinary—conjugated estrogens at steady state in postmenopausal women, 1218
urinary—phenolsulfonphthalein in rats, validity of oral bioavailability estimates, 267
—various substituted triazines in rats, 306

F

Fatty acids and derivatives, various—evaluated as stationary phases in reversed-phase TLC for correlation between structure and biological response of probiotics, 713
various—effects on absorption of lipophilic drugs from perfused rat intestine, 1211
Fenbufen—high-pressure liquid chromatographic analysis in serum and urine, 1662
Fenclorac—GLC analysis in plasma, 1171
Fenoprofen—various salts synthesized, evaluated as oral dosage forms, stability studies, 231
Ferric perchlorate—oxidation of promazine and promethazine, kinetics and mechanism, various temperatures and pH values, 168
Ferricyanide and ferrocyanide, free—chromatographic separation and spectrophotometric analyses in prepared solutions of sodium nitroferricyanide (nitroprusside), 1752
Film coating—containing UV absorber, effect on coloration and photolytic degradation of sulfisomidine tablets, 196
Flavin-catalyzed photooxidation—substituted acridan, mechanism studied, 318
Flocculation–deflocculation behavior—sulfathiazole and graphite, effect of glycyrrhizic acid, aqueous solutions, various pH values, 151
Floxuridine—GLC analysis in plasma, 417
Flucytosine—differential pulse polarographic analysis in dosage forms, 1641
Fludrocortisone acetate—tablets, dissolution, high-pressure liquid chromatographic analysis, 1397
Fluorene spiro compounds, various—synthesized, evaluated for antiallergic activity, 953
Fluorescence spectroscopy—used to characterize prototropic species of substituted pyridinemethanol at various pH values and in *n*-hexane, 1224
Fluorescence TLC–densitometry—analyses, chlordiazepoxide and metabolites in serum, 639
—analyses, diazepam, desmethyldiazepam, and oxazepam in serum, 1413
Fluorocarbons—perfluorooctyl bromide, tissue distribution in dogs after oral and intratracheal administration, 1038
4-Fluoroisoleucine—synthesized, evaluated for antimicrobial activity, 715
Fluorometric TLC—analyses, propranolol and major metabolites in human plasma and urine, 826
Fluorometry—analysis, amitriptyline, blood and tissues, 60
—analysis, coralyne sulfoacetate in serum, 1331
—analysis, indapamide in urine, 1117
—analysis, phenylpropanolamine in dosage forms, 1635
—mechanism of analysis, tetracycline complexation with calcium and organic ligands, 1518
—study of binding of 1-anilino-8-naphthalenesulfonic acid to various antipsychotics and antidepressants, 861
2-^{14}C-Fluorouracil—tissue distribution in mice after oral or intravenous administration, autoradiographic determination, 344
Fluorouracil—adsorption on glass surfaces, 1494
—nitrogen-detector GLC analysis in plasma, 1489
Fluoxymesterone—differential pulse polarographic analysis in tablets, 436
Fluphenazine and various analogs—synthesized, CNS antitumor and cytotoxic activity evaluated, 157
Fulvoplumierin—isolated from *Himatanthus sucuuba* bark, evaluated for pharmacological and anticancer activity, 1322
Furosemide—high-pressure liquid chromatographic analysis, stability in aqueous solutions and dosage forms, 808
***Fusarium moniliforme* mold**—infected sweet corn and *in vitro* cultures, toxins isolated and identified, 1768

G

Galactose-induced cataract formation—studied in guinea pigs, effect of ascorbic acid, 1478
Gastric fluid, simulated—*in vitro* adsorption of typical drugs to activated charcoal, effect of pepsin, 1181
Gelatin microcapsules—method of preparation with soluble pharmaceuticals, 409
—thermal degradation, solution and gel mass, rigidity and viscosity, applied to processing predictions, 218
Genetic phenotypes—of isoniazid acetylation in humans, determined using metabolic clearance values, 1018
Germacranolides—isolated from *Eupatorium semiserratum* and *Eriophyllum confertiflorum*, antineoplastic activity evaluated, 865
GI absorption—methotrexate from rat small intestine *in situ*, 560
—salicylate, effect of ascorbate, rat intestine *in vivo* and *in vitro*, 224
Ginseng—panaxoside content of various commercial products, TLC analysis, 1487

Glass formation—various barbiturates evaluated, 1606
Glass surfaces—adsorption of various drugs and proteins studied using controlled pore glass, 1102
GLC—analyses, chlordiazepoxide and desmethyl metabolite, bulk drug, 1176
—analyses, conjugated estrogens in urine of postmenopausal women, 1218
—*analyses, meperidinic and normeperidinic acids* in human urine, 116
—analyses, phenylpropanolamine and chlorpheniramine simultaneously, human urine, 118
—analyses, tilidine and metabolites in biological fluids, 1765
—analyses, various anticonvulsants and one sedative in commercial dosage forms, 950
—analyses, various sterols in biological fluids and extracts, 1157
—analysis, caffeine in plasma, 1093
—analysis, carbocysteine in plasma, 1753
—analysis, (2-cyclopentyl-6,7-dichloro-2-methyl-1-oxo-5-indanyloxy)acetic acid in biological fluids, 162
—analysis, derivatives of ethacrynic acid, 975
—*analysis, ditazole in rat blood and tissues, 705*
—analysis, ethambutol in biological fluids, 470
—analysis, fenclorac in plasma, 1171
—analysis, floxuridine in plasma, 417
—analysis, hydralazine pyruvic acid hydrazone in *plasma, 1150*
—analysis, hydrochlorothiazide in plasma, 726
—analysis, lidocaine in plasma, 887
—analysis, methaqualone metabolite in rat liver homogenate, 1547
—*analysis, nefopam in plasma, 1720*
—analysis, nitroglycerin in plasma, 582
—analysis, pemoline in biological fluids, 419
—analysis, phenylbutazone in human plasma, 243
—*analysis, phenylbutazone γ-oxo metabolite in* plasma, 279
—analysis, stenolol in biological fluids, 1340
—analysis, tiCrynafen and metabolites in biological fluids, 1095
—*analysis, urushiol fractions obtained from different plant parts of Toxicodendron radicans,* 483
—analysis, warfarin in human plasma, 84
and combined GLC–mass spectrometry—identification of photolysis products of aprindine hydrochloride, 722
electron capture—analysis, chlordiazepoxide in serum, 1647
electron capture—analysis, desmethyldiazepam in plasma, 427
electron capture—analysis, ibuprofen in serum, 627
electron capture—analysis, metoclopramide in biological fluids, 1073
electron capture—analysis, nalbuphine in plasma, 547
electron capture—analysis, procainamide in human serum, 371
electron capture—analysis, tocainide in biological fluids, 201
nitrogen detector—analysis, fluorouracil in plasma, 1489
radiochemical—analysis, ethinyl estradiol in human urine, 1138
—simultaneous analyses, *cis*- and *trans*-doxepin and desmethyldoxepin in human plasma, 802
—simultaneous analyses, phenol, chloroxylenol, and lidocaine hydrochloride in commercial preparations, 1627
GLC–chemical-ionization mass spectrometry—analysis, various tricyclic antidepressants in human plasma, 17
GLC–mass spectrometry—analyses, cocaine and benzoylecgonine in human urine, 811
—*analyses, doxorubicin, daunorubicin, and other* antineoplastic agents, bulk drug, 1243
—analyses, hispidin, bisnoryangonin, muscimole, and ibotenic acid in mushrooms, 485
—analyses, prednisone and prednisolone in human *plasma, 923*
—analyses, various doxorubicin and daunorubicin *glycone analogs, prepared samples, 1748*
—analysis, methadyl acetate in urine, 1483
—analysis, nadolol in serum, 653
GLC–selective ion mass spectrometry—analysis, etorphine in urine, 260
Glucocorticoids—betamethasone and various esters, spectrophotometric analyses in pharmaceutical products, 361
—*betamethasone sodium phosphate, high-pressure* liquid chromatographic analysis in dosage forms, 913
—cloprednol, bioavailability of various dosage forms in humans, 920
—*dexamethasone, absorption in humans, effect of* concomitant administration of magnesium trisilicate, 1029
—*hydrocortisone and prednisone, sugar solid dispersions in tablets, dissolution rates and stability,* 979
—hydrocortisone, penetration through mouse skin, effect of formulation factors, 789
—*hydrocortisone, stability in various types of vehicles, effect of other active ingredients, 299*
—prednisolone and prednisone, differential pulse *polarographic analysis in tablets, 436*
—prednisone and prednisolone, GLC–mass spectrometric analyses in human plasma, 923
Glycosides, various—synthesized, hemolytic activity evaluated, 1589
Glycyrrhizic acid—*effect on flocculation–deflocculation behavior of sulfathiazole and graphite,* aqueous solutions, various pH values, 151
Gold—atomic absorption spectrophotometric analysis in whole blood, 1332
Granules—*ball milling as a measure of crushing* strength, 905
Graphite—flocculation–deflocculation behavior, effect of glycyrrhizic acid, aqueous solutions, various pH values, 151
Griseofulvin—*absorption from perfused rat intestine,* effects of fatty acids, 1211
—GI absorption from aqueous phase and aqueous phases containing triolein digestion mixture, rats, 895
—*high-pressure liquid chromatographic analysis* in plasma, 805
—interaction with phenobarbital, effect of different dosage forms in rats, 466
Gymnopilus punctifolius—GLC–mass spectral analysis of various components, 485

H

Halofumarate alkyl esters, various—antifungal activity evaluated, 578
Haptens, chlorpromazine—three synthesized and characterized, antibodies developed in rabbits, antiserum titers determined, 1563
—of various tricyclic antidepressants, synthesized, coupled to bovine serum albumin, antibodies developed in rabbits, 1571
Hardness—compressed tablets, effect of partial moisture loss, 1385
granule—ball milling as a measure of crushing strength, 905
Helenalin—effects on anaerobic and aerobic metabolism of Ehrlich ascites cells, 552
Helenium microcephalum—whole plant extract, microlenin isolated, structure and stereochemistry determined, 1228
Hemolytic activity—various glycosides evaluated, 1589
***N*-Heptyl-1,2,3,4-tetrahydro-6-methoxy-1-naphthylamine methanesulfonate**—local anesthetic activity and acute toxicity evaluated, 882
Heterocycles, tricyclic—substituted indenopyrazoles synthesized, evaluated for CNS activity in mice, 1377
Heterocyclic oxamates, various—synthesized, *evaluated as antiallergy agents,* 735
High-performance liquid chromatography—analyses, four components of dihydroergotoxine in bulk drug and pharmaceutical formulations, 98
—analyses, sulfapyridine and acetyl metabolite in *biological fluids, 1250*
—analysis, indoprofen in biological fluids, 831
—*analysis, mercaptopurine in plasma, 1027*
—analysis, suprofen in plasma, 985
—analysis, vindesine in bulk drug, 1319
—fluorometry—analysis, prazosin in plasma, 1468
—simultaneous analyses, hydrochlorothiazide and reserpine in tablets, 650
—simultaneous analyses, morphine sulfate and *parabens in dosage form, 1510*
—simultaneous analyses, procainamide and *N*-acetylprocainamide in plasma, 839
High-pressure liquid chromatography—analyses, amygdalinamide and amygdalin acid in amygdalin *dosage forms, 1190*
—analyses, amygdalin and components in various dosage forms, 438
—analyses, aspirin, salicylic acid, and salicyluric acid simultaneously in plasma, 710
—analyses, camphor and parachlorophenol in pharmaceutical formulations of camphorated parachlorophenol, 266
—*analyses, clindamycin base, phosphate, and* palmitate in bulk drug and dosage forms, 1254
—analyses, dansyl derivatives of various estrogens, pharmaceutical preparations, 1735
—analyses, degradation products of procarbazine *hydrochloride in pharmaceutical formulations,* 424
—analyses, phenylephrine hydrochloride, phenyl*propanolamine hydrochloride, and brompheniramine maleate in dosage forms, 873*
—analyses, procainamide and *N*-acetylprocainamide simultaneously in plasma, 869
—analyses, quinidine and dihydroquinidine in *plasma, 269*
—analyses, sulfadiazine, sulfamethazine, and sulfamerazine in human serum, 404
—analyses, various acetyl polyamines in urine of normal humans and cancer patients, 1671
—*analyses, various catecholamines and phenyl*ephrine hydrochloride in prepared solutions and dosage forms, 1247
—analyses, various muscle relaxants and analgesics in pharmaceutical mixtures, 675
—analysis and separation of anomers of streptozocin in a commercial dosage form, 1300
—analysis, atenolol in biological fluids, 1033
—analysis, benzoyl peroxide in bulk drug and commercial preparations, 1035
—analysis, betamethasone sodium phosphate in dosage forms, 913
—analysis, chloramphenicol in plasma, 1036
—analysis, creatinine in biological fluids, 182
—analysis, creatinine in human plasma, compared to automated analysis and alkaline picrate method, 292
—analysis, cycloheximide in bulk drug and prepared formulations, 669
—analysis, dissolution of fludrocortisone acetate tablets, 1397
—analysis, dobutamine in plasma, 1756
—analysis, fenbufen in serum and urine, 1662
—analysis, furosemide in aqueous solutions and dosage forms, 808
—analysis, griseofulvin in plasma, 805
—analysis, 8-hydroxycarteolol in plasma and urine, 1623
—analysis, melphalan in plasma, 679
—analysis, phenytoin in plasma, 1462
—analysis, spironolactone in tablets, 889
—analysis, substituted tetrazolylchromone in biological fluids, 1185
—analysis, thimerosal in aqueous pharmaceutical preparations, 1636
—analysis, tocainide in blood, 1692
—determination, partition, distribution, and ionization coefficients for various compounds, 1364
—simultaneous analyses of various vitamins in *multivitamin preparations, 1444*
—simultaneous analyses, pseudoephedrine and chlorpheniramine in dosage forms, 1668
Himatanthus sucuuba—fulvoplumierin isolated from bark, evaluated for pharmacological and anticancer activity, 1322

Hispidin—GLC–mass spectral analysis in mushrooms, 485
Humidity, relative—in headspace of lyophilized vials of sincalide, correlated with product stability, 1239
Hydralazine—interference in published GLC and spectrophotometric analyses in plasma by major metabolite, 1150
Hydrated forms—of erythromycin crystalline solids, *physical characterization, dissolution rates in* aqueous solution, 1087
Hydrocarbons, aliphatic series—methylene group contribution to free energy of transfer from one phase to another, 615
Hydrochlorothiazide—*GLC analysis in plasma, 726*
—high-performance liquid chromatographic analysis, simultaneously with reserpine, in tablets, 650
Hydrocortisone—penetration through mouse skin, effect of formulation factors, 789
—stability in various types of vehicles, effect of other active ingredients, 299
—*sugar solid dispersions in tablets, dissolution* rates and stability, 979
Hydrodynamics—four different types of dissolution *apparatus compared, 1303*
Hydrogels, various—permeabilities, diffusion coefficients, *and partition coefficients for progesterone* permeation, potential for use as controlled-release drug delivery devices, 1352
Hydrolysis, *acid catalyzed—erythromycin oxime and* amine, kinetics, 1031
—2,6-dichlorobenzylthiopseudourea in basic medium, products isolated and identified, 256
—digoxin in gastric pH, colorimetric analysis, *1358*
—digoxin, kinetic study, effect of pH, 327
—etazolate hydrochloride in aqueous solutions, PMR and mass spectral stability studies, 850
—kinetics and mechanism, halogenated nitro-*soureas, effect of pH, 1527*
kinetics—triclofos sodium, effect of pH, temperature, and ionic strength, 631
—melphalan, effect of bovine serum albumin, various temperatures, 682
—*oxazepam acetate in vivo and in vitro,* stereospecificity of esterases determined, 1208
product—diazepam, official spectrophotometric analysis in dosage forms adapted to correct for potential interference, 550
rate—acetaminophen prodrug studied, dogs, 545
—solasodine, formation of solasodiene on treatment with hydrochloric acid under various conditions, 1169
Hydrophilization—of hydrophobic drugs, effect on release from capsules, 935
Hydrophobic drugs—release rate from capsules, effect of hydrophilization, 935
3β-Hydroxy-13α-amino-13,17-seco-5α-androstan-17-oic-13,17-lactam ester of chlorambucil—synthesized, antineoplastic activity evaluated, mice and rats, 1342
***p*-Hydroxybenzoic acid**—difference spectrophotometric analysis in presence of alkyl esters, 837
8-Hydroxycarteolol—high-pressure liquid chromatographic analysis in plasma and urine, 1623
Hydroxyethyltheophylline—chromatographic separation from theophylline in pharmaceutical syrup, spectrophotometric analyses, 572
Hydroxylaminoeverninomicin D—polarographic analysis, bulk drug, 719
3-Hydroxypropanethioates, 3-aryl—series synthesized, antibacterial activity evaluated, 413
3-Hydroxyquinolizidine esters, various—synthesized, structures assigned, cholinergic activity evaluated *in vitro,* 1759
Hydroxyurea and 3-ethyl analog—comparison of solid and solution conformations, 239
various—log *P* in octanol–water correlated with molecular connectivity indexes, 513
Hyperglycemic activity—various substituted thiazoles evaluated, 587
Hypnotic–sedatives—methaqualone, metabolism, effect of diphenhydramine in rat liver homogenate, 1547
—*methaqualone, one-step synthesis, diphasic titration analysis in bulk drug and tablets,* 411
—*methaqualone, two tablets, in vitro dissolution* compared to *in vivo* bioavailability in humans, 1328
—pentobarbital, absorption rates and bioavailability from capsules and suppositories in humans, 1586
Hypoglycemic activity—various substituted thiazoles evaluated, 587
Hypotensive activity—*substituted benzo[f]quinoline* evaluated in dogs and spontaneous hypertensive rats, 1639
—various substituted indazoles evaluated, 1022
Hypothermia—induced by cobaltous chloride in mice, *mechanism, effect of pretreatment with anticholinergics,* 799

I

Ibotenic acid—GLC–mass spectral analysis in mushrooms, 485
Ibuprofen—electron-capture GLC analysis in serum, time course of protein binding in humans, 627
Imidazo[1,5-b]isoquinolines, *substituted—synthesized,* evaluated for anti-inflammatory activity, 718
Imidazolidinethiones, substituted—synthesized, evaluated for CNS depressant and anticonvulsant *activity, 600*
Imidazolidinones, substituted—spectrofluorometric analyses in biological fluids, 752
2-Imidazolidinones, *1-substituted—synthesized,* anti-inflammatory activity evaluated, 548
Iminodiacetic acids, substituted—synthesized, ^{99m}Tc-complexes prepared, 1434
Immunological cross-reactions—various penicilloic *and penilloic acids evaluated in vitro, 1197*
Impurities—amygdalinamide, amygdalin acid, and 2-propanol, analyses in amygdalin dosage forms, 1190
—in meperidine bulk drug and dosage forms, TLC *analyses, 958*
—in various formulations of methotrexate, chromatographic separation, UV, NMR, and mass spectral analyses, 622
various—isolated and characterized in sulfasalazine, *387*
Indans, various substituted—synthesized, cardiovascular properties and toxicity evaluated, rats, 314
Indanyloxyacetic acid, substituted—GLC analysis in *biological fluids,* 162
Indapamide—fluorometric analysis in urine, 1117
Indazoles, substituted—synthesized, evaluated for hypotensive activity, 1022
2-Indeneacetic acid and 5-chloro derivative—synthesized, evaluated for effect on cholesterol biosynthesis in rat liver homogenates, 80
Indenopyrazoles, substituted—synthesized, evaluated for CNS activity in mice, 1377
Indolecarbohydrazides, various—effect on human platelet aggregation in ethylene glycol *in vitro,* 1025
Indole derivatives, various—mass spectrometric analyses in human urine, 478
(Indolylethyl)piperazinylureas, substituted—synthesized, evaluated for antihypertensive activity in rats and dogs, 1773
Indoprofen—high-performance liquid chromatographic analysis in biological fluids, 831
Infarct size—effect of various therapeutic agents, rats with induced myocardial infarctions, 1643
Infusion methods, two step—used to obtain successively higher plasma levels at steady state, simulated data for hypothetical drug, 1651
Inhalation delivery systems—evaluated *in vitro* using simulated respiratory system, 1428
Input functions, *in vivo*—deconvolution point–area and *area–area methods of determination compared,* 663
Instrument design—nonisothermal calorimeter, *general method for determining process-dependent* temperature change, 1592
Interactions—griseofulvin with phenobarbital, effect of different dosage forms in rats, 466
Iodinated aromatic compounds, various—toxicity in *mice, structure–activity relationships, 1154*
Iodometry—analysis, penicillin V benzathine, interference by *benzathine molecule,* 1495
Iodoxamic acid—biliary excretion, plasma protein binding, and enterohepatic circulation in rhesus monkeys, 930
Ion cluster–mass chromatography—analyses, urinary metabolites of 1-butyryl-4-cinnamylpiperazine in mice and guinea pigs, 757
Ion-exchange resins—binding of various drugs in *simulated gastric fluid,* compared to previous results with charcoal, 1329
—cholestyramine, intrinsic factor-mediated binding of cyanocobalamin, effect of pH, added electrolyte, and bile salt, 1626
Ionization coefficients—*various compounds, high-*pressure liquid chromatographic determination, 1364
constants—potentiometric determination in mixed aqueous solvents of various composition, 127
—effect on GI absorption of various cephalosporins, rats, 320
Ion-pair formation—effect on mixidine absorption, *intraduodenal administration with various ratios* of 2-naphthalenesulfonic acid as counterion, 948
—mixidine *in vitro,* determined by partitioning, 945
Ion-pair forming agents—*effect on aqueous–octanol* partition coefficient of ampicillin, 138
Ion-pair partitioning—*N,N*-dimethyl derivative of *propranolol, functional group contribution of bile salt* molecules, 847
Iontophoresis suitability—various drugs, electrical conductivity measured *in vitro,* 1439
Ipecac—*in vitro* adsorption of constituent emetine on *activated charcoal, 426*
IR spectroscopy—amphotericin B, different spectra attributed to *method of sample preparation,* 398
—identification, components in various amygdalin *dosage forms, 438*
—recommended as substitute for compendial odor *identification tests,* 539
Isoniazid acetylation—genetic phenotypes determined using metabolic clearance values in humans, 1018
—spectrophotometric analysis in presence of its *hydrazones in prepared mixtures and commercial* tablets, 661
Isoproterenol—colorimetric analysis in bulk drug and dosage forms, 779
-induced cardiac arrhythmias—effect of hemodynamic alterations in rats treated with desoxycorticosterone acetate, 1390
Isoquinoline alkaloids—formation rate by reaction of various catecholamines and aldehydes, 112
derivatives, various—synthesized, evaluated for antineoplastic activity, 740
Isothiocarbamates, various—synthesized, evaluated for antibacterial and antifungal activity, 576

J

Journals
Clinical and Experimental Hypertension, 1044
Journal of Environmental Science and Health. Part C: Environmental Health Sciences, 1044

K

Kaolin–pectin suspension—effect on bioavailability of orally administered clindamycin in humans, 1579
—*effect on GI absorption and bioavailability of digoxin in humans,* 1582
Keratolytic agents—benzoyl peroxide, high-pressure liquid chromatographic analysis in bulk drug and commercial preparations, 1035
—*salicylic acid, binding to bovine serum albumin,* affinity chromatography study, 1005
—salicylic acid, percutaneous absorption, effect of *repeated application, rats, 1685*
Khellin—spectrophotometric analyses in bulk drug and dosage forms, various methods compared, 618
Kinetic approach—mathematical model considers *dissolution of polydisperse systems and solid dos-*

age forms, various conditions, 1450
Kinetic models—coagulation and coagulation–lysis, time courses after addition of thrombin or thrombin–*streptokinase to plasma, 145*
Kinetics—acid-catalyzed hydrolysis of erythromycin oxime and amine, 1031
and mechanism—*reaction of blue tetrazolium with* various phenylhydrazines, 927
—*bilirubin formation, distribution, and elimination* in rats, effect of phototherapy, 205
—carbuterol degradation in aqueous solution, pH *effect, 1523*
—digoxin hydrolysis, effect of pH, 327
—drug transport and concurrent metabolism in *suspension cultures of mammalian cells,* equations derived, 606
—*human platelet aggregation, effect of adenosine* diphosphate, various prostaglandins, and arachidonic acid, 939
—*hydrolysis of halogenated nitrosoureas, effect of* pH, 1527
—hydrolysis of triclofos sodium, effect of pH, temperature, and ionic strength, 631
—partitioning of tetracyclines in aqueous–octanol *system, 1715*
—partitioning of tetracyclines in aqueous–octanol system, 1717
—*reaction of various substituted anilines with so*dium hydroxymethanesulfonate, equilibrium and hydrolysis rate constants calculated, 1283

L

β-Lactam antibiotics—kinetics of GI absorption and *nonenzymatic degradation in rats, 1701*
—propicillin, GI absorption, deviation from pH-partition hypothesis, rats, 1705
Lactones, *various sesquiterpene—isolated and* characterized from leaves of *Magnolia grandiflora L.,* 347
Leucine-enkephalin—narcotic agonist activity evaluated, mice, 136
Levarterenol—colorimetric analysis in bulk drug and dosage forms, 779
Lidocaine—GLC analysis in plasma, 887
Lidocaine hydrochloride—GLC analysis simultaneously with other active ingredients in commercial preparations, 1627
Ligand–erythrocyte interactions—Scatchard plots constructed from data, use of binding capacities *evaluated,* 1344
Light scattering—study of pattern of association of sodium cholate, glycocholate, and taurocholate in *aqueous electrolyte solutions, 174*
Lipid membranes, bilayer—electrically excitable, effect of local anesthetics, 965
Lipids—*triolein digestion mixture,* GI absorption of griseofulvin, rats, 895
Lipophilic drugs—prednisolone and *griseofulvin, ef*fects of fatty acids on absorption from perfused rat intestine, 1211
Liposomes, *radiolabeled—^{99m}Tc-pentetic acid, organ* distribution in mice, effect of particle size, 795
Liquid chromatography—analyses, aspirin and sali*cylic acid in multicomponent tablets, 1066*
Liquid–liquid extraction—separation of various sulfonamides from degradation products, 1415
Liquid membranes—*in vitro* removal of various barbiturates from pH 2 donor solutions, effect of temperature, phase ratio, and bile salts, 63
Local anesthetic activity—*N*-heptyl-1,2,3,4-tetrahydro-6-methoxy-1-naphthylamine methanesulfonate evaluated, 882
—various *N*-substituted 1,2,3,4-tetrahydro-1- and *2-naphthylamines evaluated, 880*
Log *P*—various hydroxyureas in octanol–water, correlated with molecular connectivity indexes, 513
Lubricants, *various—effect on dissolution rate of* compressed disks of salicylic acid, aspirin, and equimolar mixture, 535
Lupinus argenteus var. stenophyllus—*various al*kaloids isolated from aboveground portions, 430
Lyophilization—sincalide, optimum cycle developed, *vial headspace relative humidity correlated with* product stability, 1239

M

Magnesium ions—interaction with cromolyn sodium *in solution, 1403*
trisilicate—effect on dexamethasone absorption, concomitant administration in humans, 1029
trisilicate—in vitro adsorption of various progestins, estrogens, and commercial contraceptive tablets, 287
***Magnolia grandiflora* L.**—leaves, isolation and characterization of various sesquiterpene lactones, *347*
Mass chromatography–ion cluster technique—analyses, urinary metabolites of 1-butyryl-4-cin*namylpiperazine in guinea pigs, 757*
Mass spectrometry—analyses, various indole derivatives in human urine, 478
chemical ionization—analysis, various tricyclic antidepressants in human plasma, 17
Mechanism—*hydrolysis of halogenated nitrosoureas,* effect of pH, 1527
Melphalan—high-pressure liquid chromatographic *analysis in plasma, 679*
—hydrolysis, effect of bovine serum albumin, various temperatures, 682
Membranes, liquid—*in vitro* removal of various barbiturates from pH 2 donor solutions, effect of tem*perature, phase ratio, and bile salts, 63*
Menadione—blue-colored product of reaction with 2,4-dinitrophenylhydrazine identified, 258
Meperidine—TLC analyses of impurities in bulk drug and dosage forms, 958
metabolites—meperidinic and normeperidinic acids, GLC analyses, human urine, 116
Meprobamate—bioavailability of 11 commercial *products in humans, 1290*
Mercaptopurine—high-performance liquid chromatographic analysis in plasma, 1027
—*thermodynamics of dehydration, stability of hy*drate and anhydrate forms under various thermal *conditions, 488*
Metabolic clearance values—used to determine genetic phenotypes of isoniazid acetylation in humans, 1018
Metabolism, anaerobic and aerobic—Ehrlich ascites cells, effects of helenalin, 552
—*l*-bunolol in rats, urinary metabolites identified, 129
—*dextromethorphan hydrobromide, effect of sali*cylamide and acetaminophen, rats, 761
—dextromethorphan in male and female rats *compared,* 1326
drug—effect of dactylyne isolated from *Aplysia dactylomela* sea hare, 1293
drug—sites and pathways evaluated, theoretical analysis to differentiate gut wall elimination and hepatic removal, relationship between area under the curve and administration route, 703
—methaqualone, effect of diphenhydramine in rat *liver homogenate, 1547*
—normorphine in dogs, 878
—nucleic acid, protein, anaerobic, and aerobic, *in Ehrlich ascites tumor cells, effects of eu*pahyssopin, 1232
single step—evaluated for drugs in suspension *cultures of mammalian cells, equations derived,* 606
tumor cell—effect of substituted phenylalanine esters in mice, 1726
—various substituted triazines in rats, 306
—various sulfamates in rats, 226
Metabolites, aglycone—GLC–mass spectral identification in bile of doxorubicin-treated rabbit, 1748
—chlorodesmethyldiazepam, pharmacokinetics in *dogs, 1777*
—cyclophosphamide, *in vitro* cytotoxicity analyses in rat body fluids, 1009
—*hydralazine pyruvic acid hydrazone,* GLC analysis in plasma, 1150
—8-hydroxycarteolol, high-pressure liquid chro*matographic analysis in plasma and urine,* 1623
—of merperidine, GLC analyses, human urine, *116*
—γ-oxo derivative of phenylbutazone, GLC analysis in plasma, 279
tryptophan—various indole derivatives, mass spectrometric analyses in human urine, 478
urinary—of 1-butyryl-4-cinnamylpiperazine, ion cluster–mass chromatographic analyses in mice and guinea pigs, 757
Metals—gold, atomic absorption spectrophotometric analysis in whole blood, 1332
—magnesium ions, interaction with cromolyn sodium in solution, 1403
—nickel (II), complexation with polymyxin B in *aqueous media, effect of pH and ligand con*centration, 1313
salts, divalent—effect on partitioning of tetracy*clines in aqueous–octanol system,* 1717
Methadyl acetate—GLC–mass spectrometric analysis in *urine,* 1483
Methamphetamine hydrochloride—synthesized from D-phenylalanine, 1167
Methaqualone—*metabolism, effect of diphenhydra*mine in rat liver homogenate, 1547
—one-step synthesis, diphasic titration analysis in *bulk drug and tablets,* 411
—two tablets, *in vitro* dissolution compared to *in vivo bioavailability in humans,* 1328
Methionine-enkephalin—stereochemistry compared to exogenous opiates, 590
Methotrexate—*chromatographic separation, UV,* NMR, and mass spectral analyses of impurities in various formulations, 622
—GI absorption from rat small intestine *in situ,* 560
—*thermal and photolytic decomposition in aqueous* solutions, 526
^{14}C-3-Methylamino-1,2,3,4-tetrahydrocarbazole *hydrochloride*—*distribution and excretion in rats* and dogs, 1423
***trans*-4-Methyl-7,8-dihydroxy-1,2,3,4,4a,5,6,10b-octahydrobenzo[*f*]quinoline**—hypotensive activity evaluated in dogs and spontaneous hypertensive *rats, 1639*
Methyldopa—colorimetric analysis in bulk drug and dosage forms, 779
α-Methylene-γ-lactone-containing agents—evaluated for effect on tumor growth, respiration, and nucleic acid synthesis, 1235
3-*O*-Methylglucose—transfer across everted rat small intestine, effect of preadministration of phenobar*bital, benzo[a]pyrene, and proadifen hydrochloride,* 245
Methylmercuric chloride toxicity—treatment by *various sulfur-containing steroids evaluated in mice,* 1739
Methylparaben—high-performance liquid chroma*tographic analysis simultaneously with morphine* sulfate and propylparaben in dosage form, 1510
***cis*- and *trans*-3-Methyl-4-phenyl-3-butenoic acid analogs**—synthesized, evaluated for effect on cholesterol biosynthesis in rat liver homogenates, *80*
***N*-Methyl-4-piperidinyl α-benzoyloxy-α-cyclopentylphenylacetate**—synthesized, anticholinergic *and antiperspirant activity evaluated, 701*
Metoclopramide—electron-capture GLC analysis in biological fluids, 1073
Microbiological assays—*for official antibiotic refer*ence standards, formulas for quick, simple analysis of data, 1050
Microcapsules, gelatin—method of preparation with soluble pharmaceuticals, 409
Microequilibrium constants—various aminobenzoic acids, protolytic dissociation, estimated spectrophotometrically, 334
Microionization constants, equilibrium—determined for various cephalosporins, 666
Microlenin—*isolated from Helenium microcephalum* whole plant extract, structure and stereochemistry determined, 1228
Microorganisms, *various—in antimicrobial effec*tiveness test inoculum suspensions, storage below freezing, effect of various solutions, 815
Microparticles, *polyacrylamide—containing albumin,* binding of salicylic acid, warfarin, and tryptophan compared to binding in free solution, direct and *indirect determination of constants, 107*
polyacrylamide—containing immobilized proteins,

effect on stability, 693
Microspheres—intravenous administration to dogs, physiological effects evaluated, 508
radiolabeled—tissue distribution after intravenous administration to dogs, bolus and infusion compared, 504
Miotic effect—of pilocarpine, influence of various high-viscosity vehicles in rabbits, 1280
Mixidine—absorption, effect of intraduodenal administration with various ratios of 2-naphthalenesulfonic acid as counterion, 948
—ion-pair formation in vitro determined by partitioning, absorption in rats determined by lethality, 945
Models, chemical—for structure–activity relationships based on electron donor–acceptor complexes, 1310
experimental—guinea pig for study of galactose-induced cataract formation, effect of ascorbic acid, 1478
kinetic—coagulation and coagulation–lysis, time courses after addition of thrombin or thrombin–streptokinase to plasma, 145
mathematical—kinetically based equation considers dissolution of polydisperse systems and solid dosage forms, various conditions, 1450
mathematical—law of mass action for competitive binding with independent sites and classes with equivalent sites, 908
mathematical—relating phase distribution to antimicrobial activity, chlorocresol in solubilized and emulsified systems, 1260
Models, opiate-receptor—proposed, only one receptor conformation needed for binding both agonists and antagonists, 999
pharmacokinetic—developed for uptake and distribution of pilocarpine in rabbit eye, 603
pharmacokinetic—developed to predict behavior of salicylate in cerebrospinal fluid, blood, organs, and tissues, compared to experimental data with dogs, 38
pharmacokinetic—drug removal during hemoperfusion, effect of changing intercompartment clearance rates, computer simulation, 1178
pharmacokinetic—ESTRIP computer program for calculation of initial polyexponential parameter estimates, 1687
pharmacokinetic—general treatment for derivation of equations for all linear compartmental models, 187
pharmacokinetic—two-compartment and perfusion, for various cephalosporins, 191
Molecular complexing—various quinoline and naphthalene derivatives with 9-(dicyanomethylene)-2,4,7-trinitrofluorene, mechanism of π-electron donation, 165
Molecular connectivity indexes—antimicrobial and antiviral data sets analyzed, structure–activity relationships produced, 1743
—various acetylcholine antagonists, correlated to muscarinic receptor affinity, 1408
—various aliphatic ethers, anesthetic activity and toxicity related to molecular connectivity indexes, 564
—various aliphatic hydrocarbons, ethers, and ketones, related to anesthetic activity and toxicity, 566
—various hydroxyureas, correlated with log P in octanol–water, 513
—various nitrosamines, related to mutagenic potency, 725
Molecular interaction—various prostaglandins with selected polymers, application to oral dosage form design, 971
Molecular structure—method of depicting three-dimensional illustrations sensitive to small electronic perturbations developed, electrostatic potential energy contours considered, 67
—three-dimensional illustrations of narcotic molecules calculated and plotted with computer-generated method using electrostatic energy contours, 73
Monoamine oxidase, rat liver mitochondrial—activity in vitro, effect of chloramphenicol and 2-amino-1-p-nitrophenylpropane-1,3-diol, 480
Monolayers, cholesterol—penetration by cetrimonium bromide, equilibrium surface pressure–area isotherms obtained, 1054
—dipalmitoyllecithin, equilibrium penetration by cetrimonium bromide, surface pressure–area isotherms measured, 364
phospholipid—energy of interaction with doxorubicin and substituted anthracenesulfonate at air–water interface, 773
Montmorillonite—adsorption of clindamycin and tetracycline, IR and X-ray analyses of mechanism, 1081
Morphine alkaloids—biosynthesis in *Papaver bracteatum*, radiochemical study, 103
—radiochemical TLC analysis in biological fluids, compared to GLC and liquid scintillation spectrometric analyses, pharmacokinetics in dog, 1512
—stereochemistry compared to enkephalins and endorphins, 590
sulfate—chromatographic analysis in tablets, 1099
sulfate—high-performance liquid chromatographic analysis simultaneously with parabens in dosage form, 1510
Mouthwashes—ultrasonic analysis of alcohol and soluble solids, 492
Mucolytic agents—carbocysteine, GLC analysis in plasma, 1753
Muscarinic receptor affinity—various acetylcholine antagonists, correlated to molecular connectivity indexes, 1408
Muscimole—GLC–mass spectral analysis in mushrooms, 485
Muscle relaxants, various—high-pressure liquid chromatographic analyses in mixtures with analgesics, 675
Mutagenicity—various nitrosamines, related to molecular connectivity indexes, 725
Mycobacterium tuberculosis—effect of various naturally occurring and synthetic xanthones in vitro, 721
Myocardial tissue damage—effect of various therapeutic agents, rats with induced myocardial infarctions, 1643

N

Nadolol—colorimetric analysis in tablets, 1024
—GLC–mass spectrometric analysis in serum, 653
Nalbuphine—electron-capture GLC analysis in plasma, 547
Naphazoline nitrate—spectrophotometric analysis simultaneously with antazoline hydrochloride in pharmaceutical formulations, 140
Naphthalenes—solubilization by sodium cholate in 0.15 M NaCl, 854
various—mechanism of π-electron donation in molecular complexing with 9-(dicyanomethylene)-2,4,7-trinitrofluorene, 165
Naphthoic acids and naphthylamines, substituted—absolute configurations of enantiomers assigned, 1367
2-Naphthoic acids, substituted—synthesized, evaluated for effect on cholesterol biosynthesis in rat liver homogenates, 80
Naproxen—and various salts, solubility as a function of pH, 1257
—percutaneous absorption, effect of various surfactants, in vivo and in vitro correlations in rats, 1645
—percutaneous absorption, effect of various surfactants, rabbit, rat, and human skin compared, 1272
Narcotic activity—leucine-enkephalin evaluated, mice, 136
Narcotic analgesics—etorphine, GLC–selective ion mass spectrometric analysis in urine, 260
—meperidine, TLC analyses of impurities in bulk drug and dosage forms, 958
—methadyl acetate, GLC—mass spectrometric analysis in urine, 1483
—morphine, radiochemical TLC analysis in biological fluids, compared to GLC and liquid scintillation spectrometric analyses, pharmacokinetics in dog, 1512
—morphine sulfate, chromatographic analysis in tablets, 1099
—morphine sulfate, high-performance liquid chromatographic analysis simultaneously with parabens in dosage form, 1510
—normorphine, metabolism and excretion in dogs, 878
Narcotic molecules—three-dimensional illustration of molecular structure calculated and plotted with computer-generated method using electrostatic energy contours, 73
Narcotics—cocaine and benzoylecgonine, GLC–mass spectrometric analyses in human urine, 811
—thebaine, spectrophotometric analysis in Arya II population capsules of *Papaver bracteatum*, 32
Nefopam—GLC analysis in plasma, 1720
Neuromuscular blocking effect—polymyxin and colistin in rabbits and cat and frog muscle preparations, 1275
Nickel(II)—complexation with polymyxin B in aqueous media, effect of pH and ligand concentration, 1313
Nictitating membrane, rabbit—effect on miosis induction by pilocarpine hydrochloride, 1189
Nitrofurantoin—in vitro dissolution rate, effect of formulation and process variables, 1613
—solid dispersions with polyethylene glycol 6000, coprecipitates with povidone, effect on dissolution rate, 114
—various formulations, bioavailability in humans correlated to dissolution rate in vitro, 1616
Nitroglycerin—GLC analysis in plasma, 582
—percutaneous absorption in rats, effect of application site, 1345
—pharmacokinetics after intracardial, oral, and topical administrations in rats, 584
—stability in polyethylene glycol 400 and povidone solutions, 1394
Nitrosamines, various—mutagenic potency related to molecular connectivity indexes, 725
Nitrosoureas, halogenated—kinetics and mechanism of hydrolysis, effect of pH, 1527
various—differential pulse polarographic analyses in biological samples, 1160
NMR spectroscopy—analysis, cephalexin in cephradine bulk drug and dosage forms, 1481
—identification, components in various amygdalin dosage forms, 438
^{13}C-NMR spectroscopy—various tropane alkaloids, spectra determined, carbon resonances assigned, 775
Norethandrolone—differential pulse polarographic analysis in tablets, 436
Norgestimate—disposition after oral administration alone and combined with ethinyl estradiol in humans, 1406
Normorphine—metabolism and excretion in dogs, 878
Nucleic acid synthesis, tumor—effect of various α-methylene-γ-lactone-containing agents evaluated, 1235

O

Odoratin—isolated and identified from whole plant ethanol extract of *Baileya pauciradiata*, 1633
Ointment bases—various polyethylene glycols, benzocaine diffusion through human stratum corneum, 517
Ointments—sheabutter compared to others, drug release, effect of particle size, 374
Ophthalmic cholinergics—physostigmine, effect of sodium bisulfite on molecule in solution, 742
—pilocarpine hydrochloride, effect of rabbit nictitating membrane on miosis induction, 1189
—pilocarpine, miotic effect, influence of various high-viscosity vehicles in rabbits, 1280
Opiate-receptor model—proposed, only one receptor conformation needed for binding both agonists and antagonists, 999
Opiates—stereochemistry compared to enkephalins and endorphins, 590
Organotin compounds—various N-aryl-S-(triphenylstannyl)isothiocarbamates synthesized, evaluated for antibacterial and antifungal activity, 576

Ornithine decarboxylase activity—effect of (±)-2,5-diamino-2-(cyanomethyl)pentanoic acid, 1174
Oscillatory measurements—compared to steady shear rate method, carboxymethylcellulose, effect of concentration and viscosity grade, 1499
Osmolality—converted to osmolarity using partial molal volume of solute at infinite dilution, 384
Osmolarity—converted from osmolality using partial molal volume of solute at infinite dilution, 384
Oxadiazoles, various—synthesized, evaluated for effect on enzyme activity in rat brain homogenates, anticonvulsant activity in mice, and antiproteolytic activity in vitro, 987
Oxadiazole-2-thiones, substituted—synthesized, evaluated for anticonvulsant activity in mice, effect on NAD-dependent and independent oxidations and antiproteolytic activity in vitro, 1507
Oxamates, various heterocyclic—synthesized, evaluated as antiallergy agents, 735
Oxazepam acetate—hydrolysis in vivo and in vitro, stereospecificity of esterases determined, 1208
Oxazepam—fluorescence-TLC densitometric analysis in serum, 1413
Oxfendazole—radioimmunoassay in plasma or serum, 1553
Oxidation—cyclobarbital, products isolated and identified, 1019
—epinephrine in alkaline solutions, effect of sodium metabisulfite and cysteine, 1474
—kinetics and mechanism, promazine and promethazine by ferric perchlorate, various temperatures and pH values, 168
—promethazine, thermal degradation kinetics in acidic medium, effect of anaerobic and aerobic conditions, pH, metal ions, and antioxidants, 1133
—promethazine, thermal degradation products isolated and identified, 1128
—various polysorbates on storage, effect of light, temperature, and copper sulfate, 1676
Oxidations, NAD dependent and independent—effect of various substituted trimethoxybenzamides in rat brain homogenates, 1682
NAD dependent and independent—various substituted oxadiazole-2-thiones evaluated in rat brain homogenate, 1507
Oxidative degradation—pyrogallol in aqueous systems, effect of dissolved oxygen levels, 1338
Oximes—various 1-phenyl-1-nonen-3-one derivatives synthesized, 1536
γ-Oxo metabolite of phenylbutazone—GLC analysis in plasma, 279

P

Panax ginseng and *P. quinquefolium*—panaxoside content of various commercial products, TLC analysis, 1487
Panaxoside content—ginseng, various commercial products, TLC analysis, 1487
Papaver bracteatum—Arya II population capsules, spectrophotometric analysis of thebaine, 32
—biosynthesis of morphine alkaloids, radiochemical study, 103
Papaverine hydrochloride—dissolution, three commercial sustained-release products, three different apparatuses compared, 496
Paper, various grades—effect on performance of antibiotic susceptibility disks, 367
Parabens, various—solubility in water at four temperatures, thermodynamic parameters related to number of carbon atoms, 624
Parachlorophenol—high-pressure liquid chromatographic analysis in pharmaceutical formulations of camphorated parachlorophenol, 266
Parenterals, large volume—six types, size distribution of particulate matter, automatic particle counter and microscopic techniques compared, 340
small volume—particle content determinations, USP membrane filtration—microscopic and instrumental methods compared, 50
Paromomycin—effect on R-factor transfer of tetracycline resistance from *Escherichia coli* to *Salmonella pullorum*, 35
Particle content determinations—small-volume parenterals, USP membrane filtration—microscopic and instrumental methods compared, 50
Particle size—effect on dissolution rate of compressed disks of salicylic acid, aspirin, and equimolar mixture, 535
—effect on drug release from sheabutter ointment, compared to other ointments, 374
—^{99m}Tc-pentetic acid liposomes, effect on organ distribution in mice, 795
Particle-size fractions—suspensions separated by centrifugal elutriation, 673
Particles—size distribution in six large-volume parenteral solutions, automatic particle counter and microscopic techniques compared, 340
Particulate beds, dynamic—electronic monitoring of mechanical events, conductance and capacitance characteristics evaluated, 1121
Partition coefficients, aqueous-octanol—ampicillin, effect of various ion-pair or adduct forming additives, 138
octanol-water—related to permeability of various steroids across excised rabbit corneas, 786
—relationship to forward and reverse rate constants and number of CH_2 groups in a homologous series, 262
—various alkylamine antihistamines, effect on GI absorption, rats, 1041
—various compounds, high-pressure liquid chromatographic determination, 1364
Partitioning—tetracyclines in aqueous-octanol system, kinetics and thermodynamics, effect of divalent metal salts, 1717
—tetracyclines in aqueous-octanol system, kinetics and thermodynamics, effect of hydroxyl group, 1715
Pattern recognition system—based on structural descriptors, applied to prediction of duration of depressant effects of various barbiturates, 745
Paucin—isolated and identified from whole plant ethanol extract of *Baileya pauciradiata*, 1633
Pemoline—GLC analysis in biological fluids, 419
Penetration—hydrocortisone through mouse skin, effect of formulation factors, 789
Penicillamine—demonstrated as product of benzylpenicillenic acid degradation in neutral media, differential pulse polarographic study, 302
Penicillin V benzathine—iodometric analysis, interference by benzathine molecule, 1495
Penicillins, various amino—stability, solubility, and dissolution rates, effect of pH, 1059
Penicilloic acids, various—synthesized, immunological cross-reactions evaluated in vitro, 1197
Pentaerythritol tetranitrate—colorimetric analysis in dosage forms, NF method modified, 717
Pentanoic acid, substituted—synthesized, effect on ornithine decarboxylase activity evaluated, 1174
^{99m}Tc-Pentetic acid liposomes—organ distribution in mice, effect of particle size, 795
Pentobarbital—absorption rates and bioavailability from capsules and suppositories in humans, 1586
Pepsin—effect on adsorption of typical drugs to activated charcoal in vitro, 1181
Perfluorooctyl bromide—tissue distribution in dogs after oral and intratracheal administration, 1038
Permeation, cutaneous—scopolamine, mathematical model for pharmacokinetics in human skin, 1370
Permeability—interstitial space of rat diaphragm muscle to solutes of different molecular weights, 696
—of various steroids across excised rabbit corneas, related to octanol-water partition coefficients, 786
Pharmaceutical formulations—presence of contaminants, various origins, prevention methods, and detection procedures, review, 1
Pharmacokinetic models—developed to predict behavior of salicylate in cerebrospinal fluid, blood, organs, and tissues, compared to experimental data with dogs, 38
—drug removal during hemoperfusion, effect of changing intercompartment clearance rates, computer simulation, 1178
—ESTRIP computer program for calculation of initial polyexponential parameter estimates, 1687
Pharmacokinetics—*AUC* determined by constant blood withdrawal and intermittent sampling methods compared, sodium salicylate and aspirin in dogs, 875
—cephradine and cephalexin compared, capsules and tablets in humans, 1447
—chlorodesmethyldiazepam in dogs, 1777
—clonazepam in rhesus monkeys, 295
—cutaneous permeation of scopolamine, mathematical model for human skin, 1370
—deconvolution point-area and area-area methods for determining in vivo input functions compared, 663
—ditazole in rats, GLC analysis, 705
—erythromycin after intravenous administration in humans, 1057
—ethosuximide parameters during single or divided daily doses compared using MULTDOS and 1969 or 1974 NONLIN computer program, 574
—general treatment for derivation of equations for all linear compartmental models, 187
—iodoxamic acid in rhesus monkeys, 930
—morphine in dog, radiochemical TLC, GLC, and liquid scintillation spectrometric analyses compared, 1512
—nitroglycerin after intracardial, oral, and topical administrations in rats, 584
—podophyllotoxin derivative and metabolite in humans, 1106
—preliminary model of uptake and distribution of pilocarpine in rabbit eye, 603
—quinidine, three dosage forms compared, humans, 1456
—rapid estimation of total body drug clearance during constant-rate intravenous infusion, equation derived, 1776
—successively higher plasma levels at steady state obtained using two-step infusion method, simulated data for hypothetical drug, 1651
—theoretical analysis to differentiate gut wall elimination and hepatic removal, relationship between area under the curve and administration route, 703
—thiamine in rats, 818
—total clearance of dicumarol in rats, frequency distribution, 337
—warfarin and dicumarol, in vivo binding in rat liver, implications for modeling, 229
—(*R*)-(+)- and (*S*)-(−)-warfarin compared, humans, 867
Phase diagram—constructed for aspirin-acetaminophen-urea ternary system solid dispersion, 1109
Phase solubility—analysis of complexation of dinoprostone with β-cyclodextrin, 1665
Phencyclidine analogs—*N*-ethyl-1-phenylcyclohexylamine identified in street sample by NMR, IR, and mass spectral data, 885
Phenobarbital—effect of preadministration on transfer of 3-*O*-methylglucose across everted rat small intestine, 245
—interaction with griseofulvin, effect of different dosage forms in rats, 466
Phenol—GLC analysis simultaneously with other active ingredients in commercial preparations, 1627
Phenolsulfonphthalein—urinary excretion from rats, validity of oral bioavailability estimates, 267
Phenothiazine derivatives—thiazinamium, tissue distribution and biliary excretion in rats, 1147
Phenothiazines—promazine and promethazine, kinetics and mechanism of oxidation by ferric perchlorate, various temperatures and pH values, 168
—promethazine, oxidative thermal degradation products isolated and identified, 1128
—promethazine, polarographic analysis, various degradation products, spectrophotometric analyses, prepared samples, 1131
—promethazine, thermal degradation kinetics in acidic medium, effect of anaerobic and aerobic conditions, pH, metal ions, and antioxidants, 1133
various—synthesized, CNS antitumor and cytotoxic activity evaluated, 157
Phenylalanine esters, substituted—effect on tumor

cell metabolism in mice, 1726
D-Phenylalanine—starting material for synthesis of *dextroamphetamine sulfate and methamphetamine* hydrochloride, 1167
Phenylbutazone—GLC analysis in human plasma, 243
γ-oxo metabolite—GLC analysis in plasma, 279
—*various solid oral formulations, stability, effect* of temperature and humidity, 646
Phenylephrine hydrochloride—high-pressure liquid *chromatographic analysis in dosage forms,* 873
—paired ion high-pressure liquid chromatographic *analysis in prepared solutions and dosage forms,* 1247
2-Phenylethylamines, *substituted*—synthesized, evaluated for antispasmodic and cardiovascular activity, 991
Phenylhydrazines, *various—reaction with blue tet*razolium, kinetics and mechanism, 927
1-Phenyl-1-nonen-3-one derivatives- -synthesized, *evaluated for antineoplastic and antimicrobial* activities, 1543
various—synthesized, 1536
1-Phenyl-1-penten-3-one derivatives—effect on enzyme activity in rat liver mitochondria, various substrates, 1539
Phenylpropanolamine—fluorometric analysis in dosage forms, 1635
—*GLC analysis in presence of chlorpheniramine,* human urine, 118
Phenylpropanolamine hydrochloride—high-pressure *liquid chromatographic analysis in dosage forms,* 873
2-Phenyl-5-triphenylmethylthiazole—synthesized *by homolytic arylation of thiazole with* phenylazotriphenylmethane, 1432
Phenytoin—high-pressure liquid chromatographic analysis in plasma, 1462
Phenytoin-induced teratogenesis—effect of various cobalt-containing agents in mice, 377
pH measurements—used to determine dissociation constants for polyprotic, amphoteric compounds, 12
Phospholipid monolayers—energy of interaction with doxorubicin and substituted anthracenesulfonate *at air–water interface,* 773
Photolysis—aprindine hydrochloride, products identified by GLC and GLC–mass *spectrometry,* 722
Photolytic decomposition—methotrexate in aqueous solutions, 526
Photolytic degradation—*sulfisomidine tablets, effect* of film coating containing UV absorber, 196
Photooxidation, flavin catalyzed—substituted acridan, mechanism studied, 318
Phototherapy—effect on kinetics of bilirubin formation, *distribution, and elimination, rats, 205*
pH-partition hypothesis—propicillin, GI absorption, rats, 1705
pH-stat method—used to establish sink conditions for *in vitro* automated potentiometric study of dissolution kinetics of acidic drugs, 1163
Phthalimidines, substituted—synthesized, evaluated for antifungal activity, 863
Physicochemical properties—solutions, osmolality converted to osmolarity using partial molal volume of solute at infinite dilution, 384
Physiological effects—intravenous administration of microspheres to dogs, 508
Physostigmine—*effect of sodium bisulfite on mole*cule in solution, 742
Phytonadione — TLC - spectrophotodensitometric analysis in elemental diet formulations, 834
Pigments—bilirubin, intrinsic body clearance, frequency distribution, rats, 45
Pilocarpine—miotic effect, influence of various high-viscosity vehicles in rabbits, 1280
—uptake and distribution in rabbit eye, preliminary pharmacokinetic model, 603
Pilocarpine hydrochloride—miosis induction, effect of rabbit nictitating membrane, 1189
Piperazines, substituted—synthesized, antibacterial and antifungal activity evaluated, 900
pKa values—polyprotic, amphoteric compounds, determined using solubility and pH measurements, 12
Plasma concentration–time curves—*AUC* determined by constant blood withdrawal and intermittent sampling methods compared, sodium salicylate and aspirin in dogs, 875
Plasma drug levels—various tricyclic antidepressants, intrapatient variability at steady state, 554
Plasma levels—propranolol after administration of *hemisuccinate in dogs,* 1360
—successively higher at steady state, obtained using two-step infusion method, simulated data *for hypothetical drug,* 1651
Platelet aggregation, human—effect of various indolecarbohydrazides *in ethylene glycol in vitro,* 1025
inhibitors—ditazole, GLC analysis, pharmacokinetic *study of blood and tissue distribution in rats,* 705
PMR—analysis of complexation of dinoprostone with *β-cyclodextrin,* 1665
Podophyllotoxin derivative and metabolite—pharmacokinetics in humans, 1106
Polarography—analysis, chlordiazepoxide, effect of amitriptyline on commercial products and synthetic mixtures, 1297
—analysis, hydroxylaminoeverninomicin D, bulk drug, 719
—*analysis of cephalexin in dosage forms,* 1466
—analysis, promethazine, prepared samples, 1131
differential pulse—analyses, carmustine and various nitrosoureas in biological samples, 1160
differential pulse—analyses, clorazepate *monopotassium and dipotassium in pharmaceutical* preparations, 1723
differential pulse—analysis, flucytosine in dosage forms, 1641
noninvasive—applied to drug dissolution and content uniformity assessment of various capsules and tablets, 842
Polyacrylamide microparticles—containing immobilized proteins, *effect on stability,* 693
Polyamines, various acetyl—high-pressure liquid chromatographic analyses in urine of normal humans and cancer patients, 1671
Polyethylene glycol 400—effect on pulmonary dynamics in perfused isolated guinea pig lung, 1002
—nitroglycerin solutions, stability, 1394
Polyethylene glycol 6000—*solid dispersions with* nitrofurantoin, ethotoin, and coumarin, effect on dissolution rates, 114
Polymer-bound anhydrides—*used in synthesis of* cefaloram by *N*-acylation of *tert*-butyl 7-aminocephalosporanate, 110
Polymer membranes—permeabilities, diffusion coefficients, and partition coefficients for pro*gesterone permeation through various hydrogels,* potential for use as controlled-release drug delivery devices, 1352
various—permeabilities to progesterone, effect of soaking in plasma, potential for use in controlled-release drug delivery devices, 1347
Polymers—polyvinylpyrrolidone–vinyl acetate copolymer, adsorption from solution studied by *surface pressure measurement, films compared* to spread monolayers, 1464
—povidone and cross-linked polyvinylpyrrolidone, molecular interaction with various prostaglandins, application to oral dosage form design, 971
—povidone, effect on tripelennamine hydrochloride release from inert wax matrix tablets, 357
Polymethoxyxanthones, various—selective demethylation with aqueous piperidine, 1321
Polymyxin—neuromuscular blocking effect in rabbits and cat and frog muscle preparations, 1275
Polymyxin B—complexation with nickel (II) in aqueous media, effect of pH and ligand concentration, 1313
Polysorbates, various—autoxidation on storage, effect of light, temperature, and copper sulfate, 1676
Polyvinylpyrrolidone copolymer—adsorption from solution studied by surface pressure measurement, films compared to spread monolayers, 1464
—effect on dissolution and GI absorption of ellipticine, 611
Potentiometry, automated—study of *in vitro* dissolution kinetics of acidic drugs, pH-stat method used to establish sink conditions, 1163
—determination of ionization constants in mixed aqueous solvents of various composition, 127
Povidone—coprecipitates with nitrofurantoin, ethotoin, and coumarin, effect on dissolution rates, 114
—effect on tripelennamine hydrochloride release from inert wax matrix tablets, 357
—*nitroglycerin solutions, stability,* 1394
Povidone-iodine—resistance by various microorganisms *in vitro,* 1629
Powders, nonspherical—dissolution profiles, effect of particle shape, equations derived, 1674
Prazosin—*high-performance liquid chromato*graphic–fluorescence analysis in plasma, 1468
Prednisolone—absorption from perfused rat intestine, *effects of fatty acids,* 1211
—differential pulse polarographic analysis in tablets, 436
—GLC–mass spectrometric analysis in human plasma, 923
Prednisone—*differential pulse polarographic analysis* in tablets, 436
—sugar solid dispersions in tablets, dissolution *rates and stability,* 979
Preservatives—various parabens, solubility in water at four temperatures, thermodynamic parameters *related to number of carbon atoms,* 624
Proadifen hydrochloride—effect of preadministration *on transfer of 3-O-methylglucose across everted* rat small intestine, 245
Probenecid—spectrophotofluorometric analysis in *biological fluids,* 434
Probiotics, various—ω-amino acids and derivatives, reversed-phase TLC for correlation between *structure and biological response, various fatty* acids and derivatives evaluated as stationary phases, 713
Procainamide—electron-capture GLC *analysis in* human serum, 371
—high-performance liquid chromatographic analysis simultaneously with *N*-acetylprocainamide in plasma, 839
—high-pressure liquid chromatographic analysis simultaneously with *N*-acetylprocainamide in plasma, 869
Procarbazine hydrochloride *degradation prod*ucts—high-pressure liquid chromatographic analysis in pharmaceutical formulations, 424
Prodrugs—7-acetylacroninium perchlorate, two-component spectrophotometric analysis with *acronine in parenteral solutions,* 237
—dihydropyridine derivative or quaternary pyridinium salt, elimination rate from brain, mice, 685
—*ditheophylline succinate, theophylline transfer* rate across everted rat intestinal sacs, 1459
—of acetaminophen, synthesis, hydrolysis rate, and bioavailability studied, dogs, 545
potential—propranolol hemisuccinate, plasma levels in dogs, 1360
potential—7,7'-succinylditheophylline synthesized, evaluated, 1045
Progesterone—permeabilities, diffusion coefficients, and partition coefficients for permeation through various hydrogels, 1352
—permeability through various polymer membranes, effect of soaking in plasma, 1347
Progestins—ethindrone and norethindrone, *in vitro* adsorption by magnesium trisilicate, 287
—norgestimate, disposition after oral administration alone and combined with ethinyl estradiol in humans, 1406
—progesterone, permeabilities, diffusion coefficients, and partition coefficients for permeation through various hydrogels, 1352
Promazine—kinetics and mechanism of oxidation by ferric perchlorate, various temperatures and pH values, 168
Promethazine—kinetics and mechanism of oxidation by ferric perchlorate, various temperatures and pH values, 168
—oxidative thermal degradation products isolated and identified, 1128

—polarographic analysis, prepared samples, 1131
—thermal degradation kinetics in acidic medium, effect of anaerobic and aerobic conditions, pH, metal ions, and antioxidants, 1133
2-Propanol—GLC analysis in amygdalin dosage forms, 1190
Propicillin—GI absorption, deviation from pH–partition hypothesis, rats, 1705
Propranolol—β-adrenoceptor blocking activity compared in dogs and rats, oral and intravenous dosage, 132
—and major metabolites, fluorometric TLC analyses in human plasma and urine, 826
—plasma levels after administration of hemisuccinate in dogs, 1360
—TLC analysis in plasma, 1307
Propylene glycol—effect of addition on differential UV analysis of various 3-one-4-ene steroids, 275
Propylparaben—high-performance liquid chromatographic analysis simultaneously with morphine sulfate and methylparaben in dosage form, 1510
Prostaglandins—dinoprostone, complexation with β-cyclodextrin, phase solubility and PMR analyses, 1665
various—effect on human platelet aggregation with and without adenosine diphosphate, kinetic study, 939
various—molecular interaction with selected polymers, application to oral dosage form design, 971
Protein binding—ibuprofen in humans, time course studied using electron-capture GLC analysis in serum, 627
—salicylic acid, warfarin, and tryptophan to albumin in free solution and in microparticles, direct and indirect determination of constants, 107
Proteins—immobilized in polyacrylamide microparticles, effect on stability, 693
Protolytic dissociation—various aminobenzoic acids, microequilibrium constants estimated spectrophotometrically, 334
Pseudoephedrine—high-pressure liquid chromatographic analysis, simultaneously with chlorpheniramine, in dosage forms, 1668
Psychoactive agents—camazepam, blood and brain distribution in rats and mice, 1470
Psychotherapeutic agents, potential—3-methylamino-1,2,3,4-tetrahydrocarbazole hydrochloride, ^{14}C-labeled, distribution and excretion in rats and dogs, 1423
Pulmonary dynamics—effect of polyethylene glycol 400 in perfused isolated guinea pig lung, 1002
Pupillometry—used to evaluate effect of diazepam on recall ability in humans, 956
Purine ribonucleosides, substituted—synthesized, evaluated for cytotoxic activity *in vitro*, 569
Pyrazolidines, various substituted—synthesized, evaluated for anticonvulsant activity in mice, 1471
Pyridinemethanol, substituted—prototropic species characterizied from electronic absorption and fluorescence spectra at various pH values and in *n*-hexane, 1224
Pyridinium salt, substituted quaternary—and prodrug, elimination rate from brain, mice, 685
Pyrogallol—oxidative degradation in aqueous systems, effect of dissolved oxygen levels, 1338

Q

Quaternary ammonium salts—*N,N*-dimethyl derivative of propranolol, ion-pair partitioning, functional group contribution of bile salt molecules, 847
Quinacrine—protolytic dissociation, spectrophotometric evaluation, 1770
Quinazolinylformamidines, substituted—synthesized, evaluated for antihypertensive activity in rats, 1479
Quindoline—isolated from ethanol extract of roots of *Cryptolepis sanguinolenta*, 433
Quinidine—crystal and molecular structure, X-ray diffraction determination, 1698
—high-pressure liquid chromatographic analysis in plasma, 269
—pharmacokinetics and bioavailability of three dosage forms compared, humans, 1456
—various cardiac effects on isolated heart and *in vivo* in dogs, compared to dihydroquinidine, 1355
Quinidine sulfate—four commercial tablets, dissolution profiles determined and related to disintegration and absorption, 568
Quinolines, various—mechanism of π-electron donation in molecular complexing with 9-(dicyanomethylene)-2,4,7-trinitrofluorene, 165
Quinolizines, substituted phenylimino—synthesized, evaluated for antiulcerogenic activity, 1183
Quinone derivatives, acetylglycosyl—synthesized, evaluated for antitumor activity in mice, 562

R

Radiochemical GLC—analysis, ethinyl estradiol in human urine, 1138
Radiochemical TLC—analysis, morphine in biological fluids, compared to GLC and liquid scintillation spectrometric analyses, 1512
Radiochemistry—analysis, thiamine in blood, compared to fluorometric analysis, 818
—study of biosynthesis of morphine alkaloids in *Papaver bracteatum*, 103
Radioimmunoassay—danazol in human and monkey plasma, 1425
—oxfendazole in plasma or serum, 1553
Radiolabeled liposomes—^{99m}Tc-pentetic acid, organ distribution in mice, effect of particle size, 795
Radiolabeled microspheres—tissue distribution after intravenous administration to dogs, bolus and infusion compared, 504
Radiopaque media—iodoxamic acid, biliary excretion, plasma protein binding, and enterohepatic circulation in rhesus monkeys, 930
—various iodinated aromatic compounds, toxicity in mice, structure–activity relationships, 1154
Radiopharmaceuticals, potential—^{99m}Tc-complexes of various substituted iminodiacetic acids prepared, 1434
Relaxant activity, muscle—alkaloids isolated from stem bark of *Strychnos dolichothyrsa* evaluated, 171
Relaxants, skeletal muscle—dantrolene, binding to human serum albumin, fluorescence quenching study, mechanism evaluated, 1042
smooth muscle—papaverine hydrochloride, dissolution, three commercial sustained-release products, three different apparatuses compared, 496
smooth muscle—theophylline, bioavailability of commercial elixir and two tablets compared, chronic dosing in humans, 916
smooth muscle—theophylline, transfer rate across everted rat intestinal sacs, 1459
smooth muscle—theophylline, various 7-acyl- and 7,7′-acylditheophylline derivatives synthesized, evaluated as prodrugs, 1045
Release rates—benzoate anions from ion-exchange resin beads, effect of coating with various waxes, 500
Renal clearance—perturbation method evaluated using literature data assuring a fraction absorbed of unity, 591
Reserpine—high-performance liquid chromatographic analysis, simultaneously with hydrochlorothiazide, in tablets, 650
Resin beads, ion exchange—coated with various waxes, effect on release of benzoate anions, 500
Resistance—various microorganisms to chlorhexidine gluconate and povidone-iodine *in vitro*, 1629
Respiratory system, simulated—developed for *in vitro* evaluation of inhalation delivery systems, 1428
Review articles
Contamination of Pharmaceutical Products, 1
Stability of Pharmaceuticals, 443
Rigidity—gelatin solution and gel mass, thermal degradation, applied to processing predictions, 218

S

Saccharin—absorption from urinary bladder, rats, 1493
Salicylamide—dissolution rates in water and caffeine solutions, estimated using theoretical diffusion model, compared to experimental results, 95
—effect on metabolism of dextromethorphan hydrobromide in rats, 761
Salicylate—GI absorption, effect of ascorbate, rat intestine *in vivo* and *in vitro*, 224
—pharmacokinetic model developed to predict behavior in cerebrospinal fluid, blood, organs, and tissues, compared to experimental data with dogs, 38
Salicylic acid—binding to bovine serum albumin, affinity chromatographic study, 1005
—colorimetric analysis in human plasma, 289
—compressed disks alone and equimolar mixture with aspirin, dissolution rate, effects of compression force, particle size, and lubricants, 535
—high-pressure liquid chromatographic analysis in plasma simultaneously with aspirin and salicyluric acid, 710
—liquid chromatographic analysis in multicomponent tablets, 1066
—percutaneous absorption, effect of repeated application, rats, 1685
Salicyluric acid—high-pressure liquid chromatographic analysis in plasma simultaneously with aspirin and salicylic acid, 710
Saponins—solasodine glycosides, formation of solasodiene on hydrolysis with hydrochloric acid under various conditions, 1169
Scatchard plots—constructed from ligand–erythrocyte interaction data, use of binding capacities evaluated, 1344
—with positive slopes, various drugs, effect of albumin concentration, 1193
Scopolamine—cutaneous permeation, mathematical model for pharmacokinetics in human skin, 1370
Sedative–hypnotics—triclofos sodium, hydrolysis kinetics, effect of pH, temperature, and ionic strength, 631
Sedatives—chlordiazepoxide and desmethyl metabolite, derivation and GLC analyses, bulk drug, 1176
—chlordiazepoxide and metabolites, fluorescence TLC–densitometric analysis in serum, 639
—dexclamol hydrochloride, solubility, effect of enantiomeric purity, 636
—diazepam, effect on recall ability evaluated by pupillometry in humans, 956
—diazepam, fluorescence–TLC densitometric analysis in serum, 1413
—diazepam, plasma protein binding, effect of sodium oleate in rats, 891
—diazepam, spectrophotometric analysis in dosage forms, official method adapted to correct for potential interference by hydrolysis product, 550
—glutethimide, GLC analysis in commercial dosage forms, 950
—meprobamate, bioavailability of 11 commercial products in humans, 1290
1,2,3-Selenadiazoles, various substituted—synthesized, antibacterial and antifungal activities evaluated, 1336
Self-association—various dihydroxy bile salts in aqueous electrolyte solutions, turbidimetric study, 994
Sheabutter ointment—drug release compared to other ointments, effect of particle size, 374
Shelflife—pharmaceutical preparations, criticism of previously reported method of prediction by relating to plot of log $t_{0.9}$ and reciprocal of absolute temperature, 141
Silver—coordinating properties with various sulfonamides, structures of complexes studied, 284
Silver sulfonamides, various—aqueous solubility, effect of pH, 1012
Sincalide—lyophilization, optimum cycle developed, vial headspace relative humidity correlated with product stability, 1239
Size distribution—particulate matter in six large-

volume parenteral solutions, automatic particle counter and microscopic techniques compared, 340
Sodium bisulfite—effect on physostigmine molecule in solution, 742
Sodium cholate—pattern of association in aqueous electrolyte solutions, light-scattering study, 174
—solubilization of naphthalene and self-association in 0.15 *M* NaCl, 854
Sodium glycocholate—pattern of association in aqueous electrolyte solutions, light-scattering study, 174
Sodium hydroxymethanesulfonate—kinetics of reaction with various substituted anilines, equilibrium and hydrolysis rate constants calculated, 1283
Sodium metabisulfite—effect on oxidation of epinephrine in alkaline solutions, 1474
Sodium nitroferricyanide (nitroprusside)—prepared solutions, chromatographic separation and spectrophotometric analyses of free ferricyanide and ferrocyanide, 1752
Sodium oleate—effect on plasma protein binding of diazepam in rats, 891
Sodium taurocholate—pattern of association in aqueous electrolyte solutions, light-scattering study, 174
Solasodiene—formation from solasodine on hydrolysis with hydrochloric acid under various conditions, 1169
Solasodine—formation of solasodiene on hydrolysis with hydrochloric acid under various conditions, 1169
Solid dispersions—aspirin–acetaminophen–urea ternary system, dissolution rates, 1112
—aspirin–acetaminophen–urea ternary system, phase diagram constructed, physical properties evaluated, 1109
—aspirin in binary systems with urea or povidone, effect of temperature and humidity, 1631
—nitrofurantoin, ethotoin, and coumarin with polyethylene glycol 6000, effect on dissolution rate, 114
systems—various barbiturates evaluated, 1606
Solid–liquid interactions—microcrystalline cellulose–water system characterized, immersional calorimetry–vapor adsorption procedure, 1599
Solid phase syntheses—cefaloram, *N*-acylation of *tert*-butyl 7-aminocephalosporanate using polystyrene-bound anhydrides, 110
Solids—dynamic particulate beds, electronic monitoring of mechanical events, conductance and capacitance characteristics evaluated, 1121
soluble—ultrasonic analysis in pharmaceutical formulations, 492
Solid-state dispersions—various drug–urethan systems, dissolution rates compared to pure drug substances and physical mixtures, 391
Solubility, aqueous—various silver sulfonamides, effect of pH, 1012
—calcium oxalate in various 1-alkanols and ethanol–water mixtures, 733
—dexclamol hydrochloride, effect of enantiomeric purity, 636
measurements—used to determine dissociation constants for polyprotic, amphoteric compounds, 12
—naproxen, two xanthonecarboxylic acids, and various salts, as a function of pH, 1257
—various amino penicillins, effect of pH, 1059
—various classes of compounds, related to carminative activity, 277
—various parabens in water at four temperatures, thermodynamic parameters related to number of carbon atoms, 624
Solubilization—of naphthalene by sodium cholate in 0.15 *M* NaCl, 854
simultaneous—various steroid hormones in aqueous surfactants, 1419
Solvent deposition method—enhancement of dissolution rate, effect of drug-to-excipient ratio, 134
Spartina cynosuroides—tricin isolated from aerial parts, ^{13}C-NMR spectral analysis, 1325
Spasmolytic agents—3-dimethylaminomethylkhellin and khellin, spectrophotometric analyses in bulk drug and dosage forms, various methods compared, 618
Spectrofluorometry—analyses, substituted imidazolidinones in biological fluids, 752
—analysis, probenecid in biological fluids, 434
—analysis, 3′,4′,7-tris[*O*-(β-hydroxyethyl)]rutoside in urine, 1142
Spectrophotometry—analyses, antazoline hydrochloride and naphazoline nitrate, simultaneously in pharmaceutical formulations, 140
—analyses, betamethasone and various esters in pharmaceutical products, 360
—analyses, 3-dimethylaminomethylkhellin and khellin in bulk drug and dosage forms, various methods compared, 618
—analyses, theophylline and hydroxyethyl derivative in pharmaceutical syrup, 572
—analyses using blue tetrazolium reaction, various corticosteroids in pharmaceutical preparations, 792
—analyses, various degradation products of promethazine, prepared samples, 1131
—analysis, acetaminophen in plasma, 581
—analysis, antazoline in prepared solutions and dosage forms, 1610
—analysis, diazepam in dosage forms, official method adapted to correct for potential interference by hydrolysis product, 550
—analysis, isoniazid in presence of its hydrazones in prepared mixtures and commercial tablets, 661
—analysis, menadione, blue-colored product of reaction with 2,4-dinitrophenylhydrazine identified, 258
—analysis, thebaine in Arya II population capsules of *Papaver bracteatum*, 32
difference—analysis, *p*-hydroxybenzoic acid in presence of alkyl esters, 837
differential—simultaneous analysis of tyrosine and tryptophan in solutions, 729
—estimation, microequilibrium constants of protolytic dissociation of various aminobenzoic acids, 334
—evaluation, protolytic dissociation of chloroquine and quinacrine, 1770
—two-component analysis, acronine and 7-acetylacroninium perchlorate in parenteral solutions, 237
—use of vidicon spectrometer in simultaneous determination of multicomponent drug formulations without prior separation, 822
Spectroscopy—direct and difference methods of determining binding constants for daunorubicin and doxorubicin to DNA, 688
Spirofluorenes, various—synthesized, evaluated for antiallergic activity, 953
Spironolactone—high-pressure liquid chromatographic and colorimetric analyses in tablets, 889
Stability—aspirin in solid dispersion binary systems with urea or povidone, effect of temperature and humidity, 1631
—digoxin at gastric pH, colorimetric analysis, 1358
—digoxin in aqueous solution, kinetic study of hydrolysis, effect of pH, 327
—dosage form prepared by impregnating synthetic (—)-Δ^9-tetrahydrocannabinol on placebo *Cannabis* plant material, 876
—etazolate hydrochloride in aqueous solutions, PMR and mass spectral studies, 850
—furosemide in aqueous solutions and dosage forms, high-pressure liquid chromatographic analysis, 808
—hydrocortisone and prednisone sugar solid dispersions in tablets, 979
—hydrocortisone in various types of vehicles, effect of other active ingredients, 299
—β-lactam antibiotics, correlated with crystallinity determined by solution calorimetry, 767
—mercaptopurine, hydrate and anhydrate forms, various thermal conditions, 488
—methotrexate in aqueous solutions, 526
—nitroglycerin in polyethylene glycol 400 and povidone solutions, 1394
—pharmaceutical formulations, degradation mechanisms, rates, and pathways, evaluation methods, regulatory considerations, review, 443
—pharmaceutical preparations, criticism of previously reported method relating plot of log $t_{0.9}$ and reciprocal of absolute temperature to shelflife, 141
—phenylbutazone, various solid oral formulations, effect of temperature and humidity, 646
—proteins immobilized in polyacrylamide microparticles, 693
—sincalide, lyophilized, correlated with headspace vial relative humidity, 1239
—solasodine, formation of solasodiene on hydrolysis with hydrochloric acid under various conditions, 1169
—various amino penicillins, effect of pH, 1059
—various fenoprofen salts evaluated as oral dosage forms, 231
—various polysorbates, autoxidation on storage, effect of light, temperature and copper sulfate, 1676
Steady shear rate measurements—compared to oscillatory method, carboxymethylcellulose, effect of concentration and viscosity grade, 1499
Stereochemistry—at C-5 of 17α-ethylestran-17β-ol, impurity in ethylestrenol, 1187
—enkephalins and endorphins compared to endogenous opiates, 590
—substituted naphthoic acids and naphthylamines, absolute configurations assigned, 1367
Stereospecificity—esterases hydrolyzing oxazepam acetate *in vivo* and *in vitro*, 1208
Steroid hormones, various—simultaneous solubilization in aqueous surfactants, 1419
Steroid phosphates, various—high-pressure liquid chromatographic analysis in dosage forms, 913
Steroids—fluoxymesterone, norethandrolone, prednisolone, and prednisone, differential pulse polarographic analyses in tablets, 436
lipophilic—substituted androstane, bioavailability from solutions and suspensions in rats and humans, 1287
3-one-4-ene—effect of added propylene glycol on differential UV analysis, 275
sulfur containing—synthesized, evaluated in treatment of methylmercuric chloride toxicity in mice, 1739
various—permeability across excised rabbit corneas related to octanol–water partition coefficients, 786
various diaza—synthesized, antitumor activity evaluated, 283
Sterols—cholesterol, monolayers penetrated by cetrimonium bromide, equilibrium surface pressure–area isotherms obtained, 1054
various—GLC analyses in biological fluids and extracts, 1157
Stimulants, central—caffeine, GLC analysis in plasma, 1093
—dextroamphetamine sulfate and methamphetamine hydrochloride, synthesized from D-phenylalanine, 1167
—pemoline, GLC analysis in biological fluids, 419
Streptozocin—high-pressure liquid chromatographic analysis and separation of anomers in a commercial dosage form, 1300
Structural analysis, IR and X-ray—various carbonate-containing antacids, compared to naturally occurring carbonate minerals, 324
Structure–activity relationships—alkaloids isolated from various *Tabernaemontana* species or synthesized, cytotoxicity evaluated, 272
—antimicrobial and antiviral data sets analyzed by molecular connectivity method, 1743
—3-aryl-3-hydroxypropanethioates evaluated for antibacterial activity, 413
—(±)-2,5-diamino-2-(cyanomethyl)pentanoic acid, effect on ornithine decarboxylase activity evaluated, 1174
—diastereoisomeric 4-dimethylamino-3-phenyl-2-butanols and related esters evaluated for antimicrobial activity, 401
—ethoxycarbonyl cyclophosphamide analogs evaluated for antitumor activity, 709
—effect of substituted phenylalanine esters on

tumor cell metabolism in mice, 1726
—effect of various indolecarbohydrazides on human platelet aggregation in ethylene glycol *in vitro*, 1025
—effects of 2-indeneacetic acid and substituted 2-naphthoic acids and chloro derivatives on cholesterol biosynthesis in rat liver homogenates, 80
—fluphenazine and various analogs evaluated for CNS antitumor and cytotoxic activity, 157
—germacranolides isolated from *Eupatorium semiserratum* and *Eriophyllum confertiflorum* evaluated for antineoplastic activity, 865
—model system based on electron donor–acceptor complexes, 1310
—molecular connectivity indexes of various acetylcholine antagonists correlated to muscarinic receptor affinity, 1408
—1-phenyl-1-penten-3-one derivatives evaluated for effect on enzyme activity in rat liver mitochondria, 1539
—substituted imidazolidinethiones and various thioimidazolines evaluated for CNS depressant and anticonvulsant activity, 600
—substituted indenopyrazoles evaluated for CNS activity in mice, 1377
—substituted (indolylethyl)piperazinylureas evaluated for antihypertensive activity in rats and dogs, 1773
—various acetylcholine analogs evaluated as inhibitors of choline acetyltransferase, 657
—various acetylglycosyl quinone derivatives evaluated for antitumor activity in mice, 562
—various acridines, antibacterial activity related to electronic structure, 706
—various acylated amino acids evaluated in microbial antitumor screen, 520
—various adenosine analogs evaluated as smooth muscle vasodilators, dog hindlimb preparation, 121
—various alanine derivatives evaluated for cytotoxic activity, 642
—various aliphatic ethers, anesthetic activity and toxicity related to molecular connectivity indexes, 564
—various aliphatic hydrocarbons, ethers, and ketones, anesthetic activity and toxicity related to molecular connectivity indexes, 566
—various alkoxyacylaminoacylanilides evaluated for local anesthetic activity in rats, 595
—various barbiturates, prediction of duration of depressant effects using pattern recognition system based on structural descriptors, 745
—various benzo[*b*]furan derivatives evaluated for local anesthetic activity, 125
—various classes of compounds, carminative activity related to solubility, 277
—various cocaine analogs evaluated for effect on milk intake in rats, behavioral modifications in monkeys, and effect on ^{3}H-serotonin uptake by rat synaptosomes, 1656
—various diazasteroids evaluated for antitumor activity, 283
—various dopamine derivatives synthesized with *tert*-butoxycarbonyl as protecting group, CNS activity evaluated in mice, 558
—various fatty acids and derivatives evaluated as stationary phases in reversed-phase TLC for correlation between structure and biological response of probiotics, 713
—various halofumarate alkyl esters evaluated for antifungal activity, 578
—various heterocyclic oxamates evaluated as antiallergy agents, 735
—various 3-hydroxyquinolizidine esters evaluated for cholinergic activity *in vitro*, 1759
—various iodinated aromatic compounds, toxicity in mice, 1154
—various isoquinoline derivatives evaluated for antineoplastic activity, 740
—various isothiocarbamates evaluated for antibacterial and antifungal activity, 576
—various α-methylene-γ-lactone-containing agents evaluated for effect on tumor growth, respiration, and nucleic acid synthesis, 1235
—various naturally occurring and synthetic xanthones evaluated for anti-*Mycobacterium tuberculosis* activity *in vitro*, 721
—various nitrosamines, mutagenic potency related to molecular connectivity indexes, 725
—various oxadiazoles evaluated for effect on enzyme activity in rat brain homogenates, anticonvulsant activity in mice, and antiproteolytic activity *in vitro*, 987
—various 1-phenyl-1-nonen-3-one derivatives evaluated for antineoplastic activity in mice and antimicrobial activity *in vitro*, 1543
—various pyridinium- and quinolinium-2-dithioacetic acids evaluated for antitumor and antiradiation activity, 962
—various secondary disulfonamides and tetrasulfondiamides evaluated for antineoplastic activity, 857
—various spirofluorenes evaluated for antiallergic activity, 953
—various substituted 17β-aminoandrostenes evaluated for anti-inflammatory activity in rats, 1215
—various 3-substituted 1,2-benzisothiazole 1,1-dioxides evaluated for antibacterial and antifungal activity, 1323
—various substituted benzo[*b*][1,5]naphthyridines, binding with DNA studied, antitumor activity evaluated, 407
—various substituted benzo[a]quinolizines evaluated for antineoplastic and anticonvulsant activity, 871
—various substituted benzothiazoles evaluated for antibacterial activity, 281
—various substituted 1-(4-biphenylyl)-2-phenylethylamines evaluated for antispasmodic and cardiovascular activity, 991
—various 1-substituted 2-imidazolidinones evaluated for anti-inflammatory activity, 548
—various substituted indans evaluated for toxicity and cardiovascular properties, 314
—various substituted indazoles evaluated for hypotensive activity, 1022
—various substituted oxadiazole-2-thiones synthesized, evaluated for anticonvulsant activity in mice, effect on NAD-dependent and independent oxidations and antiproteolytic activity *in vitro*, 1507
—various 2-(substituted phenylimino)-2*H*-quinolizines evaluated for antiulcerogenic activity, 1183
—various substituted phthalimidines evaluated for antifungal activity, 863
—various substituted piperazines evaluated for antibacterial and antifungal activity, 900
—various substituted purine ribonucleosides and 5′-phosphates evaluated for cytotoxic activity *in vitro*, 569
—various substituted pyrazolidines evaluated for anticonvulsant activity in mice, 1471
—various substituted quinazolinylformamidines evaluated for antihypertensive activity in rats, 1479
—various substituted 1,2,3-selenadiazoles evaluated for antibacterial and antifungal activities, 1336
—various *N*-substituted 1,2,3,4-tetrahydro-1- and 2-naphthylamines evaluated for local anesthetic activity and toxicity, 880
—various substituted thiazoles evaluated for hypoglycemic and hyperglycemic activity, 587
—various substituted thiocolchicines evaluated for antileukemic and cytotoxic activity, 394
—various substituted *as*-triazines evaluated for antiviral activity, 737
—various substituted trimethoxybenzamides evaluated for anticonvulsant activity in mice and effect on enzyme activity in rat brain homogenates, 1682
—various sulfonamides and sulfonylhydrazines evaluated for antineoplastic activity in mice and effect on L-asparagine synthetase activity *in vitro*, 1550
—various sulfur-containing steroids evaluated in treatment of methylmercuric chloride toxicity in mice, 1739
—various thiazolo- and thiadiazolo[3,2-*a*]pyrimidines evaluated for effect on cyclic AMP phosphodiesterase activity *in vitro*, 1762
Strychnos dolichothyrsa—stem bark alkoloids isolated and identified, muscle relaxant activity evaluated, 171
Sugar solid dispersions—sucrose, mannitol, and sorbitol in tablets with hydrocortisone and prednisone, dissolution rates and stability, 979
Sulfadiazine—bioavailability of various dosage forms compared in humans, 1659
—high-pressure liquid chromatographic analysis in human serum, 404
Sulfamates, various—metabolism in rats compared, 226
Sulfamerazine—high-pressure liquid chromatographic analysis in human serum, 404
Sulfamethazine—high-pressure liquid chromatographic analysis in human serum, 404
Sulfamethizole—bioavailability in humans and *in vitro* dissolution, two suspensions compared, 1399
Sulfapyridine and acetyl metabolite—high-performance liquid chromatographic analyses in biological fluids, 1250
Sulfasalazine—various impurities isolated and characterized, 387
Sulfathiazole—flocculation–deflocculation behavior, effect of glycyrrhizic acid, aqueous solutions, various pH values, 151
Sulfisomidine tablets—effect of film coating containing UV absorber on coloration and photolytic degradation, 196
Sulfonamides, secondary—synthesized, evaluated for antineoplastic activity, 857
various—coordination with silver, structures of complexes studied, 284
various—separated from degradation products by liquid–liquid extraction, 1415
various—synthesized, evaluated for antineoplastic activity in mice and effect on L-asparagine synthetase activity *in vitro*, 1550
Sulfur-containing steroids—synthesized, evaluated in treatment of methylmercuric chloride toxicity in mice, 1739
Sulindac—and metabolite, binding to human serum albumin, 1077
Suprofen—high-performance liquid chromatographic analysis in plasma, 985
Surface effects—benzocaine diffusion from various polyethylene glycol ointment bases through human stratum corneum, 517
Surface pressure—*measurement used to study polyvinylpyrrolidone copolymer adsorption from solution, films compared to spread monolayers, 1464*
Surfactants—cetrimonium bromide, equilibrium penetration of dipalmitoyllecithin monolayers, surface pressure–area isotherms measured, 364
—cetrimonium bromide, penetration of cholesterol monolayers, equilibrium surface pressure–area isotherms obtained, 1054
various—effect on percutaneous absorption of naproxen, *in vivo* and *in vitro* correlations in rats, 1645
various—effect on percutaneous absorption of naproxen, rabbit, rat, and human skin compared, 1272
various—effect on release of tripelennamine hydrochloride from inert wax matrixes, 354
—various polysorbates, autoxidation on storage, effect of light, temperature, and copper sulfate, 1676
Suspensions—separated into distinct particle-size fractions by centrifugal elutriation, 673
Sweeteners, nonnutritive—various sulfamates, metabolism in rats compared, 226
—saccharin, absorption from urinary bladder, rats, 1493
Swertia angustifolia—whole plant extract, various xanthones and *O*-glucosides isolated and identified, various growth stages compared, 55

T

Tabernaemontana alkaloids, various—structural effects on cytotoxicity evaluated, 272

arborea—sap, various alkaloids isolated, cytotoxic activity evaluated, 271
holstii—reidentified as *Voacanga thouarsii*, No. 7, p. IV
johnstonii—stem bark, various alkaloids isolated, structures elucidated, cytotoxic activity evaluated, 249
Tablet dissolution—theoretical equation derived, effects of tablet disintegration and particle dissolution, 1436
Tablets, compressed—effect of partial moisture loss on hardness and *in vitro* dissolution, 1385
—containing inert wax matrix, effect of povidone on tripelennamine hydrochloride release, 357
—directly compressed and wet granulated, containing rapidly soluble, finely subdivided substance, dissolution compared with previous theoretical models, 982
—disintegration time, effect of intensity of agitation, specially fabricated and commercial formulations, 210
—hydrocortisone and prednisone sugar solid dispersions, dissolution rates and stability, 979
—sulfisomidine, coloration and photolytic degradation, effect of film coating containing UV absorber, 196
—tripelennamine hydrochloride in inert wax matrixes, effect of various surfactants on drug release, 354
Technetium Tc 99m complexes—various substituted iminodiacetic acids prepared, 1434
Teratogenesis, phenytoin and cortisone induced—effect of various cobalt-containing agents in mice, 377
Tetracycline—adsorption to montmorillonite, IR and X-ray analyses of mechanism, 1081
—complexation with calcium and organic ligands, *mechanism of fluorometric analysis*, 1518
resistance—R-factor transfer from *Escherichia coli* to *Salmonella pullorum*, effect of paromomycin, 35
Tetracyclines—partitioning in aqueous–octanol system, kinetics and thermodynamics, effect of divalent metal salts, 1717
—partitioning in aqueous–octanol system, kinetics and thermodynamics, effect of hydroxyl group, 1715
1,2,3,4-Tetrahydro-1- and 2-naphthylamines, *N*-substituted—synthesized, local anesthetic activity and toxicity evaluated, 880
(—)-Δ^9-Tetrahydrocannabinol—impregnated on placebo *Cannabis* plant material, stability of dosage form, 876
—kinetics of biphasic degradation in acidic solution, 27
Tetrahydroisoquinoline alkaloids, various—Hofmann elimination reaction with diazomethane, 473
Tetralins, substituted—absolute configurations of enantiomers of 1-methyl-1-phenyl-1,2,3,4-tetrahydro-3-naphthoic acid and *N,N*,1-trimethyl-1-phenyl-1,2,3,4-tetrahydro-3-naphthylamine assigned, 1367
Tetrazolylchromone, substituted—high-pressure liquid chromatographic analysis in biological fluids, 1185
Thebaine—spectrophotometric analysis in Arya II population capsules of *Papaver bracteatum*, 32
Theophylline—bioavailability of commercial elixir and two tablets compared, chronic dosing in humans, 916
—chromatographic separation from hydroxyethyl derivative in pharmaceutical syrup, spectrophotometric analyses, 572
—formation of charge transfer complexes with *p*-cresol, UV absorption study, 1381
—transfer rate across everted rat intestinal sacs, 1459
—various 7-acyl- and 7,7′-acylditheophylline derivatives synthesized, evaluated as prodrugs, 1045
Thermal decomposition—methotrexate in aqueous solutions, 526
Thermal degradation—gelatin solution and gel mass, rigidity and viscosity, applied to processing predictions, 218
Thermodynamic group contributions—hydroxyl, amino, and methylene, free energy of transfer from one phase to another, 615
Thermodynamic parameters—related to solubility of various parabens in water at four temperatures, 624
Thermodynamics—mercaptopurine dehydration, stability of hydrate and anhydrate forms under various thermal conditions, 488
—partitioning of tetracyclines in aqueous–octanol system, 1715, 1717
Thiadiazolo[3,2-*a*]pyrimidines, various—synthesized, evaluated for effect on cyclic AMP phosphodiesterase activity *in vitro*, 1762
Thiamine—radiochemical analysis in blood, compared to fluorometric analysis, pharmacokinetics in rats, 818
Thiazinamium—tissue distribution and biliary excretion in rats, 1147
Thiazole—homolytic arylation with phenylazotriphenylmethane, 2-phenyl-5-triphenylmethylthiazole synthesized, 1432
Thiazoles, various substituted—synthesized, evaluated for hypoglycemic and hyperglycemic activity, 587
Thiazolo[3,2-*a*]pyrimidines, various—synthesized, evaluated for effect on cyclic AMP phosphodiesterase activity *in vitro*, 1762
Thiazolylthiopropanolamine derivative—synthesized, β-adrenergic blocking activity evaluated in dogs, 1334
Thimerosal—high-pressure liquid chromatographic analysis in aqueous pharmaceutical preparations, 1636
Thiocolchicines, various substituted—synthesized, antileukemic and cytotoxic activity evaluated, 394
Thioimidazolines, various—synthesized, evaluated for CNS depressant and anticonvulsant activity, 600
Thiopseudourea, substituted—hydrolytic degradation in basic medium, products isolated and identified, 256
Thioridazine and metabolites—plasma concentrations and ECG abnormalities, relationship evaluated, humans, 155
Ticrynafen—and metabolites, GLC analyses in biological fluids, 1095
Tilidine and metabolites—GLC analyses in biological fluids, 1765
Titration, diphasic—analysis, methaqualone in bulk drug and tablets, 411
TLC—analyses, impurities in meperidine bulk drug and dosage forms, 958
—analysis, panaxoside content of various commercial ginseng products, 1487
—analysis, propranolol in plasma, 1307
—analysis, vindesine in bulk drug, 1319
fluorometry—analyses, propranolol and major metabolites in human plasma and urine, 826
reversed phase—various fatty acids and derivatives evaluated as stationary phases for correlation between structure and biological response of probiotics, 713
TLC–densitometry—analysis, cefazolin in biological fluids, 1170
TLC–spectrophotodensitometry—analysis, phytonadione in elemental diet formulations, 834
Tocainide—electron-capture GLC analysis in biological fluids, 201
—high-pressure liquid chromatographic analysis in blood, 1692
Tolazoline hydrochloride—release from inert carnauba or castor wax matrixes, 350
Tolbutamide—effect on *in vivo* binding of dicumarol to serum proteins and tissues in rats, 1492
—plasma protein binding in humans, effect of subject age, 1192
Topological indexes—molecular connectivity, antimicrobial and antiviral data sets analyzed, structure–activity relationships produced, 1743
—molecular connectivity correlated to muscarinic receptor affinity of various acetylcholine antagonists, 1408
—molecular connectivity, various aliphatic ethers, related to anesthetic activity and toxicity, 564
—molecular connectivity, various aliphatic hydrocarbons, ethers, and ketones, related to anesthetic activity and toxicity, 566
—molecular connectivity, various hydroxyureas, correlated with log *P* in octanol–water, 513
Total body drug clearance—rapid estimation during constant-rate intravenous infusion, equation derived, 1776
Toxicity—*N*-heptyl-1,2,3,4-tetrahydro-6-methoxy-1-naphthylamine methanesulfonate evaluated, 882
—various aliphatic ethers, related to molecular connectivity indexes, 564
—various aliphatic hydrocarbons, ethers, and ketones, related to molecular connectivity indexes, 566
—various substituted indans evaluated, 314
—various *N*-substituted 1,2,3,4-tetrahydro-1- and 2-naphthylamines evaluated, 880
Toxicodendron radicans—urushiol fractions obtained from different plant parts, GLC analysis, 483
Toxins—isolated and identified in extracts of sweet corn infected with *Fusarium moniliforme* mold and *in vitro* cultures, 1768
Tranquilizers—chlordiazepoxide, electron-capture GLC analysis in serum, 1647
—chlordiazepoxide, polarographic analysis, effect of amitriptyline, commercial products and synthetic mixtures, 1297
—chlorpromazine, three haptens synthesized and characterized, antibodies developed in rabbits, antiserum titers determined, 1563
—clorazepate monopotassium and dipotassium, differential pulse polarographic analyses in pharmaceutical preparations, 1723
—clorazepate, pharmacokinetic study by GLC analysis of desmethyldiazepam in plasma, 427
—etazolate hydrochloride, hydrolysis in aqueous solutions, PMR and mass spectral stability studies, 850
—oxazepam, hydrolysis of acetate ester *in vivo* and *in vitro*, stereospecificity of esterases determined, 1208
—thioridazine and metabolites, plasma concentrations, and ECG abnormalities, relationship evaluated, humans, 155
various—antimicrobial activity, effect of combination with various antibiotics, 23
Transfer rate—theophylline from solution and ditheophylline succinate suspension across everted rat intestinal sacs, 1459
Transport characteristics—interstitial space of rat diaphragm muscle, permeability to solutes of different molecular weights, 696
Transport, drug—3-*O*-methylglucose, transfer across everted rat small intestine, effect of preadministration of phenobarbital, benzo[*a*]pyrene, and proadifen hydrochloride, 245
Triazines, various substituted—blood levels related to antineoplastic activity, rats, 310
various substituted—metabolism and excretion in rats, 306
as-Triazines, various substituted—synthesized, antiviral activity evaluated, 737
Tricin—isolated from *Spartina cynosuroides* aerial parts, ^{13}C-NMR spectral analysis, 1325
Triclofos sodium—hydrolysis kinetics, effect of pH, temperature, and ionic strength, 631
Trimethoxybenzamides, various substituted—synthesized, evaluated for anticonvulsant activity in mice and effect on enzyme activity in rat brain homogenates, 1682
Triolein digestion mixture—in aqueous phase containing griseofulvin, GI absorption in rats, 895
Tripelennamine hydrochloride—release from inert carnauba or castor wax matrixes, 350
—release from inert wax matrix tablets, effect of povidone, 357
—release from inert wax matrixes, effect of various surfactants, 354
3′,4′,7-Tris(*O*-(β-hydroxyethyl))rutoside—spectrophotofluorometric analysis in urine, 1142
Trisulfapyrimidines—high-pressure liquid chromatographic analyses in human serum, 404
Tropane alkaloids, various—^{13}C-NMR spectra determined, carbon resonances assigned, 775

Tryptophan—spectrophotometric analysis simultaneously with tryptophan in solutions, 729
Tryptophan metabolites—various indole derivatives, mass spectrometric analyses in human urine, 478
Tuberculostatic antibacterials—ethambutol, GLC analysis in biological fluids, 470
—isoniazid, genetic phenotypes of acetylation determined using metabolic clearance values in humans, 1018
—isoniazid, spectrophotometric analysis in presence of its hydrazones in prepared mixtures and commercial tablets, 661
(+)-Tubocurine—syntheses by dequaternization procedures compared, mechanisms evaluated, products identified, 1204
Turbidimetry—study of self-association of various dihydroxy bile salts in aqueous electrolyte solutions, 994
Tyrosine—spectrophotometric analysis simultaneously with tryptophan in solutions, 729

U

Ultrasonic analyses—alcohol and soluble solids in pharmaceutical formulations, 492
Urethan—solid-state dispersions with various drugs, dissolution rates compared to pure drug substances and physical mixtures, 391
Uricosuric agents—(2-cyclopentyl-6,7-dichloro-2-methyl-1-oxo-5-indanyloxy) acetic acid, GLC analysis in biological fluids, 162
—probenecid, spectrophotofluorometric analysis in biological fluids, 434
Urushiol fractions—obtained from different plant parts of Toxicodendron radicans, GLC analysis, 483
UV absorber—contained in film coating, effect on coloration and photolytic degradation of sulfisomidine tablets, 196
UV spectrophotometry, differential—analysis of various 3-one-4-ene steroids, effect of added propylene glycol, 275
UV spectroscopy—recommended as substitute for compendial odor identification tests, 539

V

Vasodilator activity—various adenosine analogs evaluated, dog hindlimb preparation, 121
Vasodilators, coronary—mixidine, absorption, effect of intraduodenal administration with various ratios of 2-naphthalenesulfonic acid as counterion, 948
—mixidine, ion-pair formation in vitro determined by partitioning, absorption in rats determined by lethality, 945
—nitroglycerin, GLC analysis in plasma, 582
—nitroglycerin, percutaneous absorption in rats, effect of application site, 1345
—nitroglycerin, pharmacokinetics after intracardial, oral, and topical administration in rats, 584
—nitroglycerin, stability in polyethylene glycol 400 and povidone solutions, 1394
—pentaerythritol tetranitrate, colorimetric analysis in dosage forms, NF method modified, 717
Vasodilators, peripheral—tolazoline hydrochloride, release from inert carnauba or castor wax matrixes, 350
Vehicles, high viscosity—influence on miotic effect of pilocarpine in rabbits, 1280
various types—effect on stability of hydrocortisone, effect of other active ingredients, 299
Verongia archeri—methanolic extracts of hard and soft sponges, various compounds isolated and identified, antibacterial activity evaluated, 264
Vidicon spectrometer—used in simultaneous determination of multicomponent drug formulations without prior separation, 822
Vindesine—high-performance liquid chromatographic and TLC analyses, bulk drug, 1319
Viscoelastic properties—carboxymethylcellulose, oscillatory and steady shear rate measurements compared, effect of concentration and viscosity grade, 1499
Viscosity—gelatin solution and gel mass, thermal degradation, applied to processing predictions, 218
high—in various vehicles, influence on miotic effect of pilocarpine in rabbits, 1280
Vitamins—ascorbic acid, elimination in humans after intravenous administration, 1491
—cyanocobalamin, intrinsic factor-mediated binding to cholestyramine in vitro, effect of pH, added electrolyte, and bile salt, 1626
—menadione, blue-colored product of reaction with 2,4-dinitrophenylhydrazine identified, 258
—phytonadione, TLC–spectrophotodensitometric analysis in elemental diet formulations, 834
—thiamine, radiochemical analysis in blood, compared to fluorometric analysis, pharmacokinetics in rats, 818
various—simultaneous high-pressure liquid chromatographic analyses in multivitamin preparations, 1444
Voacanga thouarsii—previously identified incorrectly as Tabernaemontana holstii, No. 7, p. IV

W

Warfarin—(R)-(+)- and (S)-(−)-forms, elimination kinetics and anticoagulant effect compared, humans, 867
—GLC analysis in human plasma, 84
—in vivo binding in rat liver, implications for pharmacokinetic modeling, 229
Wax matrixes, inert—effect of povidone on tripelennamine hydrochloride release, tablets, 357
inert—release of tripelennamine hydrochloride, effect of various surfactants, 354
inert—release of tripelennamine hydrochloride or tolazoline hydrochloride from mixtures with carnauba wax or castor wax, 350
Waxes, various—coated on ion-exchange resin beads, effect on release of benzoate anions, 500

X

Xanthine analogs, mesoionic—synthesized, evaluated for effect on cyclic AMP phosphodiesterase activity in vitro, 1762
Xanthonecarboxylic acids, substituted—and various salts, solubility as a function of pH, 1257
Xanthones and O-glucosides—isolated and identified in Swertia angustifolia, whole plant extract, various growth stages compared, 55
various—naturally occurring and synthetic, anti-Mycobacterium tuberculosis activity evaluated in vitro, 721
various polymethoxy—selective demethylation with aqueous piperidine, 1321
X-ray diffraction—determination, crystal and molecular structure of quinidine, 1698

Y

Z

Zwitterions—pyridinium- and quinolinium-2-dithioacetic acids synthesized, antitumor and antiradiation activity evaluated, 962